2016 directory of korean pharmaceutical industry 제약협회 영문디렉토리_내지... ·...

Directory of Korean Pharmaceutical Industry

2016

1. Greeting �� 4

2. Overview of the Korean Pharmaceutical Industry �� 6

1) Current Status

2) Production Management System

3) Development of New Drugs

4) R&D Reinforcement

5) Biopharmaceuticals

6) Globalization

7) Korean Pharmaceutical Industry Vision - PHARMA 2020

Contents

3. Directory of Pharmaceutical Companies �� 13

· Regular Members(2015. 4)

A~D �� 14

E~J �� 66

K~P �� 110

R~Y �� 158

· Associated Members(2015. 4)

C~G �� 200

4. Korean Pharmaceutical Company List �� 206

Greetings to all! I am Kyeong-Ho Lee, Chairman of the Korea Pharmaceutical Manufacturers Association,

On behalf of about 200 KPMA member companies making efforts for continuous development of

Korean pharmaceutical industry and for better and healthier life of people, I would like to express my

welcoming message to all the readers of this book.

Korean pharmaceutical industry produces safe and quality medicines by strictly complying with

domestic Pharmaceutical Affairs law as well as international regulations including ICH guidelines from

developing stage of medicines to manufacturing, distributing and consuming stage.

As a result of the effort, the Ministry of Food and Drug Safety, Korean regulatory authority for safety and

quality management of medicines, joined the membership of PIC/S (The Pharmaceutical Inspection

Convention and Pharmaceutical Inspection Co-operation Scheme) in 2014 together with Japan, which

is a proof that the quality and safety of medicines made by Korea is globally recognized.

As of 2016, a total of 26 new drugs(New Chemical Entities) have been developed by Korean pharma

industry, and Korea ranks 10th in the world based on the standard of US FDA approval. Combined with

excellent biotechnology infrastructure and clinical study capability(Seoul is the best city in the world

based on the number of clinical study) and advanced IT technology, Korea now is one of the global

powerhouses in terms of biopharmaceuticals. The market size of Korean pharmaceutical industry

accounts for about 20 billion dollars and with this confidence, Korean pharma industry is knocking

on the global market though vigorous export and direct overseas investment such as constructing

manufacturing site overseas.

Welcoming Message

2016 Directory of Korea Pharmaceutical Industry4

The purpose of this directory book is to provide you with practical support for your business by

presenting the detailed information of competitive Korean pharma companies who are ready to go

global as well as brief picture of Korean pharma market. I truly understand that when trying to enter

into overseas market including Asian market, it is difficult to select appropriate potential partners and to

make a real contact with the person in charge.

Therefore, this directory consists of KPMA member company list, the actual contact point and main

business area, flagship product, technology, size and recent status of the company,

I hope this book helps you understand better of Korean pharma companies and also conduct business

exchange more actively.

Thank you

Dr. Kyeong Ho Lee

Chairman

Korea Pharmaceutical Manufacturers Association

5

Overview of the Korean Pharmaceutical IndustryKorea’s pharmaceutical market is worth approximately USD 17billion as of 2014, accounting for

about 1.5% of the global pharmaceutical market worth USD 1.06 trillion. As of 2014, the number

of pharmaceutical companies in Korea stands at 894. Among them, manufacturers of finished

pharmaceutical products are 285 with a combined workforce of 78,259 employees. The actual

output of pharmaceutical products, including finished pharmaceutical products (USD 12.2billion),

amounts to roughly USD 16 billion.

As of the end of 2014, Korea has manufactured 11,854 ETC drugs(worth USD 10,104.6 million) and

6,164 OTC drugs (worth USD 2,132 million). USD 15,801million

USD 15,801million

unit : USD 1million

Category 2010 2011 2012 2013 2014

Productrion 13,676 13,562 13,668 14,222 14,422

Export 1,555 1,707 2,029 2,036 2,223

Import 4,487 4,784 5,032 4,529 4,713

Trade balance -2,933 -3,077 -3,003 -2,492 -2,490

Market size 16,608 16,639 16,671 16,714 16,912


USD 15,801million

Production Management SystemEquipped with production infrastructure conforming to CGMP regulatory standards

Joined PIC/S in 2014

The Korean pharmaceutical industry has invested over USD 2.6billion to build a production

infrastructure that conforms to U.S. CGMPs through the GMP advancement project initiated in

the mid-2000s. The joining of PIC/S (Pharmaceutical Inspection Convention and Pharmaceutical

Inspection Co-operation Scheme) by the Ministry of Food and Drug Safety in 2014 is also expected

to further increase the global standing of the Korean pharmaceutical industry and bolster its

exports.

Development of New Drugs26 new medicines(NCE) and 52 incrementally modified drugs

Through 2015, Korea has succeeded in developing 26 new medicines since the inception of Sunpla

Injection (SK Chemicals) in 1999, an anti-cancer medicine and Korea’s very first locally developed

new medicine.

As many as eight pharmaceutical products have been locally authorized as botanical drugs as of

late 2015. Korea also produces 52 incrementally modified drugs (through 2015), including Hanmi

Pharmaceutical Company’s Esomezol – a reflux esophagitis medicine and Korea’s first incrementally

modified drug that gained FDA approval in 2013 for sales in the U.S.

7

Biopharmaceuticals Developed the world’s first stem-cell therapy productProducing four of five globally commercialized stem-cell therapy products

Korea is rising as a global biopharmaceutical power based on its outstanding biotechnology

infrastructure, advanced clinical study, and world-class IT technology. Korea’s Hearticellgram-AMI

(Pharmicell) is the world’s first stem-cell therapy product to gain approval for marketing. In 2012,

Hunterase (Green Cross) became the world’s second medicine developed to treat Hunter syndrome

and has been designated as an orphan drug by FDA.

Currently, four out of five globally commercialized stem-cell therapy products have been developed

and manufactured by Korean companies (Hearticellgram-AMI, Cartistem, Cupistem, and Neuronata-R).

Korea also boasts advanced production facilities for biopharmaceuticals. The production facilities

within the Incheon Free Economic Zone, with a current capacity of 330,000 liters a year, will be

upgraded to an annual capacity of 510,000 liters by 2018. This upgrade is expected to help the

Incheon Free Economic Zone emerge as the world’s largest biopharmaceutical production base.

The Korean government has been providing strategic support for biopharmaceuticals, including its

investment of USD 291million in 2015, in an aim to release and commercialize five biopharmaceutical

products globally by 2017.

R&D ReinforcementA continued increase in R&D investment (8.25% of sales invested)A total of 671 products in the pipeline

The Korean pharmaceutical industry continues to expand its investment in R&D each year to boost

the development of new medicines.

The R&D expenses of Korean pharmaceutical companies equipped with labs and research-

dedicated departments have demonstrated continued growth. As of 2013, the ratio of R&D

expenses to sales stands at 8.25%, equivalent to USD 1.06billion. As a result, Korean pharmaceutical

companies have 671 new medicines currently in the pipeline (as of late 2013). Among these new

medicines, 25 have already been approved by FDA to begin clinical tests, completed all the steps to

gain final approval, or gained final approval for sales.


GlobalizationExports reaching USD 2.4 billion Increased export of medicine development technologyDirect overseas investment reaching USD 150 million

The Korean pharmaceutical industry is advancing into the world in earnest as evidenced by its

increasing export of finished products, drug substances, and technology as well as its soaring

foreign direct investment (for the construction of production plants, etc.).

The total exports of pharmaceutical products sold in 188 countries in 2014 stand at USD 2.40349

billion, a 14% increase from the previous year. Pharmaceutical product exports have demonstrated

an impressive yearly growth rate of 19.7% since 2006. In 2016, pharmaceutical exports are projected

to exceed the USD 2.6 billion mark.

Since 2010, an average of 18.4 cases of technology export has been completed per year. In 2015,

a USD 4.2billion contract was concluded, representing the largest-scale single case of technology

export in the nation’s history. The total number of technology export contracts successfully signed

to this day stands at 164 (involving 32 companies).

9

unit : KRW 1million (USD 1million)

2011 2017 2020

Korean Market Size 18,000,000 (15,810)

27,000,000 (23,715)

37,000,000 (32,499)

Production Scale 15,400,000 (13,527)

30,000,000 (26,350)

50,000,000 (43,917)

Top 50 Global Pharmaceutical Companies - 1 2

Developing Global New Drugs - 4 10

R&D Investment 1,000,000 (878)

3,000,000 (2,635)

6,000,000 (5,270)

Overseas Export of Medicine 1,900,000 (1,669)

11,000,000 (9,662)

23,000,000 (20,202)

Road to becoming the 7th Largest Pharmaceutical Power in the World

Korean Pharmaceutical Industry Vision – PHARMA 2020To grow into a global top-seven pharmaceutical powerTo reinforce investment in R&D for new medicinesTo foster high-caliber pharmaceutical specialists

Korea is strengthening its foothold in the global pharmaceutical market and is emerging as an

advanced pharmaceutical producer as evidenced by its production infrastructure that conforms

to CGMP regulatory standards, the joining of PIC/S (Pharmaceutical Inspection Convention and

Pharmaceutical Inspection Co-operation Scheme), the development of 26 new medicines, and its

pharmaceutical exports worth over USD 2.2billion. Furthermore, Hanmi Pharmaceutical Company’s

cumulative exports of new medicine development technology recently totaled about USD 7billion.

As an extension of its efforts to expand its presence in the global pharmaceutical market and

thereby improve the quality of life for all humanity, Korea has established a vision and roadmap to

reinforce its investment in R&D, foster high-caliber specialists, and join the ranks of the global top-

seven pharmaceutical powers by 2020 and is working hard to achieve its vision.


1. To enhance investment in R&D for developing new drugs :

expanding government R & D support by 200% (USD 2,640 million)

2. To boost financing for investment and loan: a cumulative USD 4,400 million in funding over 5 years

3. To attract and train core experts: to create 58,000 jobs and train 10,000 expexrts

4. To expand strategic overseas advance: to achieve USD 9,660 million in exports

5. To build an advanced level of infrastructure: to become the 5th-largest clinical trial country in the world

Source: Ministry of Health & Welfare ‘the world’s seven leading

pharmaceutical powerhouse enter’ Vision -related key indicators

11

Directory of Pharmaceutical Companies


Ahn-Gook Pharm. Co., Ltd.JIN AUH

993-75 Daelim-dong, Yeongdeungpo-gu, Seoul, Korea

Sep. 1959

Pharmaceuticals, Diagnostic Medical Devices, Cosmetic

430

82-2-3289-4359

82-2-849-4123

www.ahn-gook.com

RepresentativeHeadquarter Address

Foundation DateResearch FocusTotal StaffRepresentative PhoneRepresentative Fax Web

Summary (1 Million Won)

Fiscal Year 2008 2009 2010

Sales 75,900 100,529 108,500

R&D Expenditure 4,326 6,434 8,799

Capital 69,400 85,300 99,600

Financial Figures

Historical Background : Ahn-gook Pharmaceutical co. LTD(AG) was established in Sep 1959

Nature of Business : AG is a korean leading pharmaceutical company specialising in the developing, markting and distribution of pharmaceutical specialty products and medical devices.

Mission Statement : AG has developed and supplied outstanding medicines for the last 50 years, dedicated to developing ‘advanced pharmaceutical products for health and happiness of the mankind.’

Main Focus : Since the establishment in 1959, we have accumulated experiences in pharmaceutical industry. We have been focusing on the respiratory, digestive and circulatory systems of human body.

Main Business areas : Pharmaceuticals, Diagnostic Medical Devices, Cosmetics and Export.

Company Profile

15

Main Products

Product (Ingredient) Use Exporting Countries

1. Anytin SR tab. (Trimebutine maleate 300mg)

Digestive

2. Levotension tab. (S-amlodipine 2.5mg)

Antichypertension

3. Anycough cap. (theobromine 300mg) Antitussive & Expectorant

4. Synatura Syrup. (Among 100mL Coptis Rhizoma Butanol Ext 87.5mg Ivy leaf 30% Ethanol Ext 262.5mg)

Antitussive & Expectorant SingaporeHongkong

5. Anyfen tab. (Dexibuprofen 300mg) Anti-inflammatory analgesic antipyreticPhilippines

Vietnam

6. Tobicom-S (Retinol, etc.) Honduras

7. Grandpaze-F Tab. (Trimebutine, etc.) Digestive Pakistan

8. Xaltrin xl Tab.(Alfuzosine HCl 10mg) Benign Prostatic Hyperplasia

9. HPVDNAChip kit Diagnosis of Human Papilloma virus which is risk factor of cervical cancer

10. Anyfen Syrup (Dexibuprofen 12mg/mL)

Antipyretic

New Active Substances

Product (Ingredient) Use Approval Date

Anycough cap. (Theobromine 300mg) Antitussive & Expectorant Jun. 2008

Synatura syrup (Among 100mL Coptis Rhizoma Butanol Ext 87.5mg Ivy leaf 30% Ethanol Ext 262.5mg)

Antitussive & Expectorant Mar. 2011

R&D Pipeline

Ingredient Use Stage of Development

AG NCA805 Asthma RS

AG NPN803 Nephritis Remedies RS

AG NPP709 Antitussive PII

AG SCT101 Antihypertension PI

AG SDT102 Urological agent PC

AG SFT201 Antihypertension PC

AG SPT201 Antiulcerant PIII


Contact PersonContact PhoneContact E-mail

Doyoun Cho

82-2-2630-0728

[email protected]


Fiscal Year 2012 2013 2014

Sales 60,520 68,146 77,207

R&D Expenditure 2,000 2,500 2,700

Capital

Financial Figures

Established in 1953, Aju Pharm had been developed quality drugs to cure disease in Korean market.

We had separate cephalosporin site in our factory which also produce tablet, capsule and ampoule.

Also we are exporting more than 10 countries with amount of USD 2.5 Million.

Focus Area : Antibiotics, Cardiovascular and Olive Leaf products.

Company Profile

Aju Pharm Co., Ltd.Joongkil Kim

600 Gyeongin ro, Guro-gu, Seoul, Korea

1953

Antibiotics, Cardiovascular

about 310

82-2-2630-0728

82-2-2636-7519

www.ajupharm.co.kr

RepresentativeHeadquarter AddressFoundation DateResearch FocusTotal StaffRepresentative PhoneRepresentative Fax Web

17

Product (Ingredient/Formulation) Use Exporting Countries Remarks

1. Ceftriaxone 1g Inj Antibiotics Cambodia, Vietnam OEM, ODM

2. Eperisone HCl 50mg Neuro-Muscular Vietnam

3. Ambroxol HCl 30mgAntitussive

ExpectorantsVietnam

4. Candesartan cilexetil 16mg Circulatory Phillippines

5. Olirex(Olive Leaf Ext spray) Sore throat China Food item

6. Cefotaxime 0.5g, 1g Antibiotics Yeman OEM

7. Cefuroxime 750mg Antibiotics Philippines

8. Amikacin 500mg/2ml Antibiotics Azerbaizan

Main Products

R&D Pipeline

Compound Name Code Use Stage of Development

Eperisone SR Muscular New product launch in

July, 2015

Zerocid (Omeprazole + NaHCO3)

PPIWill be launch in 3Q of

2015



Fiscal Year 2012 2013 2014

Sales 34,456 28,730 29,638

R&D Expenditure 1,821 1,695 1,783

Capital 1,112 1,112 1,112

Financial Figures

About 20 years, we Korea Arlico Pharm have been poured our energy into helping people to live healthier and happier based on the belief that life is precious and nature is the source of all life.

We value our quality through KGMP validation for better circumstance.

In the year 2010, we had 30% increase from 2009 and keep growing its sale record in 2011 and exports to 4 Countries as for April. 2011. In the near Future, we hope to find more countries to have a strong partnership.

Focus Area : NSAIDs, Anti-infective, Antihistamine & Respiratory, Dermatology, Gastrointestinal, Cardiovascular.

Company Profile

Arlico.co.Ltd.RepresentativeHeadquarter Address


Hang Gu Lee

Korea Arlico B/D, 7-21,Baumoe-ro 27-gil, Seocho-gu, Seoul, Korea

Oct. 1. 1992

Tablets, Ointments, Creams, Gels

200

82-43-535-8877

82-43-535-8175

www.arlico.co.kr


Seung Chan Han

82-2-520-6945

[email protected]

19


1. Thioct HR Tab. (Thioctic Acid 600mg / Solid oral)

Relief and treatment of diabetic multiple

neuritis

VietnamMongol

2. Acrasone Cream 10g (Betamethasone Dipropionate 0.64mg, Clotrimazole 10mg, Gentamicin Sulfate 1mg)

Anti-inflammatory action and good antifungal action

VietnamTanzania

Hongkong

3. Cozasartan Tab. (losartan potassium 50mg)

Hypertension Renal disease in

diabetic patient with hypertension

4. Curazol Cap. (Omeprazole 20mg)

Duodenal ulcer, gastric ulcer, reflux

esophagitis etc.,Ecuador

Main Products


Astellas Pharma Korea., Inc.Jeong Hai Do

GumHa B/D 6F 41-2 Chungdam-dong, Gangnam-gu, Seoul, Korea

Apr. 1. 2005

246

82-2-3448-0504

82-2-3448-0510

www.astellas.com/kr


Foundation DateTotal StaffRepresentative PhoneRepresentative Fax Web


Fiscal Year 2008 2009 2010

Sales 105,800 132,300 150,400

R&D Expenditure

Capital 11,500 11,500 11,500

Financial Figures

Astellas Pharma Korea., Inc. is a local subsidiary of Japanese pharmaceutical corporate with superior R&D and worldwide sales network. It was founded in April 1st 2005 by merging of Fujisawa pharma Korea Co., and Yamanouchi pharma Korea Co., with 100% Japanese ownership

Company Profile

21

Main Products


1. Harnal D (Tamsulosin HCI) benign prostatic hyperplasia Japan

2. Vesicare (Solifenacin Succinate) Overactive Bladder Netherland

3. Oldeca (Barnidipine HCl) Hypertension Japan

4. Berasil (Beraprost sodium) Peripheral Arterial Disease Japan

5. Protopic (Tacrolimus) Atopic Dermatitis Japan

6. Nasea (Ramosetron HCI) Nausea and Vomiting Japan

7. Prograf (Tacrolimus) Post-transplant rejection Ireland

8. Irribow (Ramosetron HCI) Irritable Bowel Syndrome Japan

9. Rapamune (Sirolimus) Post-transplant rejection

10. Perdipine (Nicardipine HCI) Hypertension


BC World Pharm Co., Ltd.


Fiscal Year 2012 2013 2014

Sales 25,496 30,375 35,692

R&D Expenditure 4,617 4,452 4,760

Capital 830 830 1,335

Financial Figures

BCWORLD PHARM is a R&D driven pharmaceutical company that has been committed to developing innovative formulations.

We are focusing on the development of niche buster products and highly marketable modified drugs.

BCWORLD PHARM not only has been certified as Korea Innovative Pharmaceutical Company (KIPC) by Korea Ministry of Health & Welfare but also designated as Advanced Technology Center (ATC) by Korea Ministry of Knowledge Economy.

Also, now we are constructing the EUGMP/cGMP facility.

Focus Area : Narcotics, Anti-TB, Carbapenem antibiotics.

Company Profile



Sung Han Hong

Gyung Building, 78, Gaepo-ro, 22-gil, Gangnam-gu, Seoul, Korea

Jun. 10. 1980

DDS (Drug delivery system)

203

82-2-2182-0400

82-2-574-5064

www.bcwp.co.kr


David Kim

82-2-2182-0452

[email protected]

23


1. Mepem Inj. (Meropenem 500mg, 1g, 2g / Injection)

Antibiotics Vietnam, Philippines

2. Sinraci Inj. (Imipenem 500mg+Cilastatin Sodium 500mg / Injection)

AntibioticsVietnam, Philippines,

Nigeria

3. BC Citicolin Inj. (Citicolin 500mg / Injection)

Central nervous system

Azerbaijan, Dominican Rep.

4. Tubes Tab. (Ethambutol+Isoniazid+Rifam

picin+Pyrazinamide / Tablet)Anti-TB

5. Tibare Inj. (Remifentanyl 1,2,5mg /

Injection)Narcotics

Main Products

R&D Pipeline


Anti-cancer BCWP-D001 Anti-cancer Formulation

Anti-cancer BCWP-D003 Anti-cancer Non-Clinical

Anti-cancer BCWP-D004 Anti-cancer Non-Clinical

Anti-cancer BCWP-D006 Anti-cancer Formulation

Schizophrenia BCWP-D009 Schizophrenia

Diabetes BCWP-D011 Diabetes Formulation

Anti-cancer BCWP-Y001 Anti-cancer Formulation

Anti-infective BCWP-Y002 Anti-infective Formulation

Antibiotics BCWP-A001 Antibiotics Clinical

Hyperlipidemia BCWP-C001 Hyperlipidemia Clinical

Antiemetics BCWP-E001 Antiemetics Launch

ADHD BCWP-E002 ADHD Formulation

BPH BCWP-E004 BPH Formulation


Binex Co., Ltd.


Fiscal Year 2009 2010 2011

Sales 32,252 47,243 53,458

R&D Expenditure 4,349 706 4,663

Capital 7,800 8,357 9,379

Financial Figures

Binex is currently comprised of three main business sectors : biologics, chemicals, and cell therapy. As the only biologics CDMO in Korea, Binex plays the key role in solving the manufacturing bottleneck of biopharmaceutical industry with accumulated experience and US and EU-GMP facility.

Company Profile


Myoung-Ho Jeong

368-3 Dadae-ro, Saha-gu, Busan, Korea

Mar. 21. 1985

biosimilar

about 300

82-32-850-3235

82-32-850-3299

www.bi-nex.com

25

Main Products


1. Contract Development and Manufacturing Service - Binex manufactures client's products both in API and finished form based on clients' need. Products are manufactured at GMP quality with proficiency at reduced time and cost.

-

2. Human Growth Hormone Growth Hormone Deficiency -

3. Small Molecule Products Digestion, Ophthalmic Solution, Etc. -

R&D Pipeline


Infliximab (Remicade biosimilar)Rheumatoid Arthritis and other inflammatory conditions

Phase I in Korea and Japan for Rheumatoid Arthritis



Fiscal Year 2012 2013 2014

Sales 312,075 327,279 359,491

R&D Expenditure 9% 7.4% 7.2%

Capital 17,440 18,283 19,170

Financial Figures

Boryung Pharmaceutical Co., Ltd. has put a strong presence as TOP leading company in Korean pharmaceutical market since its foundation in 1963. Boryung has made its continuous efforts and investment on R&D to produce high-quality products in its specialty areas such as cardiovascular, gastrointestinal, antineoplastic, antibiotics drugs and API. Boryung has devoted itself to achieve the aspiration of company, “Dedicating to the health of mankind.”

In particular, Kanarb (Fimasartan, 8th ARB NCE for antihypertension ) has been already licensed out to 14 Latin countries including Mexico & Brazil, Russia and China (16 countries in total). Following the launch of Kanarb in Mexico in Sept. 2014, further global market development has been accelerated. In 2015, Kanarb is going to be licensed to APAC & MENA regions and be launched in Russia, Brazil, and China in a few years. Also, the projects heading to the reference countries such as EU & Japan have been carried out.

Following the remarkable success in Kanarb, Boryung is confident to make another success story with its next key pipeline, Lafutidine(new generation H2RA), Cilnidipine (4th generation CCB), and Gelfos (Top antacid in East Asia), with its best clinical values in class.

Focus Area : Cardiovascular, Gastro-intestinal, Antibiotics, Oncology, API synthesis.

Company Profile

Boryung Pharmaceutical Co., Ltd.RepresentativeHeadquarter Address


Tae-Hong, Choi

Boryung B/D, 136,Changgyeonggung-ro, Jongno-gu, Seoul, Korea

Oct. 1. 1963

Cardiovascular, Oncology

1,100

82-2-708-8000

82-2-744-0682

www.boryung.co.kr


Micheal park or Jay Kim

82-2-708-8032 or 8051

[email protected] / [email protected]

27



Fimasartan Anti-hypertension Korea / 2011

Mexico / 2014Ecuador / 2014


1. Kanarb Tab. (Fimasartan) Anti hypertensionMexico, Brazil, Russia, China

NCE(New chemical entity)

2. Cilnidipine Tab. Anti hypertension 4th generation CCB

3. Lafutidine Tab. Gastric Ulcer, Gastritis new generation H2RA

4. Gelfos Susp. (ALPO4) Antacid China, TaiwanTop Antacid in East Asia

5. Pitavastatin Hyperlipimedia Japan API

6. Oncology InjectableAnticancer Chemotherapy

ASEAN, MENA

7. Cephalosporin Injectable Antibiotics Japan PMDA approved

Main Products

R&D Pipeline


Kanarb + CCB combo BKC002 Hypertension P3

Kanarb + Statin combo BKC003Hypertension

HyperlipimediaP3

Kanarb + CCB + Statin combo

BKC004Hypertension

HyperlipimediaP1

Incrementally modified drugs

BNT002 Dementia P1

New Chemical Entity BSN001Hypertension

Diabetes mellitusDiscovery

Gene therapy BCB002 Liver cancer P1

Vaccine BVN002 Vaccine P3

Vaccine BVN003 Vaccine PC



Fiscal Year 2008 2009 2010

Sales 24,709 29,567 34,943

R&D Expenditure 1,623 1,502 1,296

Capital 39,514 39,875 42,237

Financial Figures

CHO-A PHARM.CO.,LTD. has put all efforts to develop and supply excellent medicine

under a corporate slogan, “Keep People Healthy and Happy Away from Diseases” since

establishment in 1988. With fast growth over the last 20 years, CHO-A PHARM, is one of the leading pharmaceutical company in Korea producing about 300 kinds of drugs

especially OTC products and health foods. CHO-A PHARM. began producing drinkable double-neck ampoule under technical cooperation with Laphal of France in 1994 and currently has 30 kinds of proudcts and exports them to Vietnam, Yemen and Guatemala.

After establishing a manufacturing factory in 1994, CHO-A has invested to improve quantity and maximize production capacity by obtaining an approval of KGMP in 1995 as well as ISO 9001 for the first time in the pharmaceutical industry in 1996. Through the CHO-A Bio technical R&D center, CHO-A succeeded producing a somatic-cell cloned pig for the first time in Korea and cloned a pig with EPO gene character coverted in 2005. Thereby CHO-A is expected to be a prominent biotech company of the next generation.

Company Profile

CHO-A PHARM. Co., Ltd.RepresentativeHeadquarter Address


Sung-Hwan Cho

1F Ace-Techno Tower, 12, Dangsan-ro 2-gil, Yeongdeungpo-gu, Seoul, Korea

1988

270

82-2-2166-4000

82-2-2166-4111

www.choa.co.kr

29

Main Products


1. Uratonyl (L-Ornithine-L-Aspartate) Acute,Chronic Hepatic disease Vietnam

2. Hemopoly (Ferric hydroxide polymaltose complex)

Iron deficiencya anemia Vietnam

3. Calcitonic (Calcium Lactate) Calcium deficiency Vietnam

4. Elemmen (Adenosine, Thymidine) Acute, chronic hepatitis, anemia Vietnam

5. New Hem (Ferrous gluconate hydrate, Manganese gluconate, Copper gluconate)

Iron deficiencya anemia Yemen

6. Lyvitol (L-Lysine HCl, Inositol, Cyanocobalamin)

Nutrition disorder Vietnam

7. Ronalamin (Calcium Lactate) Calcium deficiency Vietnam

8. Manpos (L-Arginine-L-Aspartate) Physical mental asthemia Guatemala

9. BabycolcolReduction of symptoms resulting from

the cold Mongolia

10. Ginseng Korea (Korean Ginseng Ex.)Reduces fatigue, improve mental

conditions.Vietnam



Fiscal Year 2012 2013 2014

Sales 461,246 508,664 544,130

R&D Expenditure 50,494 61,174 74,727

Capital 32,625 23,523 23,523

Financial Figures

Chong Kun Dang Pharmaceutical Corporaiton (CKD) was spin-off from CKD Holdings on November 2, 2013. CKD is a new organization to manufacture, sales and market the pharmaceutical products, and has the excellent capabilities to develop new chemical entities (NCEs), incrementally modified drugs and generics. CKD has invested over 10% of annual revenues for R&D, and succeded to develop NCEs such as CAMTOBELL®, anti-cancer drug and DUVIE®, anti-diabetic drug. Currently, CKD has developed other NCEs including the targeted therapy for the treatment of cancer through clinical trials. Furthermore, since September 2014, CKD-732 for the treatment of Prader–Willi syndrome, an orphan disease has been developed under the clinical trial III in the United States.

Company Profile

CHONG KUN DANG PHARMACEUTICAL CORP.RepresentativeHeadquarter Address


Young-Joo Kim

8, Chungjeong-ro, Seodaemun-gu, Seoul, Korea

1941

Oncology, Immunology, Metabolism, Cardiovascular

1,858

82-2-2194-0300

82-2-2194-0369

www.ckdpharm.com


Indy Baik

82-2-3149-7849

[email protected]

31



Camtobell (belotecan) Ovarian cancer, SCLCOctober 22, 2003/Korea

Duvie (lobeglitazone sulfate) Type II diabetes July 4, 2013/Korea

R&D Pipeline


CKD-906 Dyslipidemia Phase III completed

CKD-732 Obesity Phase III

CKD-330 Hypertension Phase III

CKD-337 Dyslipidemia Phase III

CKD-391 Dyslipidemia Phase III

CKD-11101 Anemia Phase III

CKD-904 Benign prostatic hyperplasia Phase III

CKD-943 Pain, Uremic pruritus Phase III

CKD-516 Solid cancer Phase I completed

CKD-345 Hypertension+Dyslipidemia Phase I

CKD-519 Dyslipidemia Phase I

CKD-581 Lymphoma Phase I

CKD-841 Cancer Phase I

CKD-12201 Cervical cancer Phase I

CKD-12101 Neutropenia Pre-Clinical


1. Lipilou (atorvastatin calcium anhydrous)

Hyperlipidemia Asia

2. Dilatrend (carvedilol) Hypertension

3. Cipol-N (cyclosporine) Immunosuppressant Asia, S. America

4. Tacrobell (tacrolimus) Immunosuppressant Japan, Asia

5. Candemore plus (candesartan + HCTZ)

Hypertension Asia

6. Sarlotan (losartan potassium) Hypertension

7. Imotun (avocado-soya) Arthritis

8. Pregrel (clopidogrel resinate) Myocardial infarction

9. Avelox (moxifloxacin hydrochloride)

Antibiotics

10. Telminuvo (telmisartan, S-amlodipine)

Hypertension

11. Belloxa (oxaliplatin) Anticancer Asia

12. Gemtan (gemcitabine hydrochloride)

Anticancer Asia

Main Products



Fiscal Year 2012 2013 2014

Sales 449,000 414,000 430,000

R&D Expenditure

Capital

Financial Figures

CJ HealthCare started its business as Pharmaceuticals Business Unit at CJ CheilJedang Corporation from 1984.

CJ HealthCare first developed EPO[Epokine], ciprofloxacin injection[Citopcin] and simvastatin [Simvastar] pharmaceutical products in Korea. Now, CJ HealthCare has become a representative Korean pharmaceutical company in promising therapeutic areas such as oncology, cardiology, endocrinology and nephrology.

As of 1st April, 2014, CJHealthCare was spun off from CJ CheilJedang Corporation and became a separate pharmaceutical corporate entity with purpose of enhancement of expertise in pharmaceutical business to grow globally.

Focus Area : ETC (CVs, Antibiotics, IV Solution, Oncology, Endocrinology, Nephrology&Urology, Gastro Intestinal, Musculo skeletal, Respiratory, Others) & Health functional products

Company Profile

CJ HealthCare Corp.RepresentativeHeadquarter Address


Dal won Kwak, Chul ha Kim

CJ Cheiljedang Center, 330, Dongho-ro, Jung-gu, Seoul, Korea

Apr. 1. 2014

NCE , Biologicals, IMD

1,164

82-2-6740-2119

82-2-6740-2491

www.cjp.co.kr


Kwang Hee Hong

82-2-6740-2181

[email protected]

33

Main Products

R&D Pipeline


Voglibose+Metformin (FDC) VogMet® Diabetes Launched (Korea)

pemetrexed Pemta® RTU Oncology Launched in 4Q 2015 (Korea)

UNDISCLOSED NEPA antiemetics Phase III

UNDISCLOSED CJ-12420* Gastric Acid-Related Disorders Phase III (Korea)Phase I (Completed, global)

UNDISCLOSED IBAT Inhibitor Gastric Acid-Related Disorders PC

UNDISCLOSED JAK Inhibitor arthritis DS

Atorvastatin+Metformin (FDC) CJ-30056 Type 2 Diabetes/Hyperlipidemia Phase II (Korea)

Pemetrexed Soln. CJ-30045 Oncology NDA

Candesartan+Amlodipine (FDC) CJ-30059 Hypertension Phase III (Korea)

Amlodipine+Valsartan+Rosuvastatin CJ-30060 Hypertension/

Hyperlipidemia PI

Amlodipine+Valsartan +Atorvastatin CJ-30061 Hypertension/

Hyperlipidemia PI

Darbepoetin CJ-40001 Anemia PI

UNDISCLOSED CJ-40002 2nd human Growth Hormone PI

UNDISCLOSED CJ-40010 Hand-Foot-Mouth Disease PC

UNDISCLOSED CJ-40012 Retinopathy (LUCENTIS Biosimilar) DS


1. Epokine Inj. (rh-EPO)The treatment of anemia of hemodialysis patients with end-stage renal disease

Southeast Asia, Africa, The Middle East, North Africa and CIS, Latin America

Biologicals

2. Leukokine Inj. (rh- G-CSF)

The chemotherapy in advanced cancer patients and in acute Leukemia patients can cause the Neutropenia.

Southeast Asia, Africa, The Middle East, North Africa and CIS, Latin America

Biologicals

3. Vancorin Inj. (Vancomycin)The treatment of serious, life-threatening infections by gram-positive bacteria

China Antibiotics

4. Tapocin Inj. (Teicoplanin) The treatment of serious infections by gram-positive bacteria

Southeast Asia, Latin America Antibiotics

5. Moveloxin I.V. solution bag (Moxifloxacin)

The treatment of acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, community acquired pneumonia and so on

Southeast Asia Antibiotics

6. Cinezolid I.V. solution bag (Linezolid)The treatment of vancomycin-resistant Enterococcus faecium infections

Southeast Asia Antibiotics

7. Calmtop Inj. (Irinotecan) The treatment of colorectal cancer Southeast Asia Oncology

8. Pemta Inj. (Pemetrexed) The treatment of pleural esothelioma and non-small cell lung cancer Southeast Asia Oncology

9. CONDITION (Fruit extract of Hovenia dulcis, Natural Herbal Extracts, Taurine) Anti-hangover drink China, Japan, Vietnam

10. HongSamJin Gold (6-yeared red ginseng drink) Red Ginseng drink Vietnam

11. OmapOne Lipid Inj. Soybean oil, Olive oil, Fish oil, Medium-Chain Triglycerides Southeast Asia Parenteral

Nutrition

12. OmapOne Peripheral Inj. Lipid, Amino acid, Glucose Southeast Asia Total Parenteral Nutrition (TPN)



Fiscal Year 2012 2013 2014

Sales 16,009 20,402 22,753

R&D Expenditure 419 6,499 4,242

Capital 33,013 3,313 43,313

Financial Figures

CMG Pharma is the ODF manufacturing company in Korea. CMG Pharma is an affiliate company of Cha Health Group which has esteemed general hospitals and bio research centers in Korea and also in US. By the fund and support of mother company, CMG Pharma is thriving to develop global leading ODF products.

Focus Area : R&D and Manufacturing of OTF Products.

Company Profile

CMG PHARMA Co., LTDRepresentativeHeadquarter Address


Jeong Ho Kim

14, Dosan-daero 66-gil, Gangnam-gu, Seoul, Korea

Aug. 1. 2001

Oral Dissoluble Film

164

82-31-881-7663

82-31-732-1856

www.cmgpharma.co.kr


Chloe Cho

82-31-881-7663

[email protected]

35


1. Tadalafil ODF (10mg, 20mg) Erectile dysfunction -

Be test completed succesfully in Korea

2. Entecavir ODF (0.5mg, 1mg) Hepatitis type B -

Be test completed succesfully in Korea

3. Aripiprazole ODF Schizophrenia -

- Be test completed succesfully in Korea

- IND submission to FDA in 1Q, 2015

4. Montelukast ODF Asthma -Be test in June, 2015

Main Products

R&D Pipeline


Confidential CMG-14011 Nocturia Formulation Research

Confidential CMG-14012 OTC Product Formulation Research

Confidential CMG-14013 Anti-emetic Formulation Research

Confidential CMG-14014 Anti-migrain Formulation Research



Fiscal Year 2012 2013 2014

Sales 129,800 123,400

R&D Expenditure 2,730 1,690

Capital 125,400 150,500

Financial Figures

CTCBIO is a Korean pharmaceutical company which holds top 50 domestic pharmaceutical companies as solid clients and is involved in co-operative partnership with international pharmaceutical companies. Its pharmaceutical business covers development and production of super-generics with drug formulation and delivery technology. We are specialized in micro-encapsulation using fluid bed and OSF formulation. CTCBIO is capable of manufacturing various types of oral dosage forms and has business capabilities starting from formulation development and all the way to commercial production.

Company Profile

CTCBIO, IncRepresentativeHeadquarter Address


Ho Yeon Cho

13, 40-gil, Jungdae-ro, Songpa-gu, Seoul, Korea

Jun. 1993

Finished Formulations

258

82-1661-8800

82-2-449-3886

www.ctcbio.com


Chae Young Ban

82-70-4033-0233

[email protected]

37


1. Sildenafiltreatment of erectile

dysfunctionLebanon, Iraque,

Taiwan, Japan etc.

Main Products

R&D Pipeline


Donepezil free base CDFF0212Treatment of

Alzheimer's diseaseNDA applied

Desmopressin CDFF0612Treatment of primary

enuresis, nocturnal enuresis

Bioequivalence test / review of specification and test method completed

Entecavir CDFF0511Treatment of chronic

hepatitis B virusNDA applied

Tadalafil CDFF0213Treatment of erectile

dysfunction

20mg: approved5mg, 10mg : NDA applied

Clomipramine/sildenafil CDFR0812Treatment of premature

ejaculationIND (phase II) applied

Omeprazole/sodium hydrogen caronate

CDFR0209

Treatment of duodenal and gastric ulcer, GERD

and symptoms of gastroesophageal reflux

disease

NDA applied

Sodium picosulfate etc. CDFR0613Eathartic for colonology

and preoperatic treatment

Phase I



Fiscal Year 2012 2013 2014

Sales 14,680 15,362

R&D Expenditure 1,314 1,813

Capital 2,477 2,777

Financial Figures

A research oriented pharmaceutical company which has focused on developing new drugs and medicines ever since 1998 of its establishment

1. Proven R&D technology in Bio-chemistry

Applied for 45 patents for drug manufacturing-related substances and methods.

2. Stable growth foundation through drug manufacturing business

Growth foundation prepared by continuous surplus management since 2005.

Obtained may types of drugs and OTC drugs.

OEM business run paralled based on KGMP production facilities and excellent manfuactufing capacity

3. New growth engine prepared through continuous R&D

Development of Peptide Drugs , Unnatural Amino Acids Drugs , Green Technology (development of ionic liquids and establishment of refinement technology).

Focus Area : Peptide Drugs, Unnatural Amino Acids, Green Technology(Ionic Liquid)

Company Profile

C-TriRepresentativeHeadquarter Address


Kim Wan-ju / Kim Woon-jang

27, Gyeonggang-ro, Namyangju-si, Gyeonggi-do, Korea

Apr. 23. 1998

New drug/drug manufacture business, ionic liquid business

145

82-31-557-0001

82-31-557-6622

www.c-tri.co.kr


Eun-ji Jeong

82-31-560-7125

[email protected]

39


1. Citrelin Oral Disintegrating Tablet (Taltirelin hydrate / OD Tab.)

Spinocerebellar degeneration

The nation’s first licensed

2. Pliclan Tablet (1000mg / 625mg / 500mg) (Amoxicillin hydrate, Potassium clavulanate, diluted / Tab.)

Penicillins Cambodia

3. MOSAPIA Tablet(Mosapride citrate / Tab.)

GI Tract Regulators & Antispasmodics

4. BROMETIN SOFT Capsule(Bromelain, Dehydrocholic Acid, Pancreatin, Simethicone, Trimebutine maleate / Cap.)

Digestants

5. CTRI CIMETIDINE Tablet (Cimetidine / Tab.)

H2 Receptor Blockers

6. Losartin Tablet (Losartan Potassium / Tab.)

Angiotensin II Receptor Antagonists

7. CIFLUCO Capsule (Fluconazole / Cap.)

Antifungal Agents

8. PRIMOX Tablet (Amoxicillin, Pivoxyl sulbactam / Tab.)

Penicillins

9. FENLEX Tablet (Loxoprofen Sodium / Tab.)

Nonsteroidal Anti-Inflammatory Drugs

10. Pramax Cream (Pramoxine Hydrochloride / Cream)

Hemorrhoidal, Phlebitis & Varicose Preparations

Main Products

R&D Pipeline


Peptide drugs CTB-001 anticoagulant 1stage clinic

Peptide drugs Desmopressinenuresis,

diabetes insipidusdrug development

Peptide drugs eptifibatide etc. drug development

Antiviral drugs tamiflu derivatives drug development

Antiviral drugs relenza derivatives etc. drug development

green & bio technology ionic liquids and battery



Citrelin Oral DisintegratingTablet(Taltirelin hydrate / OD Tab.)

Spinocerebellar degeneration 2015.02.06 / Korea



Fiscal Year 2012 2013 2014

Sales 36,025 41,479 46,448

R&D Expenditure 1,414 1,547 1,180

Capital 24,141 27,205 24,246

Financial Figures

Since its founding in 1976, Daewoo Pharmaceutical has endeavored to promote the public health with 3 business principles - sincerity, correctness, research.

We have focused on the business of ethical drugs in the past 30 years in Korea. With the business experience, Daewoo has effort on continuous research, development and investment about facilities and human resources.

Now, Deawoo is preparing to become a global pharmaceutical company with new-drugs pipline, particularly anti-angiogenesis and anticancer drug for the next 10 years. We are investing for world class product facilities to increase oversea business and accomplish R&D projects in Daewoo R&D institute. Daewoo has committed Contract Manufacturing Organization(CMO) business with sufficient technical and marketing resources.

Even in challenging internal and external enviroment, Daewoo will be a competent global pharmaceutical company with recognized ability.

Focus Area : Opthalmic Products / Cancer Drugs / Generic Drugs

Company Profile

Daewoo Pharmaceutical Co., LTDRepresentativeHeadquarter AddressFoundation DateResearch Focus

Total StaffRepresentative PhoneRepresentative Fax Web

Yong-Hoon Ji

153 Dadae-ro, Saha-gu, Busan,Korea

Apr. 1976

1) Ophthalmic product formula modification & customization 2) Development of targeted cancer drugs with inhibition of

angiogenesis

280

82-51-204-3831

82-51-202-3397

www.daewoopharm.com


Ji-Hoon Suh

82-2-3477-1731

[email protected]

41

Product (Ingredient/Formulation) UseExporting Countries

Remarks

1. Original Relief Eye Drops (Tetrahydrozoline HCl 0.5mg/Ophthalmic Eye Drops)

Relieves red, Irritated eyes

USAOTC (USA

OEM)

2. Advanced Relief Eye Drops (Tetrahydrozoline HCl 0.5mg + Dextran 70 1mg + Polyethylene glycol 400 10mg + Povidone 10 mg/Ophthalmic Eye Drops)

Relieves red, Irritated eyes, Hydrating

moisturizerUSA

OTC (USA OEM)

3. Hyalsan Eye Drops1) Single-use disposable type 0.8 mL

(Sodium hyaluronate 0.8mg/Ophthalmic Eye Drops)2) Multi-use type

(Sodium hyaluronate 1mg/Ophthalmic Eye Drops)

Keratoconjunctival epithelial disorder

Vietnam

4. Tobeson Eye Drops (Tobramycin 3mg, Dexamethason 1mg/Ophthalmic Eye Drops)

Eye steroids,Antiallergics

Vietnam

5. Taspen-ER Tablet (Acetaminophen 650mg/Tablet, Extended Release)

Other Analgesics, Antipyretics

6. Eperisone Tablet (Eperisone HCl 50mg/Tablet)

Skeletal muscle relaxants

Vietnam, Thailand

7. Simvasterol Tablet (Simvastatin 20mg/Tablet)

Antilipidemic agents

8. Pantezol Tablet (Pantoprazole sodium sesquihydrate 45.1mg, as Pantoprazole 40mg / Tablet)

H+ Pump inhibitors

9. Pseudoephedrine Tablet (Pseudoephedrine HCl 30mg / Tablet)

Decongestants, Nasal prep

10. Romicin Tablet (Roxithromycin 150mg / Tablet)

Macrolide antibiotics Vietnam

Main Products

R&D Pipeline


Macrolactin A

Int. CL.:A61K 31/335:A61K 35/74:C12P 7/62:A61P 29/00Application number:10-2010-0029016

Anti-inflammatory Non-clinical

Macrolactin A and its derivatives

Int. CL.:A61K 31/335:A61P 19/02:A61P 19/00Application number:10-2011-0012707

Anti-angiogenesis Non-clinical

Macrolactin Compounds

Int. CL.:A61K 31/335:A61K 31/365:A61P 1/00:A61P 29/00Application number:10-2012-0011924

The prevention or treatment of inflammatory bowel

diseaseNon-clinical

Macrolactin Compounds

Int. CL.:A61K 31/335:A61K 31/365:A61P 35/00Application number:10-2013-0089955

Anticancer Drug Non-clinical



Fiscal Year 2008 2009 2010

Sales 48,385 57,468 66,971

R&D Expenditure 1,036 703 839

Capital 43,065 51,848 53,693

Financial Figures

DAEHWA has been steadily endeavoring to meet your expectation to have a healthful life and escape from a hazard of disease. We supply the best quality pharmaceutical products to the people who earnestly need them, and realize the dignity of human life through our research and development. “Nothing is more precious and valuable than life.” is our permanent spirit and goal.

And, DAEHWA was established in 1984 and has been doing our best for the health of the People through supplying best quality products to the market. And with the completion of the c-GMP facilities in 2009, we are striving to produce high quality pharmaceutical products from “Raw Material” to “Finished Products”.

Company Profile

Daehwa Pharm. Co., Ltd.RepresentativeHeadquarter Address


Han Koo Lee

1056-16 Namhyeon-dong, Gwanak-gu, Seoul, Korea

Jan. 19. 1984

API, TDDS Product, etc.

350

82-2-586-6451

82-2-587-0566

www.dhpharm.co.kr

43

Main Products


1. PROTASE Tab. (Bromelain 40mg, Crystallized Trypsin 1mg)

Fracture, sprain, internal, external and incarcerated hemorrhoid after proctoptosis and a hemorrhoidal surgery, stagnant breast, mammitis, hematoma and thrombosis

Myanmar, Vietnam, Cambodia

2. Top-Roll S.Cap. (Korea Ginseng 100mg and multivitamins etc.)

Tonic, nutritive supplement : weak, fatigable, lacking physical strength during or after disease, having febrifacient and exhaustive diseases and pregnant and lactating woman.

Myanmar, Vietnam, Cambodia, Ghana,

Bolivia

3. ALMETAMIN Tab. (Betamethasone 0.25mg, Dexchlorpheniramine maleate 2mg)

Urticaria, hay fever, allergic rhinitis, drug hypersensitivity reaction, chronic bronchial asthma, atopic dermatitis, eczema, contact dermatitis, allergic conjunctivitis

Ethiopia, Vietnam, Cambodia

4. DEMACOT Cream (Batamethasone dipropionate 0.64mg,

Clotrimazole 10mg, Gentamicin sulfate 1.0mg(potency)

Allergic dermatitis, alopecia areata, first degree burn, dermatomycosis

Vietnam, Bolivia, Cambodia, Ghana,

Mongolia

5. DICLONIC Tab. (Clonixin lysinate 125mg or 250mg)

Neuralgia, rheumatoid arthritis, myalgia. headache, toothache, menorrhalgia

Bolivia

6. BIDICA Tab. (Biphenyl dimethyl dicarboxylate 25mg)

Treatment for chronic persistent and active hepatitis that is associated with a high SGPT level or drug-induced high transaminase level

Vietnam, Ecuador, Cambodia, Mongolia

7. KEBANON Plaster (Ketoprofen 30mg)Traumatic inflammation of muscles, strains and sprains. Relief of symptoms of muscular pain.

Bolivia, Cambodia, Hongkong,

Vietnam

8. LOXONA Plaster (Loxoprofen 56.7mg)Traumatic inflammation of muscles, strains and sprains. Relief of symptoms of muscular pain.

Cambodia, Hongkong

9. RESNALIN Patch (Tulobuterol 0.5 / 1/2mg)

Respiratory distress caused by airway obstruction of bronchial asthma, acute bronchitis, chronic bronchitis, or emphysema

Myanmar, China

10. FAMOCID Tab. (Famotidine 20mg)

Gastric and duodenal ulcer, reflux esophagitis, hemorrhage of upper digestive tract, zollinger-Ellison syndrome

Ethiopia

R&D Pipeline


PaclitaxelBreast cancer, Gastric cancer, Non-small cell lung cancer,

Ovarian cancer

Clinical Study Phase IINew formulation(Oral Solution)

CetrizinePerennial allergic rhinitis,Seasonal allergic rhinitis,

Urticaria, chronic New formulation

Sildenafil Erectile dysfunction New formulation

Voglibose Diabetes mellitus New formulation

Isomers Pre-Clinical Study



Fiscal Year 2008 2009 2010

Sales 90,659 111,930 144,696

R&D Expenditure 4,425 4,935 5,683

Capital 5,944 5,944 6,454

Financial Figures

Being a partner for healthy life of human on Customers’ trust

Daewon Pharm.Co.,Ltd. is a state-of-the-art pharmaceutical company that has achieved success in commercializing Pelubi tablet and Aquafol injection. We are developing new follow-up medicines such as anti-hepatitis and anti-asthma. Now, Daewon Pharm seeks to leap forward and become a world-class global pharmaceutical company that improves human health based on advanced technologies and global expertise of over a half century of experience.

Daewon Pharm.Co.,Ltd., as a specialized company manufacturing medicines to cure various diseases, has tried to make the lives of human beings much happier and healthier. We at daewon pharm.Co.,Ltd. continue to invest in R&D, production facility and quality improvement to meet customers’ various needs.

Since it was completed in 1988, the Hyangnam factory of Daewon Pharm.Co.,Ltd. is equipped with superior manufacturing and quality control management system, and has produced over 100 kinds of medicines, i.e. solid dosage medicines, liquied dosage medicines, injectable medicines, sex hormone medicines and etc. In particular, Daewon Pharm.Co.,Ltd. has improved its competitiveness with its updated Hyangnam factory, installed with the cutting-edge systems to meet cGMP levels in Apr. 2009

Company Profile

Daewon Pharm. Co., Ltd.RepresentativeHeadquarter Address


Seung Ho Baek / Seung Ryel Bae

229-3 Yongdap-dong, Seongdong-gu, Seoul, Korea

Jan. 1958

New Chemical Entity

520

82-2-2204-7000

82-2-498-9108

www.daewonpharm.com

45

Main Products


1. Oramin Cap. (Korean Ginseng + Mulitivitamins + Minerals)

Korean Ginseng Multivitamin25 countries include Myanmar (Latin America, Asia, Africa, CIS, Middle East)

2. Megex-I Susp. (Megestrol Acetate) Anorexia, cachexia of cancer or AIDSDominican Rep., Guatemala, Peru, Panama

3. Naphine Inj. (Nalbuphine HCl) Potent AnalgesicsPhilippines, Domincan Rep. etc.

4. Rizine Tab. (Cetirizine) SympathomimeticsAsia, Latin America, Middle East

5. Codaewon Tab. (dihydrocodeine bitartrate etc.)

Potent AntitussivesHong Kong, Cambodia, Vietnam. etc.

6. Pantyrase Tab. (Pancreatin etc.) Digestives Asia, Latin America

7. Trigel Susp. (Oxethazaine etc.) AntacidsAsia, Latin America, Middle East

8. Metran Cap. & Metran Inj. (Mecobalamin)

Peripheral neuronic disorderDominican Rep., Africa, Pakistan, Afganistan

9. Forend Tab. (Alendronate) OsteoporosisPhilippines, Hong Kong, Vietnam, Guatemala

10. Wontiam Inj. (Cefotiam HCl) Cephalosporins China



Pelubi Tab. (Pelubiprofen) Alagesic & Lumbago 2008


Daewoong Pharmaceutical is the pharmaceutical company with the No. 1 sales of prescription drugs in the Korean market.

Established in 1945 in Seoul, South Korea, Daewoong Pharmaceutical offers high-quality and innovative pharmaceutical products and is one of the top market leaders in Korea. For over 60 years, Daewoong Pharmaceutical has been providing better health for people through its total dedication to healthcare. Daewoong has built strong core competency for new drug development to meet diverse medical needs and enhance human life. Building on our core strength, Daewoong Pharmaceutical has involved in becoming a global healthcare group by operating our foreign branches in SE Asia and by collaborating with global partners. We have an inspiring mission to become a top 50 global healthcare company which contributes to improving the quality of life for people worldwide.

The reinforcement of the R&D capacities through the establishment of R&D center in the USA, China and India.

Daewoong Lifescience Research Institute has been focused on developing new chemical entities, biologics, incrementally modified drugs and high-value added APIs. Daewoong has also been studying to find solutions for the unmet therapeutic needs of neuropathic pain disease, Alzheimer’s disease as well as other innovative programs like anticancer gene therapy. Daewoong is operating several overseas offices in China, Vietnam, Indonesia, Thailand, Philippines, USA, and India and has R&D centers in China, India and America.

Focus Area : GI

Company Profile

Daewoong Pharm. Co., Ltd.RepresentativeHeadquarter Address


Jongwook Lee

Bongeunsa-ro 114-gil 12, Gangnam-gu, Seoul, Korea

1945

Biologics, value added generics, generics, medical device

1,700

82-2-550-8800

82-2-550-8400

www.daewoong.co.kr


Doyoung Brian Kim

82-2-550-8936

[email protected]

47


Fiscal Year 2012 2013 2014

Sales 706,600 674,000 737,000

R&D Expenditure 70,000 67,000 73,000

Capital 28,215 28,966 28,966

Financial Figures


Remarks

1. Nabota (Botulinum toxin type A / injectable)

Glabellar lines

Thailand, Latin American countries

Contracted to export more than 90 countries including USA and EU

2. Novosis (BMP-2 / bone grafting material)

Dental sinus lifting, spinal fusion

Thailand, Philippines

3. Easyef (Epidermal growth factor / spray)

Diabetic foot ulcer, oral mucositis, acute wound healing)

Vietnam, Thailand, Philippines

Contracted to export to countries in Russia, Middle East, Latin America

4. Caretropin (Human growth hormone / injectable)

Growth hormone deficiency

Philippines, Vietnam, Iran

Contracted to export to countries in Middle East, South East Asia, and Latin America

5. Eposis (EPO, injectable)Anemia in end stage renal diseases

Vietnam, Philippines, Thailand

Contracted to export to countries in Middle East and South East Asia

6. Olostar (Olmesartan, rosuvastatin/ fixed dose combination)

Concomitant hypertension and dyslipidemia

Contracted to export US and Canada

7. Ursa (Ursodeoxycholic acid/ tablet & capsule)

Liver & bile disease including cholestasis, Gallstone, etc

Preparing to enter USA and Australia

8. Albis (Bismuth, sucralfate, ranitidine/ tablet)

Gastric & duodenal ulcer, gastritis

Vietnam

9. Luphere depotProstate cancer, Endometriosis, precocious puberty

Philippines, Vietnam

Registration process ongoing in Russia, Mexico, and US

10. Medicloreedical device for anti-adhesion

Thailand

Main Products

R&D Pipeline


Fungicidal DWJ205 Oral fungicidal program Research

APA DW206 Antiulcer program Research

Ion channel blocker DWJ208Neuropathic pain, Cancer pain

Research

PRS inhibitor DW209Lung Cancer, pancreatic cancer

Research



Fiscal Year 2012 2013 2014

Sales 96,562 106,802 111,709

R&D Expenditure 1,041 91,649 67,880

Capital 3,000 3,000 3,000

Financial Figures

DAI HAN PHARM.Co.,Ltd makes Good Pharmaceutical Products in the GMP plant, We make Infusions(Bag, Glass), Injections(Glass, PE, PP), Solutions for external use, and We have exported the product since 2005.

Focus Area : Infusions for PN, Injectable solutions

Company Profile

Dai Han Pharm. Co., Ltd.Yoonwoo Lee

3 Seonyu-ro 45-Gil Yeongdeungpo-gu, Seoul, Korea

Oct. 14. 1945

551

82-2-2678-8445

82-2-2671-9636

www.daihan.com

RepresentativeHeadquarter Address Foundation DateTotal StaffRepresentative PhoneRepresentative Fax Web


George Kim

82-2-2620-8952

[email protected]

Product (Ingredient) Use Exporting Countries Remarks

1. Iohexol Inj. 300

Myelography, angiography, urography, Computerized-tomography(CT)-contrast enhancement

VietnamExpect to be

exported

2. Iohexol Inj. 350

Myelography, angiography, urography, Computerized-tomography(CT)-contrast enhancement

VietnamExpect to be

exported

3. Luminal 10% Inj.Sedation (if urgently required), epilepsy and status epilepticus

Vietnam

4. Lefquin Infusion

pneumonia, acute pyelonephritis, multiple urinary tract infection, acute sinusitis, infection of skin and tissue, etc.

Philippines, Vietnam

Main Products

49

5. Lidocaine HCL 2%

1. Anesthesia : epidural anesthesia, nerve block, infiltration anesthesia and surface anesthesia.2. Internal medical use: ventricular arrhythmia.

Hong Kong, Philippines

Expect to be exported

6. Pan-B-Comp Inj.Supply of vitamins and prophylaxis of deficiency of vitamin B series

Cambodia

7. Vitamin K1 Inj.1. Prophylaxia and treatment of

hemorrhage disease for a newborn2. Hypoprothrombinemia

Iran, Vietnam, Philippines, Myanmar

8. Orni Inj.Hepatic coma, Treatment of precoma

Vietnam, Azerbaijan, Uzbekistan

9. Heparogen Inj.Detoxication of liver disease (hepatitis and sequela, tissue damage, hepatic cirrhosis)

Vietnam, Azerbaijan

10. Tranexamin Inj. 500mg

Hemorrhage(by leukemia, aplastic anemia, purpura, cancer, pulmonary hemorrhage, renal hemorrhage, genital bleeding, etc.)

Vietnam, Philippines, Myanmar

11. Tranexamin Inj. 250mg

Hemorrhage(by leukemia, aplastic anemia, purpura, cancer, pulmonary hemorrhage, renal hemorrhage, genital bleeding, etc.)

Vietnam, Philippines, Myanmar

12. Ketorolac tromethamine Inj. Severe pain Philippines

13. Sod. Bicarbonate Inj. 8.4% Acidosis, Acute pruritus Iraq

14. Piroxicam Inj.Rheumatic arthritis, osteoarthritis, ankylosing spondylitis etc.

Vietnam

15. Statirin Inj.Disturbance of consciousness by head trauma and surgery of brain etc.

Vietnam, Myanmar

16. Ciprofloxacin Inj.

Respiratory tract, ENT infections, renal or urinary tract infections, genital infection including gonorrhoea, GI infections, bone or joint infections, etc.

Philippines

17. Aminohex Inj.

Supply of amino acids in following cases (Hypoproteinemia, hypoalimentation, and before/after surgery)

Vietnam

18. Amicomplex Inj.

Supply of amino acids in following cases (Hypoproteinemia, hypoalimentation, and before/after surgery)

Mongolia

19. Hepavia Inj.

Improvement of encephalopathy due to acute / chronic hepatic impairment, supply of amino acids to a patient with hepatic impairment

Vietnam

20. Eyecon Sol.Rinsing and cleaning of contact lens

Japan



Fiscal Year 2008 2009 2010

Sales 36,300 50,200 56,700

R&D Expenditure

Capital

Financial Figures

Daiichi Sankyo Korea.,Ltd. is the Korean subsidiary of Daiichi Sankyo Japan, a global Pharmaceutical enterprise. Consolidation of the Daiichi Pharmaceuticals Co.,Ltd. and Sankyo Co. Ltd., gave birth to Daiichi Sankyo Korea Co.,Ltd. in April 2007, which since its launch has expanded its domain of expertise from anti-inflammatory area to cardiovascular area. Daiichi Sankyo Korea offers a fluoroquinolone antibacterial agent named Cravit, an anti-hypertension agent Olmetec and sevikar as well as an anti-dyslipidemia agent Mevalotin. The company will continue to make strides forward to secure a leading status in the pharmaceutical industry by leveraging and further diversifying its product offerings.

Daiichi Sankyo

The Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging market. While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, the Group is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabloic therapies. Furthermore, the Daiichi Sankyo Group has created a “Hybrid Business Model” which will respond to market and customer diversity and growth opportunities across the value chain. For more information, please www.daiichisankyo.com

Company Profile

Daiichi Sankyo Korea Co.,Ltd.RepresentativeHeadquarter AddressFoundation DateTotal StaffRepresentative PhoneRepresentative Fax Web

Dae Jung Kim

19F, 47 Jong-ro, Jongno-gu, Seoul, Korea

Jul. 16. 1990

122

82-2-3453-3300

82-2-3452-9756

www.daiichisankyo.co.kr

51

Main Products


1. Olmetec (Olmesartan) Anti Hypertension Imported

2. Olmetec plus (Omesartan + Hydrothiazide) Anti Hypertension Imported

3. Mevalotin (Pravastatin) Anti dislipidemia Imported

4. Sevikar (Olmesartan+amlodipine) Anti Hypertension Imported

5. Cravit (Levofloxacin) Antibiotics Imported

6. Sunrythm (Pilsicainide HCI) Antiarrhythmic agent Imported

7. Effient (Prasugrel) Antiplatelet agent Imported



Fiscal Year 2008 2008 2010

Sales 17,019 18,637

R&D Expenditure 828 744

Capital 500 500

Financial Figures

Dalim BioTech has been recognized as the best domestic pharmaceutical manufacturing/marketing firm for the treatment drugs in the field of endocrinology and Ob/Gyn with its solid sales organization covering the entire nation.

Company Profile

Dalim Biotech Co., Ltd.RepresentativeHeadquarter AddressFoundation DateResearch FocusTotal StaffRepresentative PhoneRepresentative Fax Web

Jong-Sup Chung

4, Jandari-ro 3-gil, Mapo-Gu, Seoul, Korea

2001

Diabetes, OB/GY, Surgery

163

82-2-335-1656

82-2-3140-3777

www.dalimpharm.co.kr

53

Main Products


1. Glupa Tab (Metformin HCI) 250mg / 500mg / 800mg / 1000mg

Non insulin depedent diabetes -

2. Glupa Combi Tab 500mg / 80mg (Metformin HCI, Gliclazide)


3. Diaryl Tab 2mg / 3mg / 4mg (Glimepiride)


4. Garcon Inj. (Glucagon 1mg, Sterile Water 1ml)

Hypoglycemia (insulin shock) -

5. Evoprim Soft Cap. (Evening Primrose Oil)

Diabetic neuropathy, Atopic eczema, Breast pain

-

6. Lipo-A HR Tab. 600mg (Thioctic acid) Diabetic multiple neuropathy -

7. DicaMax 1000 Tab. (Calcium carbonate 1,250mg Cholecalciferol Concentrate Powder 1,000 IU)

Bone health -

8. DicaMax D Tab. (Calcium carbonate 250mg, Cholecalciferol Concentrate Powder 1,000 IU)

Bone health -

9. Premina Tab. 0.3mg /0.625mg (Conjugated equine estrogen)

Postmenopausal syndrome -

10. Norpin Inj. 4ml / 10ml / 20ml (Norepinephrine bitartrate)

Acute hypotension or shock Thailand



Fiscal Year 2012 2013 2014

Sales 21,870 26,850 32,566

R&D Expenditure 181 245 342

Capital 7,490 44,914 56,716

Financial Figures

DHP KOREA was created for the purpose of being an special company in the field of ophthalmic drugs. As the leading ophthalmic drugs company in Korea, DHP KOREA seeks to be a world-class that continuously tries to meet customer’s need by offering safe and stable drugs. Also, we make constantly effort to comfort demand of various customers, through ceaseless produce and offer more developed products.

Focus Area : Ophthalmic Drugs

Company Profile

DHP Korea Co., Ltd.RepresentativeHeadquarter Address

Foundation DateResearch Focus


Dae Hoon Yoeu

1106 starvalley, 99, Digital-ro 9-gil, Geumcheon-gu, Seoul, Korea

Aug. 30. 2005

Ophthalmic Drugs (Dry eye, Anti-glaucoma, Anti-allergy/inflammatory/infective, etc)

110

82-2-2027-0078

82-2-2027-0079

www.dhpkorea.co.kr


Jin-Sook Ko

82-43-230-0304

[email protected]

55


1. Tearinfree EYE DROPS (Sodium Hyaluronate 0.1%) Keratoconjuntival epithelial disorder with

symptoms following :1. Endogenous disease: Sjogren syndrome,

Dry eye syndrome.2. Enthetic disease: Drug-induced trauma

after operation, Enthetic disease due to wearing contact lenses.

N/A

·‌‌Preservative-free, 30 Single Dose Units per Box·6 mL Multi Dose Bottle

2. TearinS EYE DROPS (Sodium Hyaluronate 0.18%)

N/A·‌‌Preservative-free, 30

Single Dose Units per Box

3. TearinF EYE DROPS (Sodium Hyaluronate 0.3%)



4. Dr.Fresh EYE DROPS (Sodium Carboxymethylcellulose 0.5%)

·‌‌For the temporary relief of burning, irritation, and discomfort due to dryness of the eye or exposure to wind or sun. ·‌‌May be used as a protectant against

further irritation.



5. DryFree EYE DROPS (Cyclosporine 200ug)

·‌‌For the increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca.



6. Tearsopt Free EYE DROPS ( Dorzolamide HCl 22.26mg Timolol Maleate 6.83mg)

·Open angle glaucoma·‌‌For the reduction of elevated intraocular

pressure in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta-blocker.



7. Floson EYE DROPS (Fluorometholone 1mg)

·To treat eye inflammation N/A·‌‌Preservative-free, 10


8. Flotera EYE DROPS ( Fluorometholone 1mg, Tetrahydrozoline HCl 250ug)

·‌‌For the allergic, noninfectious conjunctivitis & keratitis, severe swelling & hyperaemia, noninfectious inflammation of the anterior segment of the eye (including anterior uveitis, episcleritis & scleritis) and post-operative conditions. ·‌‌Inflammation after operation

(glaucoma, cataract)



9. LevoFresh EYE DROPS (Levofloxacin 0.5%)

·‌‌To treat by helping to kill the bacteria which are causing the infection.

N/A ·6mL Multi Dose Bottle

10. SmileO2Tears EYE DROPS ( Sodium Chloride 5.5mg, Potassium Chloride 1.5mg)

·Tired Eyes·Dryness·Contact Lens Discomfort·Dimed Eyes

N/A

·‌‌Preservative-free, 30 Single Dose Units per Box·15 mL Multi Dose Bottle

Main Products

Code Use Stage of Development

DHPNP01 Dry Eye Plant scale process development

DHPNP02 Dry Eye Plant scale process development

DHPNP03 Glaucoma Lab-scale process development

DHPNP04 Glaucoma Formulation development

DHPNP05 Allergic conjunctivitis Formulation development

DHPNP06 Cataract Formulation development

R&D Pipeline



Fiscal Year 2008 2009 2010

Sales 39,976 60,842 77,515

R&D Expenditure 1,298 1,473 1,485

Capital 8,639 11,138 9,732

Financial Figures

Dong Koo Pharm. Co, Ltd. is a local pharmaceutical company leading Dermatology market in Korea. (Top sales company in Dermatology area)

We are a manufacturer and distributor in South Korea, located in Seoul.

We are equipped with factory under GMP guideline for oral solid forms including tablet, hard cap., soft cap., ointment and cream production lines.

Our sales turnovers recorded more than 70 Million USD in 2011. We have 110 MRs and especially we have a very strong sales/marketing power for Dermatology and Urology field. We have a lot of customers in Dermatology and Urology area such as hospitals, clinics, esthetics and so on.

Company Profile

Dong Koo Pharm. Co., Ltd.RepresentativeHeadquarter AddressFoundation DateResearch FocusTotal StaffRepresentative PhoneRepresentative Fax Web

Cho Yong-Joon

222, Gochuk-ro, Guro-gu, Seoul, Korea

May. 1970

Generics, Branded generics, NCE, Neutraceuticals

260

82-2-2688-9611

82-2-2681-1880

www.dongkoo.co.kr

57

Main Products


1. Dermotasone MLE cream/lotion (mometasone furoate 1mg/g)

dermatological agent

2. Allestine tablet(epinastine HCI 10mg) antihistamine agent

3. Sponex capsule(itraconazole 100mg) antifungal agent

4. Famclover tablet(famciclovir 250mg) antiviral agent

5. Cordicare lotion 2.5% (hydrocortisone 10mg/g)

dermatological agent

6. Boneaid tablet (alendronate Na 91.37mg (70mg as alendronate))

bone modulating agent hongkong

7. Alvista soft capsule (alverine citrate 60mg, Simethicone 300mg)

gastrointestinal agent hongkong

8. Dongkoo levofloxacin tablet 100mg (levofloxacin 100mg)

Chemotherapeutic agent hongkong

9. Urofa SR tablet 0.2mg (tamsulosin HCI 0.2mg)

urological agent

10. Zansi-Q tablet (ranitidine HCI 168mg (150mg as ranitidine))

gastrointestinal agent

R&D Pipeline


Alprostadil Erectile dysfunction Clinical trial

Herbal extract Atopic dermatitis Preclinical trial

Antifungal agent Mycosis Preclinical trial

Pollen extract combinationBenign

prostatic hyperplasiaPreclinical trial

Pollen extract FBenign

prostatic hyperplasiaPilot test

FlurbiprofenAnti-inflammatory

AnalgesicPilot test

Amlodipine, Valsartan Hypertension Formulation

IbuprofenAnti-inflammatory

AnalgesicPilot test

DexibuprofenAnti-inflammatory

AnalgesicPilot test

Saw palmettoBenign

prostatic hyperplasiaFormulation

Acetaminophen combination Antipyrectics Formulation


Dongkook Pharmaceutical was founded in 1962 and from the early stage since its foundation, Dongkook has concentrated on R&D and technology innovation.

We, Dongkook Pharmaceutical is well known for its OTC products boasting of high brand values in Korea.

Besides OTC products, Dongkook has developed and produced outstanding therapeutic products through various clinical trials, e.g. Pofol Injection, intravenous anesthetic agent, Pamiray, the contrast medium produced using independently synthesized API as the first attempt in Korea, and Lorelin Depot, an anti-cancer agent, earning raves in both domestic and overseas markets.

In 1999, Dongkook completed its registration in PMDA of Japan regarding approval for the finished product in relation to Pamiray; its API, Iopamidol acquired COS (Certificate of Suitability), and Teicoplanin acquired COS in 2009 from EDQM. Bellast Injection as cross-linked hyaluronic acid filler acquired ISO certificate and CE mark from EVPU, and launched in European market. Furthermore, Dongkook completed the GMP approval in Japan for Antibiotic agent, contrast media, anesthetic agent and so on, and also completed the GMP approval in TGA of Australia in 2010.

Currently, Dongkook Pharmaceutical exports finished pharmaceutical products and API to over 50 countries around the world. It seeks to grow into a global leading pharmaceutical company that is trusted and loved by all domestic and overseas customers backed by the greatest global competitiveness.

Focus Area : Nano-emulsions, Long-acting release, Contrast media, HA dermal filler, etc.

Company Profile

Dong Kook Pharm. Co., Ltd.RepresentativeHeadquarter Address



Hung Joo, Oh / Young Wook, Lee

7, Teheran-ro 108-gil, Gangnam-gu, Seoul, Korea

Jul. 14. 1962

Nano-emulsions, Long-acting release, Contrast media, HA dermal filler, etc.

658

82-2-2191-9800

82-2-2191-9869

www.dkpharm.co.kr


Eugene Jang

82-2-2191-9800

[email protected]

59


Fiscal Year 2012 2013 2014

Sales 191,571 210,830 222,770

R&D Expenditure 7,967 9,841 9,621

Capital 147,746 162,238 172,834

Financial Figures


1. Profofol Injection General Anaesthesia

Japan, Brazil, Uruguay, Russia, Georgia, Iran, UAE, Iraq, Philippines, Thailand, etc.

2. Leuprolide Acetate InjectionProstatic Cancer Endometriosis

Brazil, Mexico, Peru, Uruguay, India, Iran, Pakistan, Kazakhstan, etc.

3. Iopamidol InjectionX-ray contrast media CAT Scanning

Armenia, Georgia, Honduras, Myanmar, Peru, Philippines, Syria, Ukraine, Yemen, etc.

4. Gadopentetate Meglumine Injection

MRI contrast mediaArmenia, Georgia, Jordan, Nigeria, Syria, Ukraine, Vietnam, etc.

5. Octreotide LAR lnjectionAcromegaly Carcinoid Tumors

Chile, Mexico, Peru, etc.

6. Streptokinase Injection Thrombolytic agentDominica, Uruguay, Egypt, Syria, Vietnam, Yemen, etc.

7. Cross-linked Hyaluronic Acid Injection

Injectable implant for filling wrinkles and folds in skin

Poland, Hungary, Peru, Indonesia, Philippines, Syria Turkey, etc.

8. Iopamidol(API) X-ray contrast mediaAustria, Germany, Japan, Tunisia, Turkey, etc.

9. Gadopentetate Meglumine (API)

MRI contrast mediaJapan, Turkey, Tunisia, Iran

10. Teicoplanin(API) Antibiotics

Austrailia, Japan, Begium, Brazil, Greece, Turkey, Tunisia, Ukraine, etc.

Main Products



Fiscal Year 2012 2013 2014

Sales 223.372 220.241 213.472

R&D Expenditure 10,897 12,317 11,771

Capital 27,931 27,931 27,931

Financial Figures

Dong Wha Pharm, as Korea’s first and oldest pharmaceutical company, is pursuing the ultimate goal of pharmaceutical industry, which is the development of new drugs.

Whal Myung Su, Korea’s first western-style medicine, by integrating the advantages of Western medicine into the royal court’s secret recipe in 1897, the first year of The Great Korean Empire. Furthermore, many pharmaceutical products such as Fucidin ointment, Lacteol and Pancold A etc., have been developed after Dong-Wha Pharmaceutical Research Institute was founded in 1973. Since present state-of-the-art laboratory building was built in 2010, it is now set to become a global hub for new drug development. The Chungju Industrial Complex (established in 2009) is equipped with equipment and facilities that satisfy Current Good Manufacturing Practice (cGMP) Regulations of US FDA In addition, the plant has been evaluated as a world-class pharmaceutical company by the installment of high-tech plant automation system. Utilizing multi-component resources, Dong Wha strategizes to develop numerous superior medicines, the most advanced drugs and new pharmaceutical products.

Focus Area : Diabetic nephropathy, allergic rhinitis, Anti-infectives, etc

Company Profile

Dong Wha Pharm. Ind. Co., Ltd.RepresentativeHeadquarter Address


Doh Joon Yoon

19F, STX Namsan Tower, 98, Huam-ro, Jung-gu, Seoul, Korea

Sep. 25. 1897

NCE (New Chemical Entity)

719

82-2-2021-9300

82-2-776-7873

www.dong-wha.co.kr


Yoon Kyung Kim

82-2-2021-9341

[email protected]

61


1. Gas Whal Myung Su-Q (Herbal extracts, Solution)

Indigestion, Nausea and vomitting,Abdnominal digesion, Anorexia

US OTC

2. Pancold (Acetaminophen etc, Solution)

Symptoms of cold(runny/ blocked nose, sneezing, cough, sputum, fever, shivering, headache, muscle ache, joint pain

US OTC

3. Each (myrrh, chamomile, ratanhia,

Paste)

Gingivitis, symptoms of pyorrhea alveolaris(gingival flare/swelling/bleeding/pus)

- OTC

Main Products

Product (Ingredient) Use Approval Date / Country

Zabofloxacin Acute exacerbation of COPD 2015. 3. 20. / Korea



Zabofloxacin DW224

Acute exacerbation of COPD,

Community Acquired Pneumonia

Phase III completed(KFDA APPROVAL)

(FDA PHASE III IND)

DW-1029M DW-1029M Diabetic nephropathy Phase II

DW-2006 DW-2006 allergic rhinitis phase II

R&D Pipeline


Summary (1 Billion Won)

Fiscal Year 2012 2013 2014

Sales 594.6 568.1

R&D Expenditure 525 627

Capital 925.7 1,077.9

Financial Figures

Dong-A ST focuses on drugs, such as domestically developed new drugs like Stillen, Zydena, and Motilitone, medical devices, diagnosis, and overseas businesses.

With its optimized research infrastructures such as its world-class, sophisticated research center completed in 2011, as well as its excellent researchers, Dong-A ST is furthering its efforts to develop global new drugs. Also, with the backing of these infrastructures, Dong-A ST vows to positively explore overseas markets, to expand its overseas exports, and to establish itself as a global pharmaceutical company, operating beyond the domestic market.

Focus Area : Manufacture of ETC drug, overseas business, medical equipments and diagnostics

Company Profile

Dong-A STRepresentativeHeadquarter AddressFoundation DateResearch FocusTotal StaffRepresentative PhoneRepresentative Fax Web

Chan-il Park

64 Cheonhodaero, Dongdaemun-gu, Seoul, Korea

Mar. 2013

New drugs

1,582(R&D Personnel : 212)

82-2-920-8114

82-2-926-9400

www.donga-st.com


Geunsung Kim

82-2-920-8366

[email protected]


1. GrowtropinⅡ®inj / AQ / cartridge (somatropin/injection)

Human growth hormone

Brazil, Iran, Peru, Colombia, Mexico

Bio-pharmaceutical

2. Eporon®inj. / PFS (erythropoietin/injection)

Renal anemia treatment

Turkey, Thailand, Chile, vietnam, Pakistan

Bio-pharmaceutical

3. AtorvastatinHyperlipidemia

treatmentJapan APIs

Main Products

63


Zydena(Udenafil) Erectile Dysfunction Dec. 2005/Korea

Sivextro(Tedizolid) Infection: ABSSSI Jun. 2014/USA / Apr. 2015/Korea


Ingredient Code Use Stage of Development

Udenafil DA-8159 Erectile DysfunctionLaunched(Korea),

Ready to NDA(USA)

Udenafil DA-8159 Benign Prostatic Hyperplasia PhⅡcompleted(USA)

Udenafil DA-8159Pulmonary Arterial

HypertensionPhⅡ(Korea)

Tedizolid DA-7218 Infection: ABSSSILaunched(USA), NDA

approved (EU)

Tedizolid DA-7218 Pneumonia: HA/VAP Ph III(Global)

Evogliptin DA-1229 Type2 diabetes NDA submitted(Korea)

5-Hydroxytryptamine4 agonist DA-6886Irritable Bowel Syndrome-

ConstipationPh I completed(Korea)

M3 receptor antagonist DA-8010 Overactive bladder Non-clinical(Korea)

SARM (selective androgen receptor modulators)

DA-4210 Sarcopenia Non-clinical(Korea)

GPR119 agonist DA-1241 Type 2 diabetes Non-clinical(Korea)

Herbal extract DA-9701 Functional dyspepsiaLaunched(Korea), PhⅡ

planned(USA)

Herbal extract DA-9801 Diabetic neuropathyPhⅡcompleted(Korea), PhⅡcompleted(USA)

Herbal extract DA-9803 Alzheimer's disease Non-clinical(Korea)

Herbal extract DA-9805 Parkinson's disease Non-clinical(Korea)

Recombinant Follicle Stimulating Hormone DA-3801Controlled Ovarian Hyper-

stimulation in Assisted Reproductive Technology

Launched(Korea)

Recombinant Follicle Stimulating Hormone DA-3801Ovulation induction in

anovulatory womenNDA submitted(Korea)

R&D Pipeline

4. CycloserineTuberculosis

treatmentIndia APIs

5. TerizidoneTuberculosis

treatmentSouth Africa APIs

6. Closerin® (Cycloserine/Capsule)Tuberculosis

treatmentEurope Ethical drug

7. Zydena® (Udenafil/Tablet)Erectile

DysfunctionBrazil, Turkey, Russia,

Malaysia, IndiaNCE

8. Monotaxel®inj. (Docetaxel anhydrous/Injection)

Anti-Malignant tumor Drug

EU approval Ethical drug

9. Bacchus® (Taurine, Royal Jelly and others/Drink)

Energy Drink Cambodia



Fiscal Year 2008 2009 2010

Sales 62,231 68,724 71,926

R&D Expenditure 1,133 1,265 1,337

Capital 124,570 128,167 127,808

Financial Figures

Since its founding in 1957, Dong Sung has advanced technologically, while at the same time developing the highest quality products and strengthening its position as one of Korean leading pharmaceutical companies.

We continuously Produce and develop the variety products such as Hair Care Products > Pharmaceutical Products (ETC, OTC), > Cosmetics, > Health Food and Beverage.

Currently, we possess Korean largest production facilities, hold 40 percent of the domestic hair dye market and are renowned for the safety, efficacy and quality of our pharmaceutical products.

Our success reflects the exceptional teamwork and commitment of the Dong Sung team to delivering the highest quality service to you, our customers. It also reflects your belief and support in Dong Sung.

Company Profile

Dongsung Pharm. Co., Ltd.RepresentativeHeadquarter AddressFoundation DateResearch FocusTotal StaffRepresentative PhoneRepresentative Fax Web

Lee Yang-Gu

683, Dobong-ro, Dobong-gu, Seoul, Korea

Nov. 25. 1957

OTC

306

82-2-6911-3600

82-505-191-6908

www.dongsung-pharm.co.kr

65

Main Products


1. Dong Sung Cheong Ro Hwan (In 1 pill Creosote 44.4mg, Cyperus rhizome powdered 16.6mg, Coptidis rhizoma powder 22.2mg, Glycyrrhiza powder 22.2mg, Citrus unshii pericarpium 22.2mg)

Dyspepsia, watery stool , vomiting and diarrhea

U.S.A

2. Dong Sung Cheong Ro Hwan (Sugar Coated Tablet) (In 1 tab. Creosote 22.5mg, Pulvis phellondendri corticis 33.75mg, Pulvis geranil herbae 25mg)

Dyspepsia, watery stool , vomiting and diarrhea

U.S.A

3. Teethrol (In 1 tab. Zea mays L. extract 35mg,)

Parodontopathy, Gingivitis, Parodontosis U.S.A

4. Teethran (In 1 cap. Tocopherol acetate 50% 10mg, Carbazochrome 2.0mg, Lysozyme chloride 30.0mg, Ascorbic acid coated 96% Type SC 156.3mg)

periodontal disease, pyorrhea alveolaris(erythema, swelling, hemorrhage, pus etc.)

U.S.A

5. Livermarine (In 1 cap. Carduus marianus L. seeds extract 200mg, Calcium pantothenate 8mg, Cyanocobalamin 1.2㎍ Nicotinamide 12mg, Pyridoxine hydrochloride 4mg, Thiamine nitrate 4mg)

chronic liver disease, fatty liver, liver cirrhosis, toxic liver disease

U.S.A

6. EMg, (In 1 cap. Tocopherol acetate 500mg, Magnesium oxide 250mg)

Improvement of muscle spasm that runs out of magnesium

U.S.A / Cambodia

7. GinKolin (In 1 cap. Ginko leaf extract 120mg)

Organic brain dysfunction accompanying athymia symptoms such as tinnitus, headache, memory impairment, attention impairment, depression, vertigo

U.S.A

8. You Green F (In 1g Urea 250mg)

keratodermia tylodes palmaris progressive (housewife`s eczema), keratodermia , ichthyosis, senile xeroderma, lichen pilaris, atopic dermatitis

U.S.A

9. Syan (In 1 Cap. Retinol palmitate 2mg, Ergocalciferol 200IU Copper Chlorophyll 0.3mg, Snake oil 296.7mg)

Construction feeling of eye, Bone defectiveness, Night blindness, Rickets prevention, Vitamin A and D supplies

U.S.A / Cambodia

10. Vaso-Q (In 1 cap. Crataegus oxyacantha fruit dried extract 50mg, Garlic oil 150mg, Ginkgo Biloba Leaf Extract 5mg, Melissa leaf extract 10mg)

Problems with the circulation of the blood : decreasing of memory, enervation, and concentration becomes worse, dizziness, chronicity tiredness

U.S.A



Fiscal Year 2012 2013 2014

Sales 5,107 4,756 6,591


Capital 1,000 1,000 1,000

Financial Figures

Elyson Pharm. was founded in 2011, on a foundation of improving quality of human life and the breakthrough research & development of novel products in mind.

Company Profile

Elyson Pharmaceutical Co. Ltd.RepresentativeHeadquarter Address


Eul Won Dhong

2F, Kyungpoong B/D, 788-26, Yeoksam 2-dong, Gangnam-gu, Seoul, Korea

Oct. 2011

Cardiovascular disease

27

82-31-8059-4706

82-31-8059-4708

www.elyson.co.kr


Min Jung Kwon

82-2-6342-7001

[email protected]

67

Main Products


1. NiferonCR 40mg (Nifedipine) Hypertension

2. Molsiton 2mg / 4mg (Molsidomine) Anti-anginal Drug

3. Oxiklorin 100mg / 200mg (Hydroxychloroquine sulfate)

Rheumatoid arthritis, Malaria and malaria prophylaxis

4. Conbloc 1.25mg/2.5mg/5mg (Bisoprolol fumarate)

Hypertension, angina, Treatment of stable chronic heart failure with reduced systolic left ventricular function

5. Nebistol 2.5mg/5mg (Nebivolol hydrochloride)

Essential Hypertension, Chronic heart failure



Fiscal Year 2012 2013 2014

Sales 715,597 793,754 854,258

R&D Expenditure 69,209 71,065 74,160

Capital 50,655 58,433 58,433

Financial Figures

Green Cross is a leading Pharmaceutical company in the biotechnology industry in Korea. Starting from the nation’s first production and sales of Plasma Fractions in 1970, which required sophisticated technology, Green Cross has striven to develop ethical drugs that are hard to produce but essential to patients. Subsequently, it is now an internationally recognized biotechnology company in blood derivative products, vaccines, and recombinant products.

• 1974-Started manufacturing the AHF, an antihemophilic factor

• 1983-Succeeded in developing the world’s third Hepatitis B vaccine

• 1988-Succeeded in developing the world’s first vaccine against the epidemic hemorrhagic fever (Hantavax)

• 2010-Launched Recombinant Factor VIII for Hemophilia A (Green Gene F)

• 2011-The influenza vaccine GC FLU became the fourth in the world to obtain Pre-Qualification approval from the WHO

• 2012-Developed Hunterase (the world’s second treatment of Hunter syndrome).

• 2013-contract with the Thai Red Cross for plasma fractionation plant project (Construction and Tech-transfer).

• 2015-Launched Neulapeg (PEG-GCSF)

Company Profile

Greencross CorporationRepresentativeHeadquarter Address


Eun-Chul Huh

107, Ihyeon-ro 30 beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do, Korea

1967

Biological Products

about 1,700

82-31-260-9300

82-31-260-9413

www.greencross.com

69

Main Products


1. Human Albumin SolutionFor general use in conditions which require plasma or serum

Asia, Middle-East, South/Central America

2. Human Intravenous Immunoglobulin

a-/hypo-gammaglobulinemina, bacterial or vial infections, idiopathic thrombocytopenic purpura, guillain barre syndrome, Kawasaki Syndrome


3. Human Hepatitis B Immunoglobulin

- For prophylaxis of hepatitis B after exposure to HBsAg- For prophylaxis of hepatitis B in neonates


4. Human Tetanus Immunoglobulin

To provide passive immunization against infection caused by clostridium tetani


5. Varicella Zoster Immunoglobulin

Passive immunity to varicella zoster virus for post-exposure prophylaxis of immunodeficiency children


6. Human Blood Coagulation Factor VIII

For the treatment of hemophilia AAsia, Middle-East, South/Central America

7. Recombinant Coagulation Factor VIII

For the prevention and control of bleeding episodes and preoperative management in hemophila A


8. Split Virion Inactivated Influenza Vaccine

For the prophylaxis against InfluenzaAsia, Middle-East, South/Central America

9. Live Attenuated Varicella Vaccine

For the prophylaxis against varicellaAsia, Middle-East, South/Central America

10. Idursulfase betaFor treatment (Enzyme Replacement Therapy) of Hunter Syndrome (Mucopolysaccharidosis II)

Asia, Middle-East etc.

11. PEG-GCSF For treatment of Neutropenia during cancer chemotherapy

Asia, Middle-East, South/Central America (under registration)

12. Shinbaro (Dried Extract Herbal Medicine)

For treatment of Osteoarthritis Asia (under registration)

R&D Pipeline

Ingredient type Use Stage of Development

GC 3110A (Quadrivalent flu vaccine)

vaccine Seasonal Influenza Clinical Phase III

MG 1109 (AI) vaccine Pre-Pandemic Flu Clinical Phase III

GC1107 vaccine Tetanus, Diphtheria Clinical Phase III

GC1109 vaccine Anthrax Clinical Phase II

GC3111A (TdaP) vaccine Tetanus, Diphtheria, Pertussis

Pre-Clinical

MG1111 vaccine Varicella Clinical Phase I

GC3106A (Cell culture) vaccine Seasonal Influenza Clinical Phase I

GC1102Hepatitis B

immunoglobulinChronic HBV infection after liver transplantation

Clinical Phase II

MG4101 Allogenic NK cell Cancer Clinical Phase I

GC1118A EGFR target Anti cancer Colon Cancer Clinical Phase I

MGAH22Fc-optimized

monoclonal antibodyBreast Cancer Clinical Phase II

GC6101A Natural Herbal Drug Gastritis Clinical Phase II

GC2107 Factor Xa inhibitor Anti-thrombotics Clinical Phase I



Fiscal Year 2012 2013 2014

Sales 56,592 59,253 57,137

R&D Expenditure 1,795 1,856 2,091

Capital 13,189 14,788 15,960

Financial Figures

GUJU PHARM. CO. LTD. is a specialized pharmaceutical manufacturer considering human life the most important value in the world.

Focus Area : Chronic metabolic disease

Company Profile

Guju Pharm. Co., Ltd.RepresentativeHeadquarter Address


Kim Woo Tae

River Tower officetel 12F, 50, Beodeunaru-ro, Yeongdeungpo-gu, Seoul, Korea

Dec. 23. 1974

Final Product (Medicine)

270

82-2-2672-1122

82-2-2679-7569

www.gujup.co.kr


Jeoung Seob Kim

82-2-2672-1122, Ext. 400

[email protected]

71

Main Products


1. Clif cap.(Cefaclor) Antibiotics

2. Atorix Tab. (Atorvastatin Calcium hydrate)

Treatment for Hyperlipidemia

3. Unazol cap.(Fluconazole) Antifungal agents

4. Bronkid syrup.(Hederae Helix Fluid) Expectorants

5. Rabiem Tab. (Rabeprazole Sodium) Proton pump inhibitor

6. Neocatin tab.(Acetyl Carnitine HCl) Cholinergic drugs

7. Neotidine tab.150mg(Ranitidine HCl) H2-blocker

8. Anicid cap.(Omeprazol) Proton pump inhibitor

9. Talimed Tab.(Talniflumate) NSAID

10. Diacerhein Cap.(Diacerhein)Treatment of Osteoarthritis



Fiscal Year 2008 2009 2010

Sales 91,900 98,700 106,900

R&D Expenditure 10,831 10,928 10,651

Capital 18,500 18,500 18,500

Financial Figures

HanAll is a top 20 Korean-based R&D pharmaceutical company established in 1973. Our company initially started R&D with the development of over 30 different combinations of cardiology products through its innovative and proprietary XC Hybrid Combination formulation technology. With the acquisition of Nautilus Biotech and strengthened bio-therapeutics pipeline, we are currently developing engineered protein therapeutics via amino acid replacement engineering and mAb fragment via domain engineering which will provide superior PK/PD profile. We also focus on the treating autoimmune disease with bio-therapeutics.

Not only do we focus on bio-therapeutics, but also strive to develop new chemical entities for the treatment of cancer due to high global needs. It is important to provide effective and safe anti-neoplastic agents with minimized adverse drug events which can significantly increase patient’s quality of life. Recently, preclinical and clinical data are emerging for a beneficial effect of Metformin which may affect cancer cell’s proliferation and apoptosis. Hence, we are presently developing new chemical entity of biguanide derivatives as an effective and safe anti-neoplastic agent.

Company Profile

Hanall Bio Pharm. Co., Ltd.RepresentativeHeadquarter Address



Sung-Wuk Kim

Daewoong B/D 9F, 12 Bongeunsa-ro 114-gil, Gangnam-gu, Seoul, Korea

Nov. 20. 1973.

Bio-therapeutics(Biobetter & antibodies), CV Combinations, AMPK activator, Anti-Atopic dermatitis.

446

82-2-2204-1753

82-2-414-8046

www.hanall.co.kr

73

Main Products


1. Reposporen inj.(Cefazedone) Antibiotics

2. Tomiporan inj.(Cefbuperazone Sod.) Antibiotics

3. Normix tab.(Rifaximin) Antibiotics

4. Hanall Glimepiride tab.(Glimepiride) Antidiabetes Vietnam

5. Glucodown OR tab.(Metformin HCl) Antidiabetes

6. Hanall tramadol inj.(tramadol HCl) NSAIDS

7. Levod tab.(Levosulpiride) Prokinetic agent

8. Hanall Fluconazole cap.(fluconazole) anti-fungal drug

9. Lenvard tab.(Rebamipide) antiulcer agent

10. Hanall finasteride tab. 5mg(Finasteride) 5alpha-reductase inhibitor Vietnam, Philippines



Spelear(Fudostein) antitussive agent 2005-01-19

R&D Pipeline


HL009(Adenosylcobalmin) Atopic dermatitisKOR Phase II completed

US Phase II IND approved

HL008(amlodipine, losartan) HypertensionKOR Phase I completed

US IND preparation

HL040(losartan, atorvastatin) Hypertension, HyperlipidemiaKOR Phase III preparation

US IND preparation

HL156(Biguanide derivative NCE) Anti-cancer Lead optimization

HL032(oral hGH) Growth hormone deficiency KOR Phase I ongoing

HL143(sc IFN) Hepatitis C US Phase I ongoing

HL036(anti TNF-alpha) Rheumatoid arthritis Lead optimization

HL161(FcRn) Autoimmune disease Lead optimization



Fiscal Year 2012 2013 2014

Sales 314,648 327,936 348,311

R&D Expenditure 17,600 19,100 17,859

Capital 5,800 5,800 6,297

Financial Figures

HANDOK, a leading innovation-driven pharmaceutical/health-care company in Korea, develops, manufactures and distributes healthcare solutions to improve the health and quality of human life. Handok has a core business focus in diabetes, cardiovascular, muscular skeletal, psychoneurotic disease, human vaccines, medical devices, diagnostics and consumer health. Handok, founded in 1954, grew as a joint venture with Hoechst/Aventis/Sanofi from 1964 to 2012. Handok has also established strategic collaborations in several areas with multiple multinational pharmaceutical companies.

Focus Area : diabetes, cardiovascular, muscular skeletal, psychoneurotic disease, human vaccines, medical devices, diagnostics and consumer health

Company Profile

Handok Inc.RepresentativeHeadquarter Address



Young-Jin Kim

132, Teheran Street, Gangnam-Gu, Seoul, Korea

Apr 27. 1954

Diabetes & Metabolic disorders, Oncology, Eye disorders, Quality of life products, Orphan disease

896

82-2-527-5114

82-2-527-5001

www.handok.co.kr


So-Hyun Kwon

82-2-527-5316

[email protected]

75

Main Products


Amaryl M (Glimepiride+Metformin/Tablet)

Anti-diabetic drug

14 countries (Taiwan, Indonesia, Philippines, Hungary, Russia, Dubai, South Africa etc.)

The first fixed dose combination of glimepiride and metformin HCl in Korea

Amaryl Mex (Glimepiride+Metformin/Sustanined – release Tablet)

Anti-diabetic drug

6 countries (Singapore, Hungary, Croissy, Philippines, Kazakhstan etc.)

applied by DRM technology (Dual Release Micro-coating Technology)

Ketotop (Ketoprofen/plaster)Arthritis and muscle pain

4 countries (Singapore, Malaysia, Vietnam etc.)

No.1 plaster in Korea

R&D Pipeline


HL5201 DiabetesPreclinical

development

HL5945 Alopecia discovery

HL5128 Orphan discovery

HL5226 Cancer discovery

HL3501 Glaucoma discovery

HL5171 Cancer discovery

HL3715 Diabetes discovery

HL2351Auto-inflammatory

disordersPhase I

HL2356Growth Hormone

DeficiencyPhase II

HL2353 Factor VII Discovery

HL1513 Diabetes NDA



Fiscal Year 2008 2009 2010

Sales 20,384 21,687

R&D Expenditure 646

Capital 2,100

Financial Figures

We have a lot of specialized technologies in the natural medicine field, such as Korean traditional medicines. Since our modern Korean traditional medicines, resulting in many accomplishments in the biotechnology sector. Those accomplishments includes development of anticancer substances as well. In 1984, we produced and supplied successfully Korean traditional medicine solutions(i.e., Galgeuntang, Sipjeondaebotang, Sosihotang etc.) to the market. In 1992, we saw another success for development of the anticancer substance having a brand of MESIMA.

Company Profile

Hankooksinyak Pharm. Co., Ltd.RepresentativeHeadquarter Address


Sang Wook Han

805-15 Jungsan-ri, Yangchon-myeon, Nonsan-si, Chungcheongnam-do, Korea

Feb. 27. 1961

Korean traditional herbal medicine

260

82-41-740-8900

82-41-740-8849

www.hsp.co.kr

77

Main Products


1. Chunsim heart disease, hypotension, etc. -

2. Keopoongshibodan stroke -

3. Woohwangchongshim-won stroke, atherosclerosis, hypertension, etc. Japan

4. Mankyungdan stroke, sciatica, etc -

5. Mesima gastrointestinal cancer Japan

6. Yukmihwan urinary difficulty -

7. Ickbodan fortifying, kidney-essence -

8. Shinbanwan diabetes -

9. Oakbihwan constipation -

10. Chongwidan stomach catarrh, indigestion -



MESIMA Immuno-stimulating drug 1990.2.28

R&D Pipeline


Korean medicine GST anti-atopic dermatitis Evaluation of GST



Fiscal Year 2012 2013 2014

Sales 99,567 116,792 130,347

R&D Expenditure 8,655 10,312 11,327

Capital 7,700 9,255 9,255

Financial Figures

With the corporate mission of protecting the precious human life from various forms of diseases, Hanlim has consistently endeavored to improve the health standards of people over 30 years, and with your warm encouragements we have grown to become one of the leading companies in the ethical drug market in Korea.

In 1993, the future-oriented GMP factory was completed together with the founding of the Central Research Center. As a part of the long-term investment scheme of the company, we continue to make a great investment in accumulating advanced technologies and securing outstanding research team to perfectly assist the development of new drugs.

Hanlim will do our best in the future to enhance the health of mankind as a leading pharmaceutical company.

Lastly, we would like to express our sincere appreciation to the people of every fields, including doctors and pharmacists who have encouraged us to come this far.

Focus Area : Alimentary Drugs, Cardiovascular Related Agents, Antianemics, Restoratives, Hemostatics, Allergy&ENT Disease Related Agents, Endocrine&Metabolism related agents, Ophthalmologic drugs, Antineoplastics&Adjuvants, Psychoneural Drugs, Corticosteroids.

Company Profile

Hanlim Pharm. Co., Ltd.RepresentativeHeadquarter Address


Jae-Yoon Kim

42, Seocho-daero 52-gil, Seocho-gu, Seoul, Korea

Sep. 1974

350

82-2-3489-6000

82-2-3489-6101

www.hanlim.com


Sung-dae Kim

82-2-3489-6127

[email protected]

79

Main Products


1. Dages Cap (Pepsine, Papain, Diastase, Cellulase, Pancreatin, Pancrelipase, UDCA)

Alimentary Drugs China

2. Heparin Inj. (Heparin Sodium)Hemostatics, Anticoagulants

and related agentsVietnam,

Singapore

3. Easy-DROP Eye drops (Hydroxypropylmethylcellulose, Glycerin, Polyethyleneglycol400)

Ophthalmologic DrugsUSA, Cambodia,

Nigeria

4. NUMAREN EYE DROPS (Hydropropylmethyl cellulose, Dextran 70)

Ophthalmologic Drugs

USA, Myanmar, Cambodia, Hongkong,

Vietnam, Mongol

5. POSOD EYE DROPS (Potassium Iodide, Sodium Iodide)

Artificial eye drops Vietnam, Hong

Kong, Singapore, Nigeria

6. QUINOVID Ophthalmic ointment (Ofloxacin)

Ophthalmologic Drugs Vietnam

7. QUINOVID Ear drops (Ofloxacin) Ophthalmologic Drugs Vietnam

8. DESONA Nasal spray (Budesonide)

Allergy&ENT Disease Related agent

Cambodia, Vietnam, Mongol,

Cambodia, Guatemala

9. PEPTAZOLE Inj. (Pantoprazole Sod. sesquihydrate)

Alimentary Drugs Vietnam

10. PROTAMINE SULFATE Inj. (Protamine Sulfate)

Hemostatics, Anticoagulants and related agents

Iran, Mongol

R&D Pipeline


HL-PIF mixed hyperlipidemia phase III

HL301 Bronchitis phase II

HL-SAS hypertension phase I

HL-CER osteoarthritis phase I

HL-217 AMD phase I

HL-HAS dry mouth IND

HL-BRO allergy IND


Summary (1 Billion Won)

Fiscal Year 2012 2013 2014

Sales 674 730 761


Capital 20 21 24

Financial Figures

Hanmi Pharmaceuticals is a Korea-based global pharmaceutical company focused on the development and commercialization of new pharmaceutical products.

Focus Area : Biologics , Anti-Cancer Drug

Company Profile

Hanmi Pharm. Co., Ltd.Lee Gwan Sun

14, Wiryeseong-daero, Songpa-gu, Seoul, Korea

1973

Biologics / NCEs

1,824

82-2-410-9114

82-2-410-9259

www.hanmipharm.com


81

Main Products


1. Amosartan(Amlodipine + Losartan / Tablet)

Hypertension

Southeast Asia, MSD(Russia, Mexico, Vietnam, Colombia, Costa Rica, Dominican Republic, El Salvador, Guatemala, Honduras, Malaysia, Panama, Philippine, Ecuador)

2. Esomezol (Esomeprazole / Capsule)

GERD US

3. Ceftriaxone (FDF) (Ceftriaxone / injectable)

AntibioticsEurope, Middle east, Nigeria, Singapole

4. Fontiam (Cefotiam / injectable)

Antibiotics China

5. Ceftriaxone (API) AntibioticsEurope, Middle east, Mexico, Pakistan

6.Cefotaxime (API) AntibioticsEurope, Middle east, Turkey, Mexico

7.Ceftazidime (API) AntibioticsEurope, Middle east, Mexico

8.Ceftizoxime (API) Antibiotics Japan

9.Cefixime (API) Antibiotics Europe, Japan

10.Cefpodoxime (API) Antibiotics Europe, Japan

R&D Pipeline


LAPS Exendin 4 HM11260C Diabetes Phase II

LAPS GCSF HM10460A Neutropenia Phase II

LAPS hGH HM10560A Growth hormone Phase II

LAPS Insulin 115 HM12470 Diabetes Phase I

LAPS GLP/GCG HM12525A Diabetes Phase I

LAPS Combo Combination Diabetes Pre clinical

Poziotinib(Pan her) HM 781 36B Lung cancer Phase II

Oraxol Gastic cancer Phase II

EMSI HM61713 Lung cancer Phase II

Luminate ALG-1001 Retina disease Phase II

BTK inhibitor HM71224 RA Phase I

RAF Inhibitor HM95573 Solid tumor Phase I

KX2-391 Solid tumor Phase I

Oratecan Solid tumor Phase I



Fiscal Year 2012 2013 2014

Sales 45,317 46,038 47,500


Capital 3,436 3,436 3,436

Financial Figures

Han Wha Pharma (HWP) is a pharmaceutical company based in Seoul, Korea. HWP is well established in manufacture, distribution, marketing/sales and export of pharmaceutical products. HWP is recognized to doctors and pharmacists as a specialized company that has ethical products in certain therapeutic areas such as alimentary, cardiovascular, genito-urinary, neuro-muscular, and respiratory system. Aiming to become a global enterprise, HWP has introduced global marketing techniques through an organic partnership with several overseas companies. As a result, HWP has continued making record growth in sales by successfully launching new products in the domestic market to meet customer needs based on market research. In sales activities, HWP has grown into a most trusted company among customers by successfully supplying high-quality and superior medicines to hospitals and clinics. HWP has expanded its business area to dietary supplements. HWP family consists of NaturaLife, a subsidiary focused on nutrition supplements, NaturaLife Asia, a subsidiary focused on Asia business, and Weider Asia, a subsidiary focused on sports nutrition business in Asia.

Focus Area : Gastro-intestinal system, Respiratory system, Central nervous system etc.

Company Profile

Hanwha Pharma. Co., Ltd.RepresentativeHeadquarter AddressFoundation DateResearch FocusTotal StaffRepresentative PhoneRepresentative Fax Web

Kyoungrak Kim

76 Hwarang-ro 32-gil, Sungbuk-gu, Seoul, Korea

Jul. 4. 1976

Respiratory diseases etc.

300

82-2-959-3161

82-2-959-3621

www.hwpharm.com


Jong Hoon Kim

82-2-959-3161

[email protected]

83

Main Products


1. Antibio Probiotics Vietnam

2. Ramnos Probiotics Malaysia

3. Muteran Mucolytics -

4. Wingli-M Anti-diabetics -

5. Winexge Anti-hypertension -

6. Telmiam Anti-hypertension -

R&D Pipeline


YJP-14 Cardiovascular agent Phase II

YJP-40 Respiratory agent Phase III

YJC-10592 Anti-atopic dermatitis Preclinical

YJC-50018 Anti-rheumatoid arthritis Preclinical



Fiscal Year 2012 2013 2014

Sales 6,190,651 5,865,021 5,320,896

R&D Expenditure 78,894 35,727 49,028

Capital 5,777,685 5,254,988 5,915,659

Financial Figures

Hawon believes that “To contribute to the health and happiness of people through developing good medicines”. We will keep the level of global standards of competition and place high priority on R&D for devised out new products and raw materials of new brand.

Focus Area : Antibiotic Drug etc

Company Profile

Hawon Pharm. Co.RepresentativeHeadquarter Address


Dae-ho Kooh

2~4F, Time B/D 312 Nonhyun-ro, Gangnam-gu, Seoul, Korea

May. 4. 1981

Natural Medicine

158

82-70-8260-6030

82-2-554-4557

www.hawonpharm.co.kr


R&D Department

82-70-8260-6030(#3)

[email protected]

85

Main Products

Product (Ingredient) UseExporting Countries

Remarks

1. Fazidone Inj. 1g,2g (Cefazedone sodium 1g,2g)

- urinary tract infection, cholangitis, intrauterine infection, adnexitis

2. Hawon Ceftriaxone Inj. 1g,2g (Ceftriaxone Na 1g,2g)

- pneumonia, bronchitis and breathing device infection

- ear, nose and throat infection- nephritis and urinary tract infection- sepsis- bone and joint infection- skin, laceration and soft tissue

infection- peritonitis, cholecystitis, cholangitis- meningitis

Mongolia

3. Ciploxacin Inj. 200mg (Ciprofloxacin 2mg)

- Respiratory Infections- ENT infections, Oral, Teeth, jaw

infections - kidneys, urinary tract infection

4. Myal Inj. (Sodium hyaluronate/10mg)

- Osteoarthritis of the knee , shoulder treatment

5. Coxicam Cap. (Meloxicam 7.5mg)

- perceived exercise barrier- Symptomatic treatment of

rheumatoid arthritis- Symptomatic treatment of poker

back

Vietnam

6. Furoxetil Tab. (Cefuroxime axetil 300.72mg (cefuroxime axetil(as cefuroxime) 250mg ))

- upper airway infection : otitis media, tonsillitis, pharyngitis

- lower respiratory tract : acute bronchitis and chronic bronchitis, pneumonia

- urogenital system infection : nephropyelitis, cystitis, urethritis

7. Remist Tab. (Rebamipide 100mg)

- Ulcer- Gastric mucosal lesions in the

following diseases ( erosion , bleeding , redness, swelling) improvement of acute gastritis , acute exacerbation of chronic gastritis group

8. Fronan Cap. (Fluconazole 50mg)

- Acute or recurrent vaginal candidiasis

- Hand , nail fungus , athlete's foot ( foot ringworm ) , tinea corpus , wanseon ( groin ringworm ), Skin and skin fungal infections , including candida eorureogi

9. Lipitrol Tab. (Atorvastatin calcium 10.35mg)

- Reduced risk of myocardial infarction- Reduced risk of stroke- Vascular regeneration and reduce

the risk of chronic stable angina

10. Mosadin Tab. (Mosapride citrate 5.29mg)

- Functional due to poor digestion digestive symptoms ( heartburn , nausea, vomiting )



Fiscal Year 2012 2013 2014

Sales 11,704 23,544 29,200

R&D Expenditure 1,916 1,832 2,602

Capital 2,042 2,304 3,158

Financial Figures

We, humedix, have platform technology for application of biocompatible polymers just like hyaluronic acid and PEG.

And then, we are trying to research and develop the improvement of drugs with biocompatible polymers.

We’ve rapidly grown up recently due to our products developed with hyaluronic acid and have been listed in korean stock market(KOSDAQ),

Focus Area : application of biocompatible polymer as hyaluronic acid and PEG etc.

Company Profile

Humedix. Co., Ltd.RepresentativeHeadquarter Address


Bong-Yeol Chung

Unit 603 Mega Valley, 268, Hagui-ro, Dongan-gu, Anyang-si, Gyeonggi-do, Korea

2003

Biomaterials & Applications

79

82-70-7492-5618

82-31-421-5623

www.humedix.com


Jong Oh Lee

82-70-7492-5609

[email protected]

87

Main Products


1. Sodium Hyaluronate (Sodium Hyaluronate/Powder)

Remedies for Arthritis Worldwide -

2. High Hyal Plus Inj. (Sodium Hyaluronate/Injection)

Remedies for Arthritis Worldwide-

3. High Hyal Inj. (Sodium Hyaluronate/Injection)

Remedies for Arthritis Worldwide -

4. High Eye Inj. (Sodium Hyaluronate/Injection)

Ophthalmological surgical aids Worldwide -

R&D Pipeline


cross-linked hyaluronic acid improvement of osteoarthritis pre-clinical

conjugated Vit. D derivative whitenning pre-clinical

scFv macular degeneration pre-clinical



Fiscal Year 2012 2013 2014

Sales 122,059 131,050 156,508

R&D Expenditure 8,146 8,785 9,849

Capital 4,744 5,322 5,650

Financial Figures

Huons, started as Kwang Myung Pharm in 1965, has grown to a competent global company, producing original and effective essential medicine and medical products, through continual challenges and innovation over 50years.Huons is putting a ceaseless effort for human healthy life without disease.Our goal is to achieve 1billion USD in 2020 and aiming to be the TOP 10 global company at the industry in Korea.To prepare the future, Huons built new factory in 2009. Huons has constructed state-of-the art manufacturing facility in compliance with Korea, US and cGMP. Huons is increasing the investment on innovative research and development. Huons, having obtained many patents as the results of its research, is not becoming complacent and is working hard for development of new medicines, with the global pharmaceutical market entrance. Focus Area : - Manufacturing Pharmaceuticals (including Injections, Dental Anesthetics, Plastic Ampoules, Eye Drops)- Well-being Products- Medical Devices - CMO

Company Profile

Huons Co., LtdRepresentativeHeadquarter Address


Jae Kap, Jun

C-901 PangyoInoBelly, 621 Sampyeong-dong, Bundang-gu, Seongnam-si, Gyeonggi-do, Korea

Jul. 30. 1965

540

82-2-854-4700

82-2-6455-0740

www.huons.com


Taek Keun, Yoo

82-70-7492-5080

[email protected]

89

Main Products


1. Lidocaine and Adrenaline injection

Dental anesthetics20countries including Japan

2. Heparin sodium 25000unit Injection

Essential Hypertension Pakistan, Georgia, Mongolia, Vietnam

3. Norepinephrine bitartrate injection

Myocardial infarction, Shock by sepsis

Venesuela, Chile, Philippines

We have started to register it in KSA.

4. Sodium chloride injection

Flushing compatible intravenous tubing system and in dwellling intravascular access devices.

USA510K Approval in US FDA

5. Cyclosporin 0.05% eye- drop

Dry eye syndrome Iran, etc.

We have made distribution agreement for Iran and other conturies.



Clacier Eye drop (Cyclosporin 0.05%) Dry eye syndromeMarch, 2015 / Korea(Modified generic)

R&D Pipeline


HL-09 Magnoliae Cortex Ext. HU002 Fatty Liver Phase II

HSP23 Lonicera Japonica T. Ext. HU003 Sepsis Phase I

Cyclosporine combination HU007 Dry eye syndrome Pre-clinical

Honeybush HU018 Wrinkle reduction Pre-clinical

HU017(NCE) HU017 IBD Pre-clinical

Ultracet + Eperisone HU016 Analgesic Pre-clinical

Peptide HU015 Decubitus ulcer Phase I

Botulinum toxin type A HU014Temporary improvement of

glabellar linesPre-clinical

acid α-glucosidase HU023 Pompe disease Pre-clinical



Fiscal Year 2012 2013 2014

Sales 101,116 106,627 107,837

R&D Expenditure 8,083 8,368 8,243

Capital 14,000 14,000 14,000

Financial Figures

We, Hyundai Pharm. with corporate philosophy in “Contribute to public health promotion” which embodies humanistic philosophy in improving public health and quality of life and CEO’s philosophy focused in transparent enterprise spirit, implements organization’s vision and value and actively handle fast changing business are in order to have a new leap forward in 21st century.

Focus Area : Caridovascular, CNS, Oncology support, Women’s Health Care, Respiratory

Company Profile

Hyundai Pharm. Co., Ltd.RepresentativeHeadquarter Address



Han Koo Lee

Hyundaipharm Bldg, Bongeunsa St 135, Gangnam-Gu, Seoul, Korea

1965

Pharmaceutical products, Health food drinks, Medical equipment & device

Over 400

82-2-2600-3951

82-2-2693-7628

www.hyundaipharm.co.kr


Yuna Chae

82-2-2600-3883

[email protected]

91

Main Products


1. Surfolase Capsule (Acebrophylline 100mg)

Acute, chronic respiratory disease, acute, chronic bronchitis, bronchial asthma, paranasal sinustis, dried rhinitis

China IND submission

2. Minoxyl solution 5% (Minoxidil 5g/100mL )

Main pattern baldnessHong Kong, Vietnam, Cambodia, Myanmar

Preparation, Approval, Submission, Approval

3. Hyundai Moolpas-F Solution (Methyl salicylate, dl-camphor, etc)

Antiinflammatory analgesic, pernio

Hong Kong, USA, Mongolia

Approval, Registration, Approval

4. Bumooly-S Solution (Diphenhydramine HCl, Dibucaine HCl, etc)

Eczema, dermatitis, erosion, miliaria, rhus dermatitis, pruritus, pernio, insect bite, hives

USA Approval

5. Varosc Tablet (Amlodipine besylate 5mg)

Hypertension, coronary artery disease

Vietnam, Cambodia Approval, Approval

6. Olanpin Tablet (Olanzapine 5mg, 10mg)

Treatment of schizophrenia, bipolar disorder

Hong Kong, Macao Approval, Preparation

7. Mirtapin Tablet (Mirtazapine 15mg)

Treatment of episodes of major depression

Hong Kong, Macao Approval, Preparation

8. Mirap SR tablet (Pramipexole HCl)

Idiopathic parkinson's disease

Thailand Submission



Fiscal Year 2012 2013 2014

Sales 9,122 9,347 14,930

R&D Expenditure 309(3%) 372(4%) 305(2%)

Capital 10,111 12,930 14,997

Financial Figures

Icure Pharmaceutical Inc. is a privately held specialty drugs company with its HQ located in Seoul, R&D Center in Pyeongtack-si and KGMP approved manufacturing facility in Anseong-si in Korea. Icure’s business strategy is to develop innovative transdermal drug delivery systems for local, systemic and device aided delivery of drugs. Icure is developing the transdermal formulations that enhance therapeutic value of the drugs by reducing side effects, enhancing efficacy and promoting patient compliance.

The company has successfully developed and commercialized several pharmaceutical plasters and patches for the treatment dementia associated with Alzheimer’s Disease, rheumatic arthritis pain, nicotine replacement therapy.

These products have been licensed to several leading Korean Pharmaceutical firms for sales in Korea.

Focus Area : Central nervous system, Respiratory, Nicotine Replacement Therapy, Pain management, Skin care

Company Profile

Icure Pharm. Inc.RepresentativeHeadquarter AddressFoundation DateResearch FocusTotal StaffRepresentative PhoneRepresentative Fax Web

Young Kweon Choi

7, Saimdang-ro 1-gil, Seocho-gu, Seoul, Korea

May. 29. 2000

TDDS(Transdermal Drug Delivery System)

93

82-2-6959-6909 (Ext.232)

82-2-2-6959-8509

www.icure.co.kr


Tom Chung

82-70-5038-3399

[email protected]

[email protected]

93

Main Products


Rivaderm Patch(Rivastigmine)

Treatment of mild to moderate dementia

of the Alzheimer’s and Parkinson’s disease

Exoderm Patch (Nicotine)

Nicotine replacement therapy

NSAIDs Plaster(Ketoprofen/ Diclofenac Sodium, diethylammonium/ Flurbiprofen/ Indomethacin /Felbinac/ Loxoprofen)

Relief for Rheumatic arthritis pain

Russia, Hong Kong, Bolivia, India

Lidogesic Cataplasma(Lidocaine)

Local anesthetics

Tulobuterol Patch (Tulobuterol)

Treatment of bronchial asthma and chronic

obstructive pulmonary disease (COPD)

Teeth whitening strips(Hydrogen perxide)

Teeth whitening treatment

Taiwan, Finland

Cosmetics Patch and Facial mask

Anti wrinkles, Whitening, Moisturizing

Several countries

Skin care Product Anti wrinkles,

Whitening, Moisturizing

R&D Pipeline


Donepezil Patch Treatment of mild to moderate dementia

associated with Alzheimer`s disease and

Parkinson`s disease

Clinical study Phase I

Ropinirole Patch Formulation phase

Fentanyl PatchRelief for Severe cancer

painBE Study phase

Granisetron Patch Prevention for nausea

and vomiting caused by cancer chemotherapy



Fiscal Year 2008 2009 2010

Sales 6,020 7,416 8,359

R&D Expenditure - 31 47

Capital 3,900 4,700 4,700

Financial Figures

Based on our ideology ‘adding life’ for the people, IKSU keeps trying to be trustworthy

and reliable company respecting human beings. Since foundation in 1970 IKSU developed ‘Kohohwan’ for treatment of neuralgia & ar thritis and ‘Woohwangchungsimwon’ which is acknowledged as traditional miracle drug for life-saving. Recently IKSU has got preliminary GMP which is the first in herbal liquid preparation thereby having a chance to get more reliable and diverse products launched such as ‘Banhasasimtang liquid’.

Company Profile

Ik-Su Pharm. Co., Ltd.RepresentativeHeadquarter Address


Yong jin Jung

3F, Iksu B/D, 315, Gucheonmyeon-ro, Gangdong-gu, Seoul, Korea

Mar. 10. 1986

Herbal medicine

97

82-2-416-1115

82-2-426-1112

http://www.iksu.co.kr

95

Main Products


1. Yongpyo wonbang woohwang chungsimwon pill/liquid

Cerebral apoplexy (total paralysis, hemiplegia, speech defect, coma, lethargy condition, facial paralysis), hypertension, palpitation, anxiety neurosis, acute & chronic convulsion, autonomic imbalance, insensibility

2. Yongpyo woohwangchungsim won pill/liquid

Cerebral apoplexy (total paralysis, hemiplegia, speech defect, coma, lethargy condition, facial paralysis), hypertension, palpitation, anxiety neurosis, acute & chronic convulsion, autonomic imbalance, insensibility

3. Iksu banhasasimtang liquid

Following symptom of the person with stuffiness of epigastrium, nausea, anorexia, soft stools or diarrhea : acute&chronic gastric catarrh, fermental diarrhea, dyspepsia, gastric ptosis, gastraneuria, weak stomach, hangover, heartburn, stomatitis, nervousness

4. Cheers liquidMaldigestion, vomiturition, thirst, headache caused by heavy drinking

5. Iksu kalgeuntang liquidCommon cold, coryza, headache, pain of shoulder and hands

6. Yongpyo ansinhwan pill/liquidInsomnia, unrest, anxiety, thirst, palpitation, neurasthenia, shortness of breath, amnesia

7. Iksu kohohwan pill Neuralgia, arthralgia, myalgia

8. Iksu samsoeum liquid Headache, fever, cough caused by cold

9. Iksu chungkantang liquidFollowing symptom of the person with liver damage, being easily angry : nervousness, eye fatigue

10. Atomoms liquid Xeroderma : use when skin is dried and chapped



Fiscal Year 2012 2013 2014

Sales 346,030 378,247 401,330

R&D Expenditure 31,102 35,326 37,585

Capital 318,869 321,860 328,399

Financial Figures

Founded in 1941, ILDONG PHARMACEUTICAL CO., LTD has been contributing to healthier and happier lives of mankind for more than 70 years. We are developing innovative and outstanding products by utilizing all knowledge and know-how that we have piled up. We are mainly manufacturing anticancer, probiotics, HA and antibiotics in our state-of-the art plants.

Focus Area : Anti-cancer medicine, Antibiotics, Hyaluronic acid, Probiotics and Vitamins

Company Profile

Il Dong Pharm. Co., Ltd.RepresentativeHeadquarter AddressFoundation DateResearch FocusTotal StaffRepresentative PhoneRepresentative Fax Web

Jung-chi Lee

2, Baumoe-ro 27-gil, Seocho-gu, Seoul, Korea

Mar. 14. 1941

ETC, OTC, Neutrient food

1,449

82-2-526-3114

82-2-526-3030

www.ildong.com


Nathan Ahn

82-(0)2-526-3500

[email protected]

97

Main Products


1. Capecitabine Anti-cancer AsiaThe 1st approved product by MFDS

2. Imatinib Anti-cancer CIS -

3. Levofloxacin Quinolons Asia, Japan FDF / API

4. Hyaluronic acid Osteoarthritis Russia FDF / API

5. Aronamin series Vitamin B complex Asia -

6. Biovita Probiotics Asia, Latin- America, -

7. Sulbutiamine Vitamins Latin-America -

R&D Pipeline


Besifovir - hepatitis B Phase III

Product A ID1201 dementia Phase II

Product B IDP73152 refractory Infections Phase I

Product C IDF11774 antineoplastics Phase I

Product D IDV12002 viral infections Phase I

Product E IDX-1197 antineoplastics Preclinical

Product F GX-G6 diabetes Preclinical

Product G - antineoplastics Research

Product H - arthritis Research

Product I - diabetes Research

Product J - antineoplastics Research



Fiscal Year 2012 2013 2014

Sales 77,161 62,807 62,829

R&D Expenditure 1,903 1,402 1,213

Capital 318,059 322,744 328,683

Financial Figures

ILSUNG Pharmaceuticals is one of the well-known pharmaceutical companies in Korea. ILSUNG has been focused on antibiotics, anesthetics and contrast media and is expanding to GI, CV, CNS and other areas. ILSUNG is famous for its in-licensing activities with global partners such as GSK (UK), Bracco (Italy), Abbott / Baxter (USA), Ono / Teijin (Japan). ILSUNG is selling various kinds of the branded products such as Augmentin, Suprane, and Rytmonorm. In addition to this, ILSUNG is interested in exporting business for contrast media and CMO business for antibiotics based on well organized KGMP manufacturing facilities approved by PMDA for contrast media and antibiotics.

Focus Area : Antibiotics, Anesthesia, Contrast Media, GI, CV, CNS

Company Profile

Ilsung Pharm Co., Ltd.Suk Keun Yoon

44-7 Wonhyoro1-ga, Yongsan-gu, Seoul, Korea

Feb. 15. 1961

Antibiotics, Anesthesia, Contrast Media

245

82-2-3271-8705

82-2-718-7239

www.ilsung-ph.co.kr



Ji Young Lee

82-2-3271-8824

[email protected]

99

Main Products


1. Raypam Injection (Iopamidol)

CT Contrast Media

2. Sevoprane Inhalation (Sevoflurane)

Anesthesia

3. Augmentin (Amoxicillin + lavulnate)

Antibiotics

R&D Pipeline


Iohexol CT Contrast Media

Iopromide CT Contrast Media

Ioversol CT Contrast Media

Iomeprol CT Contrast Media

Meglumine Gadoterate MRI Contrast Media

Gadobutrol MRI Contrast Media


IL-YANG Pharmaceutical Co., Ltd. has been exerting its intended efforts to manufacture superior pharmaceutical products for the last half a century and it is still going on. Since it took the first step to supply pharmaceutical products in Korea, since 1946, IL-YANG has been advancing into a top-ranking pharmaceutical company in the world with developing in the area of Gastrointestinal, Hematology, Vaccine, and Virology. IL-YANG established vaccine plant in April 2011 with production capacity of 60mil doses per year. IL-YANG has been exporting a variety of pharmaceuticals to approximately 30 countries including USA and Europe. IL-YANG established two branches in China, YANGZHOU IL-YANG PHARM. Co., Ltd. and TONGHUA IL-YANG HEALTH PRODUCTS Co., Ltd. for manufacturing and distribution of finished pharmaceuticals in China. Since their establishment, the sales and business are expanding enormously. In Sept. 2014, YANGZHOU IL-YANG had completion ceremony for newly built CGMP plant which is compliance to EU-GMP standard.

Focus Area : Gastroenterology, Urology, Oncology, Virology, Biopharmaceutical

Company Profile

Il-Yang Pharm. Co., Ltd.RepresentativeHeadquarter Address


D. Y, Kim

110, Hagal-ro, Giheung-gu, Yongin-si, Gyeonggi-do, Korea

Jul. 1. 1946

Gastroenterology, Oncology, Virology

620

82-2-570-3700~7

82-2-570-3708~9

www.ilyang.co.kr


Fiscal Year 2012 2013 2014

Sales 146,460 147,731 210,000

R&D Expenditure 15,564 16,440 12,400

Capital 45,850 45,850 45,850

Financial Figures


Sun Park

82-2-570-3787

[email protected]

101

Product (Ingredient/Formulation) Use RemarksSupect Cap Radotinib 2nd line of CML-CP New Drug

Noltec Tab Ilaprazole Gastric Ulcer, Deodenal Ulcer, Erosive Esophagitis New Drug

Il Yang Flu Vaccine Pre-filled

Syringe inj

Trivalent purified inactivated influenza

virus antigenInfluenza Vaccine Generic

Rosatan Tab Losartan potassium Hypertetion Generic

Nizaractine Cap Nizatidine H2-blockers Generic

Neusilin A Tab Magnesium Aluminum Silcate Antacid, Absorbent Generic

Andilac-S Cap Lactobcillus Acidophillus Digestive Generic

Mutacil Powder Psyllium husk Habitual constipation, irritable bowel syndrome Generic

Motive Tab Mosapride Cirtate Anticonvulsive Generic

Etive Tab Itopride HCI Anticonvulsive Generic

Montidin Tab Levosulpiride Anticonvulsive Generic

Telmisartan Tab Telmisartan ARB Generic

Betaprol Tab Bisoprolol β-blockers Generic

AmBP Tab Amlodipine Mesylate Monohydrate CCB Generic

Furix Tab Furosemide Diuretics Generic

Indapam Tab Indapamide Diuretics Generic

Atrovastatin Tab Atorvastatin Hyperlipidaemic Generic

Pista Tab Pitavastatin Hyperlipidaemic Generic

Actigli Tab Pioglitazone Hypoglycemic agent Generic

Hinechol Tab Bethanechol Chloride Autonomic nervous system Generic

Poverin Tab Propiverine HCI genitourinary, Urinary frequency, urinary incontinence Generic

Sildenafil Tab Sildenafil citrate Erectile dysfunction Generic

Arthalgyl Inj Aspirin lysine Fever reducer, Pain reliever Generic

Nutrix Tab Acetly-L-Carnitine Improvement of brain metabolism Generic

Bonaring A Tab Dimenhydrinate Motion sickness, Vomiting, Nausea, Meniere’s disease Generic

Alvorin Tab Levocetirizine Antihistamine Generic

Epinastine Tab Epinastine HCI Antihistamine, Antiallergy Generic

Kukuratum Syrup Pelagonium sidoides Acute laryngitis Generic

Ambosol Inj Amino acid Amino acid Generic

Ibandronsan Tab Ibandronic Acid Osteoporosis Generic

Clopidogrel Tab Clopidogrel CVA, Cardiac infarction, Peripheral artery disease Generic

Glimed Tab Glimepiride non-insulin dependent diabetes mellitus Generic

Finasterid Tab Finasteride Neurogenic bladde, r Nervous pollakiuria Generic

Cefadroxil Cap Cefadroxil Pyelonephritis, Cystitis, Urethritis Generic

Nofaxin Tab Levofloxacin Antibiotic Generic

Aldrin Tab, Susp* Almagate Antacid action Generic

Noigel Susp* Aluminium magnesium silicate 1g Antacid action Generic

Main Products


Noltec (Ilaprazole) Anti-ulcer agentDec. 2007 / ChinaOct. 2008 / Korea

Supect (Radotinib) Anti-CML agent Jan. 2012 / Korea



Ilaprazole NERD, H.Pylori Phase III

Radotinib CML-CP 1stline Phase III Completed

IY7640 Anti-viral Phase I

Flu Vaccine Quadvalent Flu Vaccine Phase I

R&D Pipeline

* Exporting Countries : Vietnam, Cambodia, Mongolia, Etc.



Fiscal Year 2012 2013 2014

Sales 5,583 8,164 7,097

R&D Expenditure 2,269 4,202 4,293

Capital 5,621 6,396 6,939

Financial Figures

Since 2001, ISU Abxis has established its own platform technologies and product pipelines with a desire of being an axis of all therapeutic antibody industry as its name stands (ABXIS=AntiBody + aXIS). Beginning with the successful development and market-launch of Korean first therapeutic antibody in 2006, ISU Abxis has led Korean biopharmaceutical industry specialized in biosimilars and biobetters. Consequently in 2013 and 2014, ISU Abxis launched two biotherapeutics for orphan diseases of Gaucher and Fabry. ISU Abxis has accumulated the world class manufacturing and QC/QA management through the full development and manufacturing experiences in the globally harmonized compliance.

Focus Area : Orphan drug, Anti-cancer drug

Company Profile

Isu Abxis Co., Ltd.RepresentativeHeadquarter Address


Daeseong Kim

Global R&D Center C-5F, 22 Daewangpangyo-ro, 712 beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, Korea

Mar. 28. 2001

Oncology, Metabolic disorder

93

82-31-696-4700

82-31-696-4690

www.abxis.com


Juneyoung Park

82-31-696-4620

[email protected]

103


1. Clotinab®(Abciximab)Adjunct to Percutaneous Coronary Intervention (PCI)

Twelve countries including India, Turkey, Columbia, Venezuela and etc.

The first therapeutic antibody developed in Korea and the world’s second Abciximab

2. Abcertin®(Imiglucerase)Enzyme Replacement Therapy (ERT) for Gaucher disease (GD)

Under the registration in around 20 countries

The first drug for GD developed in Korea and the world’s second Imiglucerase

3. Fabagal®(Agalsidase beta)Enzyme Replacement Therapy (ERT) for Fabry disease (FD)

Launched only in Korea in 2014

The first drug for FD developed in Korea and the world’s second Agalsidase beta

Main Products


Recombinant Factor IX ISU304 Hemophilia B Non-clinical study (Toxicity)

Novel drug (mAb) ISU104 Breast cancer Non-clinical study (Efficacy)

Trastuzumab ISU103 Breast cancer Non-clinical study (Ready)

Eculizumab ISU305Paroxysmal nocturnal hemoglobinuria (PNH)

R&D

R&D Pipeline



Fiscal Year 2012 2013 2014

Sales 426,819 451,968 512,736

R&D Expenditure

Capital 241,405 237,602 235,213

Financial Figures

Since foundation in 1959, JEIL has made efforts with a sense of mission to contribute to pharmaceutical industry and our society by development of superior medicines for promoting people’s happiness and health.

JEIL established own central research laboratory for formulation and synthesis of drugs, followed by successive construction of KGMP factory in 1986. JEIL’s chemical production facilities are entirely controlled by BGMP according to GMP guideline for bulk chemical production related to general, special, and aseptic pharmaceuticals. In 2012. JEIL completed Anti-cancer Plant and Cephalosporin Plant according to cGMP standard and obtained GMP approval.

We are specialized in developing and producing patent terminated products to make first generic in exportable countries and trying to reach customer’s needs with current products.

Focus Area : cardiovascular drug, urologic drug, antibiotics API

Company Profile

Jeil Pharm. Co., Ltd.Suk Je Sung

343, Sapyeong-daero, Seocho-gu, Seoul, Korea

Mar. 7. 1959

1,044

82-2-549-7451

82-2-549-4045

www.jeilpharm.co.kr

RepresentativeHeadquarter AddressFoundation DateTotal StaffRepresentative PhoneRepresentative Fax Web

Contact Person

Contact Phone

Contact E-mail

International Business Dept. (Export), Bussiness Development & Licensing Dept. (License in/out)

export : +82-2-549-7451 (내선) licensing : +82-2-549-7451 (520)

[email protected] (export) [email protected] (licensing)

105


1. Cefditoren Pivoxil Antibiotic

2. Cefcapene Pivoxil Antibiotic

3. Imipenem Cilastatin Mix. Antibiotic

4. Rosuvastatin Cardiovascular

5. Ketoprofen Plaster TDS

6. Imipenem/Cilastatin Inj. Antibiotic

7. Cool Pap TDS

8. Sany Plaster TDS

9. Epinastine HCl Respiratory

10.Valtra Tab. Antiviral

Main Products


JPI-289 (NCE) JPI-289 PARP-1 inhibitor / Stroke Phase Ib

JPI-283 (NCE) JPI-283 oncology preclinical

JLP-1310 JLP-1310 hyperlipidemia + type 2 DM FDC phase I

JLP-1207 JLP-1207 BPH/LUTs FDC phase I

JLP-1401 JLP-1401 hypertension + type 2 DM FDC phase I

R&D Pipeline



Fiscal Year 2012 2013 2014

Sales 37,144 40,234 45,236

R&D Expenditure 3,393 2,241 2,913

Capital 6,000 6,000 6,000

Financial Figures

Jin Yang Pharmaceutical Co., Ltd. was established in 1971 and has been staying ahead of the pharmaceutical industry in Korea with our full automatic production system in the most modern and up-to-date plant and by being designated as a company conforming to KGMP (Korea Good Manufacturing Practice). We have also been leading the development of the pharmaceutical industry in Korea through cooperation with the world’s premier pharmaceutical companies. In July 2000 our company joined in the KOSDAQ Listed Companies Association so that we laid the groundwork for the more stable company, and furthermore, one of the most excellent companies in the 21st century. For more than forty years, based on the principle of honesty and sincerity, all the staffs and employees of our company has been putting all their efforts into building a better world with the aim of developing good quality drugs for health and happy life of the people and with the faith of managing the company in a profound respect for humanity. We promise to be a company that keeps on doing research and development for the improvement of life quality of the people and clients can give their confidence to our company. We will contribute to healthy life of the people by bending over backwards to help you not to lose your healthy body and happy life.

Focus Area : Cardiovascular, Gastronitestinal

Company Profile

Jin Yang Pharm. Co., Ltd.Jae-Joon, Choi

31, Hyoryeong-ro, Seocho-gu, Seoul, Korea

Jul. 1. 1971

IMD, Generic

220

82-2-3470-0300

82-2-3470-0390

www.jinyangpharm.com



Chul-Ho, Han

82-2-3470-0371

[email protected]

107


1.Clivix tab.(Clopidogrel)Antithrombotics,

Antiplatelet AgentsVietnam

2. Eszol Caps.(Esomeprazol) Antiulcerants Vietnam

3. Gynodron Tab.(Alendronate) Osteoporosis Vietnam

4. Nacton Tab.(Nabumetone) NSAIDs Vietnam

5. Gyno-plus Tab. (Black cohosh, Hyperici)

Hormone & Synthetic Agents

VietnamMalaysia

6. Cloxin tab.(Clonixin) NSAIDsVietnamBolivia

7. Ramista tab.(Rebamipide) Antiulcerants Vietnam

8. Dapid tab.(Indapamide) Essential hypertension Hong-Kong

9. Miary tab.l(Glimepiride) Anti-diabetics Malaysia

10. Freegra ODF(Sildenafil) Erectile Dysfunction Nigeria

Main Products


Entecavir Antiviral Agents Launch expected

Celecoxib NSAIDs Launch expected

Atorvastatin Antilipidemic AgentsFormulation development &

BE study

Rosuvastatin Antilipidemic AgentsFormulation development &

BE study

Esomeprazole(magnesium trihydrate)

Antiulcerants Formulation development

Vitis viniferaTreatment of venous

insufficiencyFormulation development

R&D Pipeline



Fiscal Year 2008 2009 2010

Sales 437,648 455,147 443,276

R&D Expenditure 19,942 22,173 24,231

Capital 23,033 23,774 24,487

Financial Figures

Since its foundation, JW Group has led the hospital market based on respect for life and the pioneering spirit, and is now being reborn as a global healthcare company to lead the industry into the 21st century.

Based on leading competitiveness in the ethical drug market, JW Pharmaceutical has built up strong sales network across the country and superior pipelines in I.V solutions, antibiotic, cardiovascular, gastrointestinal, nephrology, anticancer and neuropsychiatry. And now, it is pioneering the rapidly growing new field such as diabetes and so on. It has been striving to produce and provide innovative new technologies and services heading for healthy lives of human beings on the basis of its founding spirit of “Respect for life”.

Company Profile

JW Pharmaceutical CorporationKyung Ha Lee

2477, Nambusunhwan-ro, Seocho-gu, Seoul, Korea

1945

Anti cancer, Formulation research

1,872

82-2-840-6777

82-2-841-1213

www.jw-pharma.co.kr



109

Main Products


1. Carbenem Antibiotics (Imipenem/Cilastin)

Infection byGram - positive

bacteria

· Japan, China · EU (Spain, Germany)· South-East Asia (Hongkong, Indonesia, Malaysia, Mongol, Parkistan, Philippines, Syria, Thailand, Vietnam, Yemen, Nigeria, India, Bangladesh etc.)· CIS (Russia, Kazakhstan, Belarus, etc.)· Latin America (Brazil, Mexico, Argentina etc.)

2. I.V SolutionsSupply

electrolytes and trace elements

· South-East Asia (Vietnam, Cambodia, etc.)

3. Antifungal Agents (Itraconazole, ketoconazole)

Infection by fungi· Japan· South-East Asia (Indonesia, Parkistan etc.)

4. Other antibiotics (Cefmetazole, amikacin)

Various infection· Japan· South-East Asia (Vietnam etc.)

5. Anticancer drugs (Cytarabine, Alkyloxan, 5-FU)

Care for variouscancer including

hematologicalcancer

· South-East Asia (Turkey, Malaysia, Bangladesh etc.)



Q-ROXIN (Balofloxacin) Antibiotics100mg: 6th, May, 1993200mg: 7th, Jul, 1995

Zepeed (Avanafil) Erectile Dysfunction 17th, Aug, 2011

R&D Pipeline


WnT Hematological Malignancy Phase I clinical trial approved by FDA in April, 2011

Oxaliplatin (Oral formulation)

Metastatic Colorectal Cancer Pre-clinical study for IND application

Montelukast Anti-AsthmaBUSH-Tab® Tech (Formulation research)

To be launched in January, 2012



Fiscal Year 2008 2009 2010

Sales 16,003,885,516 15,520,406,585 13,049,056,754

R&D Expenditure 840,026,917 597,463,118 365,380,138

Capital 23,821,672,987 13,818,671,875 13,603,417,008

Financial Figures

Since its foundation in 1997, KMS PHARM CO., LTD. has devoted itself to provide high-quality pharmaceutical and herbal medicines to the local pharmacies and hospitals, and overseas customers such as Vietnam, Myanmar, Hongkong, etc. KMS PHARM has successfully accomplished a whole production line in compliance with KGMP (Korea Good Manufacturing Practice) compatible with WHO GMP and , has been providing quality medicines.

Company Profile

KMS Pharm Co., Ltd.RepresentativeHeadquarter Address


Kyung joo Lee

232, Sinwon-ro, Yeongtong-gu, Suwon-si, Gyeonggi-do, Korea

Jul. 1997

60

82-31-215-5456

82-31-215-5925

www.kmspharm.com

111

Main Products


1. L-Viem Tab(Lysozyme 90mg) Enzyme Vietnam

2. Trirog Tab(Trimebutine maleate 100mg) Indigestion Vietnam

3. Hepaphil S.C(DDB 3mg) Hepatic protector Vietnam

4. Mipisul Tab(Levosulpiride 25mg) Indigestion Vietnam

5. KMS Losartan potassium Tab (Losartan potassium 50mg)

Hypertension Vietnam

6. Yuraf Tab (Tramadol HCI 37.5+Acetaminophen 325mg)

Anti-inflammatory Vietnam

7. KMS Domperidone maleate Tab (Domperidone maleate 12.72mg)

Indigestion Vietnam

8. KMS Ciprofloxacin HCI Tab. (Ciprofloxacin HCI 582mg)

Antibacterial antibiotics Vietnam

9. Ketrazin Tab(Levocetirizine 2HCI 5mg) Antihistamins Hong Kong

10. Suzyme Tab(Lysozyme 90mg) Enzyme Myanmar



Fiscal Year 2012 2013 2014

Sales 177,779 267,881 439,080

R&D Expenditure 7,418 11,997 17,200

Capital 9,742 9,742 10,550

Financial Figures

Since founded in 1990 as a joint venture company with Nihon(Japan) Kolmar, Kolmar has grown to the biggest Korean Pharmaceutical contract manufacturer.

Kolmar Korea has extended our business to pharmaceutical business from 2002. And provide specialized production system with total outsourcing service on development and production of pharmaceutical and quasi-drug.

Kolmar Korea has provided customized contract manufacturing service with customers who want to outsource their pharmaceutical products, cosmetics and healthcare foods to be more competitive and to develop new formulations feasible in the market.

Focus Area : CMO (Contract Manufacturing Organization), Generic drug

Company Profile

Kolmar Korea Co.,Ltd.RepresentativeHeadquarter Address


Cho Hong Koo

12-11, Deokgogae-gil, Jeonui-myeon, Sejong, Korea

May. 15. 1990

650

82-2-3485-0497

82-2-515-1532

www.kolmar.co.kr


M.S.Pyo

82-2-3485-0397

[email protected]

113


1.Painless Tablet Anti inflammatory Philippines EU-GMP 추진품목

2.Hiforge Tablet Hypertensive Ajerbaijan

3.Cerephone Dry Syrup Anti-biotic Vietnam

4.Azithrobiotic Dry Syrup Anti-biotic Vietnam

5.Romaryl Cream Anti-fungi HongKong

6.Levocetirizine HCl Tab. Anti-histamine The Philippines

7.Minoxidil solution Male pattern

alopeciaJapan

Main Products


Tadalafil Erectile dysfunction BE

Amlodipine + Olmesartan

Hypertension BE

Celecoxib Antiinflammatory BE

Atorvastatin Calcium Hyperlipidemia BE

Entecavir Treatment of HBV BE

R&D Pipeline



Fiscal Year 2012 2013 2014

Sales 61,674 65,104 71,820

R&D Expenditure 3,962 2,175 2,922

Capital 24,430 20,229 21,747

Financial Figures

KOLON Pharma has been producing and supplying outstanding medicines and health functional foods to promote national health.

Our company will proceed to develop as an exceptional pharmaceutical company with excellence in technologies, labor force, and customer-oriented product development.

Focus Area : Pediatric Respiratory Drug etc

Company Profile

KOLON PHARMARepresentativeHeadquarter Address


Woo Seok Lee

Kolon Tower Annex 6th Floor, 13, Kolon-ro, Gwacheon-si, Gyeonggi-do, Korea

Oct. 5. 1958

Pediatric Respiratory Diseases

378

82-2-2120-8300, 8400

82-2-2120-8301

www.kolonpharm.co.kr


Seok Jung Yun

82-2-2120-8346

[email protected]

115


1. COMY (Chlorpheniramine maleate, Phenylephrine hydrochloride / Syrup, Tablet)

Improvement of all symptoms due to common cold or allergic rhinitis, Cough

2. FOSTER 100/6 HFA (Formoterol fumarate dihydrate, Beclometasone dipropionate / Inhaler)

Regular treatment of asthma where use of a combination product (inhaled corticosteroid and long-acting beta2-agonist), severe COPD(Chronic Obstruction Pulmonary Diseases) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators

3. TOPISOL MILK LOTION (Methylprednisolone aceponate / Lotion)

Eczema(atopic dermatitis, psoriasis eczema, etc.)

4. CUROSURF INJ. (Poractant alfa / Injection)

Treatment of Respiratory Distress Syndrome (RDS) in newborn babies. Prophylactic use in premature infants between 24 and 31 weeks estimated gestational age at risk from RDS or with surfactant deficiency.

5. COUGHJIN (Ammonium chloride, Chlorpheniramine maleate, Dihydrocodeine tartrate, Dl-methylephedrine HCl / Syrup)

Cough, Sputum

6. KOFXIME (Cefpodoxime proxetil / Tablet, Dry Syrup)

Treatment of susceptible acute, community-acquired pneumonia caused by S.pneumoniae or nonbeta-lactamase producing H.influenza acute uncomplicated gonorrhea caused by N. gonorrhoeae; uncomplicated skin and skin structure infections caused by S.aureus or S.pyogenes; acute otitis media caused by S.pneumoniae, H.influenzae, or M. catarrhalis; pharyngitis or tonsillitis; and uncomplicated urinary tract infections caused by E. coli, Klebsiella, and Proteus

7. BICOGREEN (Aloe capensis, Aloe extract, Bisacodyl, Chelidonii Herba, Curcuma Root, Frangula extract, Rhubarb Extract, enna leaf / Tablet)

Constipation, improvement of symptoms (anorexia, abdominal distention,intestinal putrefaction, hemorrhoid)

Main Products



Fiscal Year 2012 2013 2014

Sales 11,517,041 12,124,578 12,100,153

R&D Expenditure 402,665 213,818 177,080

Capital 17,356,368 17,457,246 18,287,237

Financial Figures

Established in 1982, Korea Otsuka Pharmaceutical Co.,Ltd. is a joint-stock company that provides excellent and innovative medicines as part of its mission of contributing to the Korea healthcare industry. We have large-scales production facilities in Korea for the consistent production of finished goods from synthesis of life. Moreover our products have help treat patients in Korea and improve quality of life. Moreover our products been exported Europe, Asia and the Middle East contributing to the taken an active part in international clinical studies, and strived to expand our business starting with the healthcare business in 2012.

Focus Area : CNS, Neurology, Cardiology, Gastroenterology.

Company Profile

Korea Otsuka Pharmaceutical Co., Ltd.Sungho Moon

226 Yeoksam-ro, Gangnam-gu, Seoul, Korea

Jul. 9. 1982

340

82-2-3287-9000

82-2-3287-9019

www.otsuka.co.kr

RepresentativeHeadquarter AddressFoundation DateTotal StaffRepresentative PhoneRepresentative Fax Web


Taejin Kim

82-2-3287-9124

[email protected]

117


1. ABILIFY Tab. Anti-psychotic agentHong-Kong, Philippines, Thailand, Indonesia

2. ABILIFY ODT Anti-psychotic agent OPEL(Europe)

3. PLETAAL Tab. Anti-platelet agentHong-Kong, Philippines, Thailand, Vietnam, Malaysia

4. PLETAAL SR Cap Anti-platelet agent

5. MUCOSTA Tab. Anti-ulcer agentPhilippines, Thailand, vietnam, Cambodia, Malaysia

6. SAMSCA Tab. Aquaretic agent Philippines, Thailand

7. Meptin Tab. Anti-asthmatic agent

8. Meptin swinghaler Anti-asthmatic agent Philippines, Indonesia

9. OBUCORT swinghalerAnti-asthmatic agent(Inhalation)

Philippines, Thailand, Indonesia

10. Mikelan Tab. Anti-arrhythmic agents

11. Busulfex IVHSCT (hematopoietic stem cell transplantation)Conditioning agent

12.Lorelco Tab.Anti-hyperlipidemic agent

Main Products



Fiscal Year 2012 2013 2014

Sales 44,744 50,046 54,829

R&D Expenditure 1,010 1,350 1,453

Capital 3,300 4,200 4,200

Financial Figures

Korea Pharma Co., Ltd.(KP) established in 1974, have acquired KGMP as we have safe and stabilized production systems. KP maintain the production process to assure the efficacy, safety and stability of all our products such as oral solid forms, oral liquid forms, topical liquid forms, ointment etc. We have built up perfect Q.C. systems, and we are supplying our products to the domestic markets, and exporting to over 16 countries to be widely recognized the manufacturing and technological achievements in the world.

Focus Area : CNS Drug, Colon Cleansing Agent, Alimentary Preparation etc.

Company Profile

Korea Pharma Co., Ltd.RepresentativeHeadquarter Address


Jae Don Park

8F, 58, Nonhyeon-ro 85-gilm Gangnam-gu, Seoul, Korea

Sep. 3. 1974

Developing innovative new medicines

242

82-2-558-1277

82-2-558-1678

www.koreapharma.co.kr


Jin Wook Lee

82-70-4742-8845

[email protected] [email protected]

119


1. VASTIA Tab. 5mg/10mg (Donepezil HCl 5mg, 10mg)

Central nervous system agent

Hong Kong

2. ALBIX Tab. 10mg (Memantine HCl 10mg)


Hong Kong

3. KOTASE Tab. (Bromelaine 40mg & Crystalline Trypsin 1mg)

Anti-tumefacient enzyme preparation

Myanmar, Vietnam

4. BAB Chewable Tab. (Hydrous dibasic calcium phosphate 100mg, Calcium lactate 25mg, Vitamins, etc.)

Alimentary preparation

Myanmar

5. AMOROLFINE Nail Lacquer (Amorolfine HCl 5g)

Topical antifungal agent for

onychomycosis

6. CRICOLON Tab. (Dibasic Sodium phosphate anhydrous 398mg, Monobasic Sodium phosphate monohydrate1,102mg)

Tablet type colon cleansing agent

7. RISDON Tab. 1mg/2mg (Risperidone 1mg, 2mg)


8. PAROXETINE Tab. 20mg (Paroxetine HCl 22.8mg)


Main Products



Fiscal Year 2008 2009 2010

Sales 35,145 43,544 60,233

R&D Expenditure - - -

Capital 1,950 2,150 2,150

Financial Figures

KOREA PRIME PHARM. CO., LTD. is specializes in manufactures and sales of pharmaceutical drugs(ETC) and Hospital doctors prescribe medications, and going to achieve higher growth rate of 30% per year rather than the average growth rate of the pharmaceutical industry.

Furthermore, domestic pharmaceutical companies are noticed to a big change by Korea-US FTA agreement recently. Therefore, Our company cope with the policy changes of the domestic pharmaceutical industry and the opening of the global pharmaceutical market, and we think to develop new products as a top priority in order to grow as a global company, and are focusing on doing business making new drugs(improved new drugs, Biomedicine, drug formulation development, and so on) by R&D cooperation.

In particular, our company awarded “2009, Korea Health Industry Award”, and “Grand Prize”in the part of independent medium venture company. With this opportunity, we will increasingly continue to work hard with the responsibility of the development of domestic pharmaceutical health industry.

Company Profile

Korea Prime Pharm. Co., Ltd.RepresentativeHeadquarter Address


Kim Dae Ik

7~9F, Daein B/D, 211 Jungang-ro, Dong-gu, Gwangju, Korea

May. 31. 1995

Medicine

253

82-62-233-1110

82-62-233-3296

www.koreaprime.co.kr

121

Main Products


1. Denical Tab. ( Calcium lactate pentahydrate 271.8㎎

Calcium Gluconate 240㎎ Precipitated Calcium Carbonate 240㎎ Dried Ergocalciferol 0.118㎎)

In case of calcium shortage/supplyVietnam

Cambodia

2. Throgin Tab.(Roxithromycin 150mg)Pharyngolaryngitis, acute bronchitis, tonsillitis, bacterial pneumonia, otitis media, sinusitis, periodontitis, etc.

VietnamCambodia

3. Rocin Tab.(Ciprofloxacin 250mg)Respiratory tract infection, infections in ear, nose, throat, mouth and tooth, renal and urinary tract infection, etc.

VietnamCambodia

4. Anflaim Tab.(Ofloxacin 100mg)respiratory tract infections, urinary tract infections, dermatological infections, gynecological infections

VietnamCambodia

5. Simbidan Tab.(Simvastatin 20mg)hyperlipidemia, prophylactic use in hypercholesterolaemic patients with ischaemic heart disease

Vietnam

6. Loxorofen Tab. (Loxoprofen sodium 68.1mg) (60mg as anhydrous)

1. Anti-inflammation and analgesia in the following diseases and symptoms : Chronic rheumatoid arthritis, osteoarthritis, low back pain, scapulohumeral periarthritis and neck-shoulder-arm syndrome.

2. Anti-inflammation and analgesia after operation, trauma or tooth extraction.

3. Anti-pyresis and analgesia in the following diseases : Acute upper respiratory tract inflammation (including acute upper respiratory tract inflammation accompanied by acute bronchitis)

VietnamCambodia

7. Talpain Tab.(Talniflumate 370mg)

Rheumatoid arthritis, osteoarthritis, (degenerative arthritic disease), sciatic neuralgia, amenorrhoeic pain, pain caused by trauma, inflammation and pain after surgery, tendosynovitis, sprain, adnexitis, pharyngitis, tonsillitis, otitis, sinusitis

VietnamCambodia

8. Exad Cap. (Nizatidine 150mg)Duodenal ulcer, gastric ulcer, Gastric oesophageal reflux disease

VietnamCambodia

9. Borad Tab.(levosulpiride 25mg)

Alleviation of the following symptoms due to functional dyspepsia: abdominal fullness, epigastric discomfort, and stomach soreness, belching, nausea and vomiting

VietnamCambodia

10. Apepsia-m Tab. (Domperidone maleate 12.72mg) (10mg as Domperidone)

Following diseases and dyspepsia in case of drug administration nausea, vomiting, anorexia, abdminal Distension, abdominal pains, flatulence, etc.

VietnamCambodia

R&D Pipeline


Sildenafil citrate Treatment for erectile dysfunction. Bioequivalence Test completion


· Business Activities : Manufacture, Marketing & Sales of Pharmaceuticals and Other Healthcare Products

· Number of registered products : about 224 items

· Investment in R&D : 12.6% of net sales (2013’)

· Market Sales : $136M (2014’)

· Growth Rate from 2013 to 2014 : 10.3%

· Incrementally Modified Drug : Clanza®CR, Clavixin®Duo Cap, Cilostan®CR, Kalomin®Tab.

KUP is export-oriented company. KUP is aiming to be not only a local leader but also global leading company by offering wide range of generics as well as differentiated products, incrementally modified drugs.

KUP has broad and well balanced portfolio of 244 products and exports 416 different items to 32 countries through global marketing, and oversea manufacturing facilities in USA, Vietnam, and has a business alliance with oversea companies. Especially KUP established manufacturing facility in Alabama, US for manufacturing and distrubuting drugs and health functional foods in 2003. This facility have allowed KUP to expand markets in US, Japan, and Europe with know-hows of FDA regulatory processes.

KUP invested in Research&Development. KUP invested about 12% of net sales and 10% of total employees in R&D continuously. KUP is successful developing innovative drugs and commercializing it. As a result, KUP has launched four IMDs - Clanza®CR Tab., Calvixin®Duo Cap., Cilostan®CR Tab., Kalomin®Tab. In addition, KUP has well balanced R&D portfolio including differentiated products of anti-neoplastic, Anti-hypertensive, and Antithrombotic Dugs.

KUP has been acknowledged at home and abroad. KUP was nominated as Forbes’ ‘Asia’s 200 Best Under A Billion’ over two consecutive years. KUP is one and only pharmaceutical company in Korea nominated by the Forbes magazine as one of the ‘Asia’s 200 Best Under A Billion’ over two consecutive years (2009~2010). KUP was awarded the Best Drug Research Award in Korea for CilostanCR in 2015.

Company Profile

Korea United Pharm. Inc.RepresentativeHeadquarter Address



Duk-young Kang

22, Nonhyeon-ro 121-gil, Gangnam-gu, Seoul, Korea

Dec. 3. 1987

Drug delivery system - Novel Controlled Release Formulation - Novel Fixed Dose Combination

738

82-2-512-9981

82-2-548-4599

www.kup.co.kr


Joosung Bae

82-2-558-8612

[email protected]

123

Main Products

Product (Ingredient/Formulation) Remark

1. Clanza®CR Tab. (Aceclofenac 200mg / Controlled Release Formulation)

· Indication : Pain caused by rheumatism (Antiinflammatory Analgesic drug)· Improved dosing regimen from b.i.d. to q.d.· Less side effects of gastrointestinal

2. Cilostan®CR Tab.(Cilostazol 200mg / Controlled Release Formulation)

· Indication : Ischemic symptoms, Thrombosis (Antithrombotic drugs)· Improved dosing regimen from b.i.d to q.d.· Reduced side effects of headache & tachycardia

3. Clavixin®Duo Cap. (Clopidogrel 75mg and Aspirin 100mg / Fixed Dose Combination)

· Indication : Acute coronary syndrome (Antithrombotic drugs)· Improved patient compliance

4. Kalomin® Tab. (Pelargonium Sidoides(as dry extract) 20mg / New Dosage Formulation)

· Indication : Upper respiratory tract infections (Antitussive)· Improved patient compliance for adults

R&D Pipeline


Unigril®CR Tab. UI03SPG300CT Antithrombotic drugs Clinical Trial

Levonazine®CR Tab. UI04LDP090CT Antitussive Clinical Trial

Losasc® Tab. 5/50, Losasc® Tab. 5/100

UI15AML055MTUI18AML0510MT

Anti-hypertension Clinical Trial

DTX031 UI19DTX031IV Anti-neoplastic Clinical Trial

Gastin®CR Tab. UI05MSP015CT GI modulator Clinical Trial


Fiscal Year 2012 2013 2014

Sales 134,816 136,885 151,485

R&D Expenditure 16,999 16,959 19,000

Capital 134,039 140,393 159,349

Financial Figures



Fiscal Year 2012 2013 2014

Sales 115,774 100,700 133,200


Capital 46,790 55,646 63,256

Financial Figures

Specializing in production of infectious disease preventive medicine(Vaccine) and disposable medical devices, Korea Vaccine has contributed to people’s health since 1954.

Focus Area : Pediatric vaccine and disposable medical supply.

Company Profile

Korea Vaccine Co., Ltd.RepresentativeHeadquarter Address


Deok-Ho Choi

128, Mongnae-ro, Danwon-gu, Ansan-si, Gyeonggi-do, Korea

Jan. 1956

Vaccines

260

82-31-495-6397~8, 82-2-443-1961~5

82-2-2249-0363

www.koreavaccine.com


Sungbae Ha

82-2-443-2008

[email protected]

125


1. Freeze-dried BCG vaccine (percutaneous)

Prevention of TuberculosisGlobal

distributorship

2. Kovax Polio PF. Prevention of Poliomyelitis

3. Typhoid Kovax Inj.Prevention of Thphoid

bacillus

4. Kovax Influ PF (Influenza Vaccine)

Prevention of Influenza

5. IL-YANG Flu Vaccine (Influenza Vaccine)

Prevention of InfluenzaGlobal

distributorship

6. Vari-L Vaccine Inj. Prevention of VaricellaGlobal

distributorship

7. CD.JEVAX Inj.Prevention of Japanese

Encephalitis VirusGlobal

distributorship

Main Products



Fiscal Year 2012 2013 2014

Sales 43,900 41,555 45,392

R&D Expenditure 1,495 1,632 1,945

Capital 5,500 5,500 5,500

Financial Figures

We are a manufacturer, a distributor, an exporter and an importer of medicines, health functional foods and cosmetics related to human life. We have always been eager to be the most reliable and trustworthy pharmaceutical company that can bring the highest value to the society, clients and employees since its establishment in 1980. Our business has been focused on OTC medicines in the beginning and extended to ETC medicines after enforcement of the separation system of prescribing and dispensing drugs. Currently, we are concentrating on developing life style modification products.

We are opened to collaborate with anyone in any business field as we have been collaborating research projects with universities, governments and other research institutions. Regarding flexibility, we not only provide pharmaceuticals but also diagnostic tools, medical food, and cosmetics to help modifying life style.

We will cope actively by adopting changes of society and pharmaceutical circumstances. Also, to keep our promise of the forthcoming future, and work harder than ever had before. Running our business through differentiation and pliability, we expect to satisfy our customers, shareholders, and employees.

Focus Area : Central Nervous System Drugs

Company Profile

Korean Drug Co., Ltd.RepresentativeHeadquarter Address


Sang Hun Park

34, Nonhyeon-ro 28-gil, Gangnam-gu, Seoul, Korea

Jan. 1980

Central Nervous System Drugs

245

82-2-529-6100

82-2-529-6114

www.nicepharma.com


Soon Ho, Bang

82-31-634-7100 (ext.610)

[email protected]

127


1. Neuromed (Oxiracetam/Tablet, Syrup, Inj)

Alzheimer’s-type dementia, multi-infarct dementia, Oraganic Brain Syndrome

China

2. Gabatin (Gabapentin/Tablet, Capsule)

Epilepsy, Neuropathic painSri Lanka, Vietnam, Philippines, Myanmar, Cambodia

3.Neurocept (Donepezil / Tablet)

Alzheimer’s-type dementi Vascular Dimentia

Philippines, Sri Lanka

4. Lukema (Montelukast / Tablet, Chewable Tablet)

Asthma, Allergic rhinitis Vietnam, Philippines

5. Zypeace OD (Olanzapin / OD Tablet)

Schizophrenia, Bipolar Disorder

6. Allertec (Cetirizine / Tablet)

Allergic rhinitis, Allergic conjunctivitis, chronic idiopathic urticaria, skin itching

Philippines, Vietnam, Cambodia, Sri Lanka, Singapore

7. Isotren (Isotretinoin / Soft Capsule)

Severe Acne Vietnam, Cambodia

8. Plamed (Clopidogrel / Tablet)

Improvement of atherosclerotic symptoms, decrease the risk of thromboembolism

Vietnam

9. Ginkgo-mexin (Ginkgo Biloba leaf ext. / Tablet, Soft Capsule)

Peripheral arterial circulatory disorders, dizziness, tinnitus

Vietnam

Main Products


Neuromed (Oxiracetam) Brain metabolics 1992-03-11 / Korea



crude extract KDC14-01 Osteophorosis Preclinical

crude extract KDC14-02 Atopic dermatitis Preclinical

R&D Pipeline



Fiscal Year 2008 2009 2010

Sales 121,638 122,565 131,308

R&D Expenditure 2,710 2,177 1,769

Capital 65,248 71,936 75,942

Financial Figures

Under the company motto of “respect for human life”, we, Kukjepharm Ind. co., Ltd.

have devoted our constant attention to manufacturing various medicines of highest quality by using a state-of-the art synthesis technology and sophisticated facilities complying with GMP guideline recommended by WHO.

Company Profile

Kukje Pharm. Ind. Co., Ltd.RepresentativeHeadquarter Address


Jong-Hoon Ra

96-8, Yatap-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, Korea

Jul. 27. 1959

461

82-31-781-9081

82-31-781-6040

www.kukjepharm.co.kr

129

Main Products


1. cefminox Inj. Anti biotics China

2. spectinomycin Inj. Anti biotics Iran

3. Tricef cap. Anti biotics Vietnam

4. Netilmycin Inj. Anti biotics Vietnam

5. Cualone Eye-drop. Ophthalmic agents Vietnam

6. cefotaxime Inj. Anti biotics Vietnam

7. ceftriaxone Inj. Anti biotics Vietnam

8. ceftazidime Inj. Anti biotics Vietnam

9. Tronamycin Inj. Anti biotics Vietnam

10. Peratam Inj. Anti biotics Vietnam

R&D Pipeline


TG-1001 Diabetic Retinopathy Early stage

LM-1002 GERD Early stage

LP-1003 Lumbar spinal stenosis Early stage

RB-1004 acute, chronic gastritis Early stage



Fiscal Year 2008 2009 2010

Sales 276,173 276,585 289,435

R&D Expenditure 6,500 6,630 6,150

Capital 52,400 52,400 52,400

Financial Figures

Kwang Dong Pharmaceutical Co., Ltd. has tried its utmost to manufacture superior medicines for the last half a century since it took the first step to supply medicines in Korea, a barren land for the medical industry in 1960’s. Kwang Dong has been advancing in to a top-ranking pharmaceutical company in the world through thee establishment of the most advanced factories in Pyungtaek City. We have been enjoying an excellent reputation in technology over forty years because of the goods quality and dependability of our goods. We are one of leading pharmaceutical manufacturer in Korea having GMP factory for ETC, OTC, drink and nutrition supplement. So, we have been exporting to our pharmaceutical products (Finished products) to sell all over the world.

Company Profile

Kwang Dong Pharm. Co., Ltd.Primary Logo Secondary Logo

Primary Signature Secondary Signature

Sung won choi

Gasan B/D, 85 Seochojungang-ro, Seocho-gu, Seoul, Korea

Oct. 16. 2012

Pharmaceutical

749

82-2-6006-7258~9

82-2-6006-7024

www.ekdp.com



131

Main Products


1.Bicalude Tablet (Bicalutamide 50mg)

Advanced prostate cancer in combination with LHRH analogue therapy or surgical castration

Vietnam, Nigeria

2.Lenara Tablet (Letrozole 2.5mg) Breast cancer

3.Kwangdong Woohwang Chungsimwon

Stroke, Hypertension, Palpitation, Mental anxiety, Acute

Vietnam

4.Sedera ODF (Sildenafil citrate 50mg)

Treatment of erectile dysfunction

5.Cool strip ODF (Cetylpyridinium chloride 1.5mg)

Preventive treatment of pharyngitis, amygdalitis, stomatitis

6.KD-Fen Plaster (Diclofenac Diethylammonium 120.0mg)

Analgesia, anti-inflammatory : arthrosis deformans, tenontothecitis,tennis elbow, myalgia, post traumatic pain

Hong Kong

7. Clisia Solution(Clindamycin phosphate 1.188g/100mL (1g as Clindamycin)

acne vulgaris Hong Kong, Cambodia

8.Beaurasen Injection(placenta 100mg, Benzyl Alcohol 0.03mg)

menopausal disorder Malaysia, Hong Kong

9. Kwangdong Ceftriaxone Sodium Inj. (Ceftriaxone Sodium1g)

Treatment of community-acquired or mild to moderate health care-associated pneumonia

Afghanistan, Vietnam

10. Iritesin Injection(Irinotecan 20mg)

1. after 5-FU therapy recurrent, progressive metastatic rectal cancer, colon carcinoma

2. combined treatment with 5-FU or Leucovorin, progressive metastatic rectal cancer, colon carcinoma without other therapy

3. gastric cancer (incapable surgery or requrrent)

4. small cell lung cancer5. progressive small cell lung cancer

Georgia

R&D Pipeline Category Product

NameDevelopment

Phases indicantDosage

FormDevelopment

Type

Central Nervous System

KD501Clinical test

Phase II dementia oral

License in from Elcomscience (Kor)

Self developed

KD103 Developingdementia,

Alzheimer's diseaseconsidering Self developed

Metabolic disease

KD101 Pre clinical obesity oral Self developed

Endocrine System

KD802 Pre clinical short

statureInjection

License in from Genexine (Kor) /

joint research

Digestive trouble

Ramosetron ODF

INDantinauseant

medicineoral / film Self developed



Fiscal Year 2012 2013 2014

Sales 152,822 162,238 170,278

R&D Expenditure 4,408 4,724 5,357

Capital 10,758 10,758 10,758

Financial Figures

Kyongbo Pharm. has committed Contract Manufacturing Organization(CMO) business with sufficient technical and marketing resources. As one of major manufacturers of APIs and finished dosages in Korea, we will put utmost efforts along with the best staff of R&D and quality assurance to be a global pharmaceutical manufacturer. Our modern facilities and infrastructure guarantee that our products meet superior quality in accordance with cGMP standards.

Focus Area : General API, Anti-Cancer API, Cephalosporins API, Carbapenem API

Company Profile

Kyongbo Pharm. Co., Ltd.RepresentativeHeadquarter Address


Taewon Kang

174, Sirok-Ro, Asan-Si, Chungcheongnam-Do, Korea

Mar. 31. 1987

GENERIC

352

82-2-365-2301

82-2-2175-2388

www.kbpharma.co.kr


Richard Kim

82-2-2175-2387

[email protected]

133


1. ATORVASTATIN Hypolipidemic Japan

2. CEFTIZOXIME Anti-BioticChina, Japan, South

east Asia(SEA)

3. CEFTRIAXONE Anti-BioticEU, Japan, SEA, Russia

etc

4. CLARITHROMYCIN Anti-Biotic Japan

5. PRANLUKAST Anti-asthmatic Japan

6. Loxoprofen Anti-inflammatory Turkey

7. SULBACTAM β-lactamase inhibitor Japan, Russia

8. Cefroxadine Anti-Biotic Japan

9. Cefotaxime Anti-Biotic Russia, SEA etc

10. Clopidogrel Anti-platelet Japan

Main Products


Tenofovir Disoproxil HBV Pilot scale

Duloxetine HCl Antidepressant Pilot scale

Ezetimibe Hyperlipidemia Pilot scale

Cinacalcet HCl Hypercalcemia Completed Process validation

Dabigatran Etexilate Anticoagulant Pilot scale

Vildagliptin Diabetes Pilot scale

Sitagliptin Phosphate Diabetes Pilot scale

Memantine HCl Alzheimer'S Disease Completed Process validation

R&D Pipeline



Fiscal Year 2012 2013 2014

Sales 41,919 47,768 50,528

R&D Expenditure 1,097 1,925 3,623

Capital 2,000 2,000 2,000

Financial Figures

Korean affiliate of Kyowa Hakko Kirin Co., Ltd. Japan

A global specialty pharmaceutical company mainly focused on Hemato-oncology, Nephrology, Immunology and CNS area with world leading high technology on antibody.

Focus Area : Hemato-oncology, Nephrology, Immunology and CNS area

Company Profile

Kyowa Hakko Kirin Korea Co., Ltd.RepresentativeHeadquarter Address


Tae se Kwon

5F, Pungrim B/D, 124, Teheran-ro, Gangnam-gu, Seoul, Korea

May. 24. 1991

Hemato-oncology, Nephrology, Immunology, CNS

74

82-2-3471-4321

82-2-3471-4322

www.kyowa-kirin.com/kr/


1. Neulasta (Peg filgrastim) Neutropenia

2. Grasin (Filgrastim) Neutropenia

3. Nesp (Darbepoetin alfa) Anemia

4. Regpara (Cinacalcet HCl)Secondary

Hyperparathyroidism

5. Renagel (Sevelamer HCl) Hyperphosphatamia

6. Nplate (Romiplostim)Idiopathic Thrombocytopenic

Purpura

7. Mitomycin-C (Mitomycin) Cancer

Main Products


Sang Heon Lee

82-2-2181-2926

[email protected]

135


Romiplostim AMG531Idiopathic Thrombocytopenic PurpuraAplastic anemia

LaunchedPhase II

Mogamulizumab KW0761

Leukemia/LymphomaCutaneous T-cell LymphomaPeripheral T-cell LymphomaAdult T-cell Leukemia/LymphomaSolid TumorAsthma

LaunchedPhase IIIPhase IIPhase IIPhase IPhase I

AntithrombinGamma

KW3357

Disseminated Intravascular Coagulation,Congenital Antithrombin DeficiencyDisseminated Intravascular Coagulation,Congenital Antithrombin

LaunchedPhase IPhase I

Granisetron Chemotheraphy induced Nausea and Vomiting

Launched

Tivantinib ARQ197 Hepatocellular Cancer Phase III

Benralizumab KHK4563 Asthma Phase III

Brodalumab KHK4827 Psoriasis Phase III

Istradefylline KW6002 Parkinson's Disease Phase III

Mesalazine Z206 Ulcerative Colitis Phase III

ASKP1240 Organ Transplant Rejection Phase II

BIW8962 Cancer Phase II

KHK4577 AtoPhase Ic Dermatitis Phase II

KHK7580 Secondary Hyperparathyroidism Phase II

BardoxoloneMethyl

RTA402 CKD in Patients with Type 2 Diabetes Phase II

KRN23

X-linked Hypophosphatemic Rickets(XLH) inpediatric patientsX-linked Hypophosphatemic Rickets/Osteomalacia(XLH) in adultpatientsX-linked Hypophosphatemic Rickets/Osteomalacia(XLH)in adult patients

Phase II

Phase I

Phase I

KHK2823 Cancer Phase I

KHK2898 Cancer Phase I

KHK4083 Autoimmune diseases Phase I

KHK2804CEP37250

Cancer Phase I

KHK6640 Alzheimer's Disease Phase I

Tivozanib KRN951 Cancer Phase I

R&D Pipeline



Fiscal Year 2008 2009 2010

Sales 81,300 104,210 124,095

R&D Expenditure 4,111 4,657 4,017

Capital 13,575 13,575 13,575

Financial Figures

Kyung Dong Pharm. Co., Ltd. established a GMP factory in 1987 to manufacture medical products with good quality. Since we were approved as a designated KGMP company in 1991, we have been producing more than 80 items including tablets, capsules, injections, and solutions. We have approved BGMP manufacturer since 2001 and also have the cGMP and EU-GMP grade facilities for general finished product and API.

Company Profile

Kyung Dong Pharm. Co., Ltd.RepresentativeHeadquarter Address


Ryu Deokhee

9F, Kyungdong B/D, 1926 Nambusunhwan-ro, Gwanak-gu, Seoul, Korea

Sep. 1975

Circulatory system, Digestive system

435

82-2-570-6135

82-2-576-8815

www.kdpharma.co.kr

137

Main Products


1. Cilostazol(API) Anti-platelet Japan

2. Cefmetazole sodium(API) Antibiotics China

3. Aclovir Inj. (Acyclovir) Antiviral Japan, Pakistan

4. Ceftisone inj. (Ceftriaxone sodium) Antibacterial Pakistan

5. Lihel Tab. (Biphenyl Dimethyl Dicarboxylate) Liver therapy Vietnam, Philippines

6. Rebamide Tab. (Rebamipide) Anti-peptic ulcer Japan

7. Cefpivo Tab. (Cefcapene pivoxil) Antibiotics

8. Atrovan Tab. (Atorvastatin Calcium) Hyperlipidemia

9. Cansata Tab. (Candesartan) Anti-hypertensive

10. Valtrep Tab. (Valsartan) Anti-hypertensive



Inhiplat Tab. (Clopidogrel Camsylate)

Anti-platelet 2008. 05. 07

Esoprazol Cap. (Esomeprazol base) Anti-peptic ulcer 2010. 03. 12

R&D Pipeline


Cilastatin sodium Antibiotics KFDA Approved

Telmisartan Anti-hypertensive KFDA Approved

Aripiprazole Antipsychotics R&D

Miglitol Anti-diabetic R&D

Celecoxib Antipyretic, Analgesic R&D

Entecavir Antiviral, Liver therapy R&D

Cefazedone sodium Antibiotics R&D



Fiscal Year 2008 2009 2010

Sales 43,701 46,869 45,983

R&D Expenditure - - 337

Capital 11,192 14,692 15,350

Financial Figures

KyungNam Pharmaceutical has been representing the domestic vitamin C market by its steady seller ‘Lemona’ which has been receiving constant love for 28 years since the first release in 1983. As proving its popularity, it has been awarded “Brand Award of the Year for four consecutive years hosted by the Korean Consumers’ Forum and shown 73 percent of overwhelming public support in vitamin C product field in 2011. In addition, KyungNam has been occupying the unrivaled No.1 title in the Human placenta market, which is the origin of the life energy.

Moreover, KyungNam has been leading the general medicines market through its product such as PM, a typical athlete‘s foot medicine, and Minol Troche, a sore throat drug.

Company Profile

Kyung Nam Pharm. Co., Ltd.RepresentativeHeadquarter Address


Hee-Cheul Lee

17F, Keumkang Tower B/D, 410 Teheran-ro, Gangnam-gu, Seoul, Korea

Jun. 1. 1957

Vitamin & Human Placenta

244

82-2-3490-5105

82-2-3490-5129

www.kyungnampharm.co.kr

139

Main Products


1. Lemona pulvis (vitamin B,C) vitamin America, Hong Kong,

Mongolia

2. KN vitamin C Tab. (vitamin B,C) vitamin

3. Lemo vita C Tab. (vitamin B,C) vitaminAmerica, Hong Kong,

Mongolia

4. Jahasaengryeok (Human Placenta) Tonic nutrition Hong Kong, Mongolia

5. Plagensia inj. (Human Placenta) relieve menopausal symptoms

6. PM Solution (Salicylic Acid) athlete's foot treatments

7. Minol troche (Cetypyridinium Chloride) relieve Throat inflammation


About Laboratorios Cinfa S.A. in Spain (Headquarter)

Cinfa is a Spanish pharmaceutical company with more than 40 years of expertise in the industry. It has a professional team of more than 900 workers motivated by a common health project: giving people access to affordable and high quality treatments. In order to achieve this goal, it has the most advanced technologies and facilities. Cinfa provides the most pharmaceutical brands in Spanish homes. It is presented in 52 countries and currently expanding internationally. Its portfolio comprises five lines of products: prescription drugs, OTC products, orthopedic devices, dermo-cosmetics and nutraceutical solutions. Its commitment with innovation, international expansion and environmental issues are the mainstays of the company.

About Laboratorios Cinfa Ltd. in Korea

Cinfa Korea was established in 2012 as a business legal entity of Cinfa to provide quality products and services to Asian as well as Korean. Cinfa Korea is the first station in Asia region of Cinfa. Currently, Cinfa is continuously making progress of registration of generic products and OTC products. Respibien is the first OTC item marketed in Korea, which is distributed by Jeil Pharm. Furthermore, various medical devices and cosmetics are marketed in Korea. In case of medical devices, graduated compression stockings and various supporters including pregnancy belt are marketed under the brand name of “Farmalastic” via hospitals, clinics and pharmacies. In case of cosmetics, customized skin care solutions are provided under the brand name of “Be+[bemas]” mainly via hospitals and clinics. Cinfa Korea is always opened to discussion for any business development from Asian region as well as Korea.

Focus Area : OTCs, Medical Devices (Class 1) and Dermo-cosmetics

Company Profile

Laboratorios Cinfa Ltd.RepresentativeHeadquarter Address


Joo-Cheol Lee

7F, Medica B/D, 190, Hyoryeong-ro, Seocho-gu, Seoul, Korea

Aug. 21. 2012

Medicines, Cosmetics, Medical devices

20

82-2-3488-6400

82-2-3488-6401

www.cinfakorea.com


Jihyun Kim

82-2-3488-6400

[email protected]

141


1. Respibien (Oxymethazoline HCl)

Rhinitis Imported from Spain

2. Farmalastic compression stocking Thrombosis Imported from Spain

3. Farmalastic pregnancy belt Supporter Imported from Spain

4. Be＋ 24h facial moisturizing calming deep revitalizing cream

moisturizer Imported from Spain

5. Be＋ very dry nourishing face and body moisturizer

moisturizer Imported from Spain

Main Products



Fiscal Year 2012 2013 2014

Sales 30,100 27,887 27,000


Capital 3,560 3,560 3,560

Financial Figures

Since 1976, Medica Korea has remained dedicated to achieving its business goals and enhancing social responsibility which is the improvement of human health through using better medicine. We produces all of the company’s products under the guidance and supervision of strict KGMP procedure. It also distributes its high-quality medicine to wholesalers, clinics and hospitals through exclusive sales channels.

Focus Area : Acne Treatment, Antihistamin, Antifungal agent, Gastrointestinal agent, Cardiovascular, Respiratory system agent, Neuropsychiatric drug. etc.

Target country : Vietnam, Philippines, Cambodia, Mongolia, Hongkong, Singapore, Chille, Myanma, etc.

Company Profile

Medicakorea Co., Ltd.RepresentativeHeadquarter Address


Duk Han Lee

2F, Medica B/D, 190, Hyoryeong-ro, Seocho-gu, Seoul, Korea

May. 20. 1976

ETC, OTC Drugs, Cosmetics, Food supplements

165

82-2-585-7799

82-2-585-9690

www.medicakorea.co.kr


Jina Park

82-70-4018-8009

[email protected]

143


Remarks

1. NIMEGEN Soft cap.10/20 mg (Isotretinoin 10,20mg)

Cystic acne and acne conglobata treatment

Singapore, Hong kong

The first Bioequivalence

approval as of Isotretinoin formulation

2. GREEN PAM Cap. (Thymomodulin 80mg)

Supplementary treatment of bacterial and viral infections.

Vietnam, Cambodia

3. MEDICA RANITIDINE HCI Inj. 25mg (Ranitidine hydrochloride 25mg/2mL)

Short-term treatment of active duodenal ulcer, benign gastric ulcer, GERD

Philippines

4. POINTY Cap. (Diacerhein 50mg)Treatment of osteoarthritis disease

Vietnam

5. MUCOSTEN INJ. 10% (Acetylcysteine 100mg/mL)

Acute Chronic & Asthmatic bronchitis

Dominican Republic

6. Allutec Tab. (Cetirizine Hydrochloride 10mg)

Rhinitis, Conjunctivitis, Eczema, Dermatitis, etc

Hongkong, Philippines &

etc.

7. TABEL Inj. (Ketorolac tromethamine 30mg)

Non-narcotic analgesics.Short-term treatment of Moderate to severe acute pain

Philippines

8. RANITIDINE HCI MEDICA Inj. 25mg (Ranitidine hydrochloride 25mg)

Treatment of erosive esophagitis, Short-term treatment of active duodenal ulcer,benign gastric ulcer, GERD

Philippines

9. TOPASE Tab. (PancreatinⅠ 175mg Dimethicone 25mg Ox bile ext. 25mg Hemicellulase 50mg)

Indigestion, Overeating, Dyspepsia, etc

Cambodia

10. PIRACETAM Tab. 800mg (Piracetam 800mg)

Cerebral damage and Symptoms of cerebral wound, Post-cerebral operation, Severe renal impairment disease

Vietnam

Main Products


Nimegen Soft Cap. 10mg (Isotretinoin 10mg)

Cystic acne and acne conglobata treatment

Approved

SALBUTRON SR Cap.4mg (Salbutamol sulfate 8mg)

Asthmatic bronchitis, Chronic bronchitis, emphysema disease

Approved

NEWBORN Tab. 25 I.U.(Kallidinogenase 25 I.U.)

Hypertension, Meniere’s disease, Buerger’s disease, menopausal disorder, circulatory disturbance of chorioretinal disease

Approved

MUCOSTEN INJ. 10%(Acetylcysteine 100mg/mL)

Acute Chronic & Asthmatic bronchitiｓdisease

Approved

CALDIOL Soft Cap.20㎍(Calcifediol 20㎍)

Chronic renal failure, Metabolic bone disease

Approved

R&D Pipeline


MG Co.,Ltd. is major manufacturer specialized in ‘Nutrition Infusion Therapy Products’ and our business market focuses on manufacturing of Parenteral and Enteral Nutrition Products and extends to its related areas.

Supplying nutrition at right time is mandatory for prompt curing a disease or illness, especially for following persons.

A surgical patient who is incapable of taking nutrition

Hypoproteinemia and Malnutrition patient

Wasting disease patient due to burn or gash

Immunosuppressive patient

With a long-term experience and accumulated technology, for the first time in Korea, we succeeded in localization of MG TNA which is 3-chamber bag product. Also we have provided 2-chamber bag product, MG Combi, and Lipid LCT(Lipid emulsion) etc. with our own technology. Furthermore, we recently developed the new products of FOMS Lipid and FOMS TNA, which are the combination of Fish oil, Olive oil, MCT oil and Soybean oil.

We, MG Co.,Ltd. and our employees promise our effort and endeavor to provide best quality products in Nutrition Therapy. Furthermore, we will hold an outstanding position for taking care of human health in 21st centuries

Focus Area : Nutrition infusion therapy products

Company Profile

MG Co., Ltd.RepresentativeHeadquarter Address


Chul-Soo Shin

27, Yongso-2-gil, Gwanghyewon-myeon, Jincheon-gun, Chungcheongbuk-do, Korea

Sep. 16. 2003

Nutrition infusion therapy products

85

82-2-2057-1002

82-2-2057-1003

www.medi-green.co.kr


In-Soon Han

82-2-2057-1002

[email protected]

145


Fiscal Year 2012 2013 2014

Sales 16,856 16,286 15,344


Capital 6,712 7,252 9,164

Financial Figures


1. MG TNA inj. IVH for NPO inpatients VietnamUnder registration in Iran, Kazakhstan, Syria

2. MG TNA-peri inj. IVH for NPO inpatients Mongolia, VietnamUnder registration in Iran, Kazakhstan, Syria, Philippines

3. MG Combi-peri inj. IVH for NPO inpatients MongoliaUnder registration in Syria Kazakhstan

4. Lipid LCT inj. 10% / 20% Supply EFA & Calory MongoliaUnder registration in Iran

5. FOMS TNA inj. IVH for NPO inpatients -Under registration in overseas countries

6. FOMS TNA-peri inj. IVH for NPO inpatients -Under registration in overseas countries

7. FOMS Lipid inj. 20% Supply EFA & Calory -Under registration in overseas countries

Main Products


Amino acid solution including Glutamine (Non-PVC bag)

Glutamine Amino acids Nutrition

Stability

Selenium for injection Supply for Selenium Formulation

Zinc for injection Supply for Zinc Formulation

Multi-minerals for injection Supply for Zn, Se, Cu, Mn, Cr Formulation

Dextrose, Amino acids, Lipid(New formular for 3-chamber bag)

IVH for NPO inpatients Review the formular

Dextrose, Amino acids, Lipid, Vitamins, Elements etc.(The first 4-chamber bag product)

IVH for NPO inpatients Review the formular

R&D Pipeline



Fiscal Year 2012 2013 2014

Sales 1,907 4,586 10,558


Capital

current assets: 1,733



non-current asset: 2,708



Financial Figures

MOTHER’S PHARMACEUTICAL CO., LTD. is a manufacturing plant of tablets, hard capsules authorized from Korea Food & Drug Administration. We took over a pharmaceutical company, which had manufactured oriental medicine more than 35 years. We have even expanded our business areas to chemical medicine based on natural product research experience. We have been rapidly developing to become the best pharmaceutical company.

Focus Area : Oriental Medicine, Digestive System Drug

Company Profile

Mother’s Pharmaceutical co., LtdRepresentativeHeadquarter Address


Si-Eun Lee

703-ho, 1-dong, (Lotte Itcastle,) 98, Gasan digital 2-ro, Geumcheon-gu, Seoul, Korea

Dec. 19. 2011

57

82-2-2026-8890

82-2-2026-8094

www.motherspharm.com


Sun-young Jung

82-70-7457-8819

[email protected]

147


1. STOEM Tab. (Artemisia Asiatica 95% Ethanol ext. 60mg)

Chronic gastritis, acute gastritis improvement

ETC

2. BENZNAL Tab. (Trimebutine Maleate 100mg)

Gastroesophageal reflux disease

OTC

3. TRILOCIN Tab. (Bromelain 40mg, Trypsin Crystalline)

Inflammation reduction OTC

4. RANITIEM Tab. (Ranitidine Hydrochloride 84mg)

Hypergastric acidity, heartburn

OTC

5. DIGEST Tab. (Dimethicone 25mg, Hemicellulase 50mg, Ox Bile Extract 25mg, Pancreatin 175mg)

Dyspepsia, sense of stomach distension release

OTC

6. LEBCETIN Tab. (Levocetirizine HCl 5mg)

Allergic coryza, dermatitis and eczema

ETC

7. AFELAC Tab. (Aceclofenac 100mg) Ostarthritis, backache ETC

8. ATOTIN M Tab. (Atorvastatin 10mg) Hypertension ETC

9. LAXOFEN M Tab. (Loxoprofen 60mg)

Analgesic anti-inflammatics, rheumatoid arthritis

ETC

10. ALKILL Tab. (Albendazole 400mg) Roundworm, threadworm OTC

Main Products


Oriental Medicine Osteo-arthrosis Formulation Development Stage

Atorvastatin Blood pressure Research stage

Rosuvastatin Hyperlipidemia Research stage

Itraconazole Onychomycosis, Pityriasis versicolor Research stage

Esomeprazole GERD

(gastroesophageal reflux disease)Research stage

Chemical Medicine Chronic hepatitis B Formulation Development Stage

R&D Pipeline



Fiscal Year 2008 2009 2010

Sales 86,000 98,000 100,000

R&D Expenditure

Capital

Financial Figures

Myung-In Pharmaceutical Company (Myung-InI) is the Korea located pharmaceutical company.

Myung-In is engaged in the development, production and marketing of pharmaceuticals and active pharmaceutical ingredients. The company’s comprehensive therapeutic produt’s range include anti-psychotics, cardiovascular drugs, neurological drugs, anti-diabetics and several OTCs. Myung-In conducts its most operations in Korea and about to start business in China. Myung-In headquartered in Seoul and the plant is located in Gyeongi province. We have 341 employees.

The company recorded revenue over $100 billion during the financial year (FY) ended December 2010, which is 10 times as much as that of 1995.

Company Profile

Myung In Pharm. Co., Ltd.RepresentativeHeadquarter Address


Hang-Myung Lee

Myungin B/D, 95, Banpo-daero, Seocho-gu, Seoul, Korea

Apr. 1. 1985

341

82-2-587-9060

82-2-585-0352

www.myunginph.co.kr

149

Main Products


1. Igatan Gum disease

2. Disgren Anti-thrombosis China

3. Rispen Schizophrenia

4. Coniel Hypertension

5. Carmazepine Epilepsy

6. Zanapam Anxiety disorder

7. Proctin Depression

8. Traline Depression

9. Newpram Major depressive disorder

10. Parox Major depressive disorder



Disgren (Triflusal) Anti-thrombosis 13.12.1993

Glibomet Diabetes 20.08.2001

Almiride Parkinson's disease 13.02.2003

R&D Pipeline


Pregabalin Neuropathic pain Approved

Amisulpride Schizophrenia Approved

Levitiracetam Epilepsy Waiting for approval from MFDS

Methylphenidate HCl ADHD Waiting for approval from MFDS

Clopidogrel + Aspirin Antiplatelet Waiting for approval from MFDS

Propafenone Arrhythmia Preparing BE

Oxacarbazepine Epilepsy Preparing BE


In 1983, Myungmoon Pharm. Co., Ltd. was established for the improvement of national health. It is achieving remarkable development via research and development, production, and sales based on its founding principle: Advancement, Harmony, and Creation.

Myungmoon Pharm. Co., Ltd. is an acknowledged manufacturer to produce the finished medicines; Injection, Tablet, Capsule, Patches, Solution and Creams.

Nowadays, Myungmoon Pharm. Co., Ltd. produces more than 250 specialized and general medicines and has more than 400 specialized and general medicine licenses to be able to manufacture. Myungmoon Pharm. Co., Ltd. is focusing on our research and development efforts so that Myungmoon Pharm. Co., Ltd. is launching more than 20 new products every year.

Myungmoon Pharm. Co., Ltd. established the new plant for API in 2008. Myungmoon Pharm. Co., Ltd has Gabapentin(USP) and the other 8 API products now, how ever, Myungmoon Pharm. Co., Ltd. would have many new API products in the foreseeable future.

To gain a foothold on biomedicine products, outsourcing strategies are preceding the use of trusted clinical agency CRO and production agency CMO, and Myungmoon Pharm. Co., Ltd has already started to develop human growth hormones through a bio-venture corporation. Within 2 or 3 years, Myungmoon Pharm. Co., Ltd. should be launching bio-similar, including EPO and the processing of the complement of plants for biomedical products as well as the development of advanced medical bioethics, including monoclonal antibodies.

Myungmoon Pharm. Co., Ltd. is sharply developing to be a professional and global treatment company in the world.

Company Profile

Myung Moon Pharm. Co., Ltd.RepresentativeHeadquarter Address


Kyu Huok Lee

Myungmoon B/D, 7, Gangnam-daero 54-gil, Gangnam-gu, Seoul, Korea

Sep. 1983

Medicines, Bio-Product

450

82-2-6711-2000

82-2-572-5137

www.mmpharm.co.kr

151


Fiscal Year 2008 2009 2010

Sales 77,390 92,246 100,914

R&D Expenditure 1,401 1,741 1,789

Capital 5,100 5,293 5,500

Financial Figures

Main Products


1. Kimite Patch (Scopolamine 1.5mg) Motion sickness Vitenam, China, Hong-Kong

2. Dobutamine Inj. (Dobutamine HCl 280.3mg/5ml)

Cardiac stimulants Vietnam, Pakistan, Nigeria

3. Inopan Inj. (Dopamine HCl 200mg/5ml) Cardiovascular drug Vietnam, Pakistan, Nigeria

4. Ketocin Inj. (Ketorolac tromethamine 30mg/1ml)

Nonsteoidal Anti-inflammatory drug

Vietnam, Philippines, Dominican Rep.

5. Bupivacaine HCL Heavy Inj. 0.5% (Bupivacaine HCL 21.12mg/4ml)

Local Anesthetics Vietnam, Nigeria, Dominican Rep.

6. Pyrinol Tab. (Pyridostigmine Bromide 60mg)

Parasympathomimetics Chile, Malaysia

7. Levonia Tab. (Levonorgestrel 1.5mg) Contraceptive Vietnam, Mexico

8. Tipem Inj. (Imipenem 500mg, Cilastatin 500mg)

Antibiotics Vietnam

9. Esgen Vaginal Cream (Estropipate 1.5mg/g)

Hormons Guatemala

10. Neocoline Inj. 500mg (Citicoline 500mg/2ml)

Parkinson’s diease Uzbekistan, Vietnam

R&D Pipeline


Sonatropin-PEG conjugate (Bio-Product)

GROWTH Hormone Finished Process(Lab Scale)

Erythropoietin(Bio-Product) Erythrogenesis Finished Process(Lab Scale)

Flumanzenil Inj. 0.5mg Antidote for Midazolam Launching on April, 2012

Valsartan 160mg, 80mg Hypertension Launching on April, 2012

Lansoprazole 30mg Antipeptic ulcer drug Launching on August, 2012

Sildenafil 100mg Erectile dysfunction Launching on August, 2012

Raloxifene 60mg Osteoporosis Launching on July, 2013



Fiscal Year 2008 2009 2010

Sales 20,879 25,847 31,263

R&D Expenditure 1,164 1,228 1,611

Capital 28,515 30,146 38,915

Financial Figures

Pharmaking is the leader of pharmaceutical industry in the field of hepatoprotective medicine. We have been investing more than 20% of its total sales into R&D for the development of new medicines. As a result, the first hepatoprotective medicine in Korea named “Nissel” was developed in July 1990. Furthermore, after obtaining a patent for a new hepatoprotective medicine and completing the phase Ⅱ, III clinical trials, “Pennel” was launched in Feb. 1998. Pharmaking Co., Ltd. has been exporting the flagship hepatitis medicine “Pennel” to Egypt for more than 10 years. Its superiority has been internationally recognized, driving the expansion of overseas sales in numerous countries, including Vietnam, Cambodia, Malaysia, Turkey and the UAE.

Company Profile

Pharmaking Co., Ltd.RepresentativeHeadquarter Address


Wan Bae Kim

4, Sujeong-ro 306beon-gil, Sujeong-gu, Seongnam-si, Gyeonggi-do, Korea

May. 14. 1975

liver/GI diseases

145

82-31-739-3300

82-31-739-3392

www.pharmaking.co.kr

153

Main Products


1. PENNEL capsule (Garlic oil 50mg, Biphenyl dimethyl dicarboxylate 25mg)

Acute and chronic hepatitis followed by the increase of transaminase

Egypt

2. NISSEL (Biphenyl dimethyl dicarboxylate 25mg)

For Hepatitis followed by the increased number of transaminase caused by chronic hepatitis with the continuously increased number of SGPT or by drugs

Vietnam, Mongolia

3. EUROCEL(Health food) (Eurocel Ext. Powder* 96.7%: Patriniae Radix 35%, Phellodendron amurense 35%, Yin-Chen Wormwood 20%, Schisandrae Fructus 10%), Sucrose ester of fatty acid 1.92%,Silicon Dioxide 1.38%

Acute and chronic hepatitis C USA

4. UDB (Biphenyl dimethyl dicarboxylate 12.5mg, Ursodesoxycholic acid 50mg)

chronic hepatitis followed by the continuously increased number of SGPT

5. RABET Tab. (Rabeprazole sodium 10mg)

Gastric ulcer, Duodenal ulcer, Oesophagitis erosiva

6. REVODRO Tab. (Levodropropizine 60mg)

Cough: Acute and Chronic Bronchitis

7. ITO Tab. (Itopride HCl 50mg) Functional dyspepsia

8. SIMVAMAX Tab. (Simvastatin 20mg)

1) To reduce the risk of coronary attack of patients with coronary artery disease, peripheral vascular disease, stroke or cerebrovascular disease2) Primary Hyperlipidemia

9. ROZAPLUS Tab. (Losartan potassium 50mg, Hydrochlorothiazide 12.5mg)

Diabetic nephropathy; Hypertension; Cardiac failure

10. PHARMAKING REBAMED Tab. (Rebamipide 100mg)

Gastric ulcer, Erosion, bleeding, flare, edema of gastric mucous membrane by acute gastritis and exacerbation of chronic gastritis



NISSEL(Biphenyl dimethyl dicarboxylate 25mg)

Acute and chronic hepatitis followed by the increase of transaminase

1990.07.10

UDB(Biphenyl dimethyl dicarboxylate 12.5mg, Ursodesoxycholic acid 50mg)

chronic hepatitis followed by the continuously increased number of SGPT

1997.12.30

PENNEL(Garlic oil 50mg, Biphenyl dimethyl dicarboxylate 25mg)

For Hepatitis followed by the increased number of transaminase caused by chronic hepatitis with the continuously increased number of SGPT or by drugs

1998.07.25

R&D Pipeline


New chemicalNAFLD(Non-Alcoholic Fatty Liver

Disease)Phase 2 clinical trial in process

New combination drug ASH(Alcoholic steatohepatitis) Phase 2 clinical trial IND approved

New herbal medicine Acute Bronchitis Phase 2 clinical trial IND approved

New chemical Gastritis Application of phase 1 clinical trial

New modified chemical Asthma, Allergy Pre-clinical trial(PK/PD) in process

New herbal medicine Inflammation Pre-clinical trial(in vivo) in process



Fiscal Year 2012 2013 2014

Sales 32,700 39,300 44,200

R&D Expenditure 1,500 2,700 3,300

Capital 20,680 34,065 40,020

Financial Figures

Pharmbio Korea Co., Ltd. is an emerging, innovative company established in 1999, specializing in registration, ex/importing, manufacturing, and marketing of innovative pharmaceutical products in Korea. It is one of the most influential companies in many therapeutic areas.

Focus Area : Urology, gastroenterology, neurosurgery, orthopedics, general surgery, immunology, etc.

Company Profile

Pharmbio Korea Co., LtdRepresentativeHeadquarter Address


Bong Kil Nam

7F, Samho B/D A, 83 Nonheyon-ro, Seocho-gu, Seoul, Korea

May. 1. 1999

25

170

82-2-587-2551~4

82-2-529-7454

www.pharmbio.co.kr


Jun Sang Nam

82-10-4558-8033

[email protected]

155


1. Picolight (Sodium Picosulfate, Magnesium Oxide(light), Citric Acid(anhydrous)/Powder)

Pre-colonoscopic preparation

Discussing out-licensing in in Vietnam, etc.

2. Urocitra-K (Potassium citrate/Tablet)

Uric acid lithiasis MyanmarDiscussing out-licensing in Vietnam, etc.

3. Urocitra-C (Potassium Citrate, Citric Acid Hydrate/Powder)

Uric acid lithiasis Discussing out-licensing in Cambodia, etc.

4. Endonse (Pronase B/Powder)Pre-endoscopic

preparation

5. Ribon (Risedronate Sodium Hydrate/Tablet)

Postmenopausal osteoporosis

Discussing out-licensing in Singapore, Hong Kong, etc.

6. Gagron (Pentasan Polysulfate Sodium/Capsule)

Interstitial Cystitis

7. Movilax (Polyethylene Glycol3350, Electrolytes/Powder)

Chronic constipation

8. Zinkistin (Zinc Histidine Dihydrate/Capsule)

Zinc deficiency

9. Acupan Capsule (Nefopam Hydrochloride/Capsule)

pain controller Discussing out-licensing in Nigeria, etc.

Main Products



Fiscal Year 2012 2013 2014

Sales 18,981 23,276 27,323

R&D Expenditure 1,228 1,327 1,283

Capital 1,510 1,580 1,786

Financial Figures

PMG Pharm has been a leading pharm in the market for treatments of rheumatoid arthritis, osteoarthritis, anti-osteoporosis and related diseases and its main business has been focused on the development of DMARDS, DMOADS and NSAIDs etc. At 13 Mar 2012, a Layla Tab has been registered as a new treatment for the osteoarthritis. Layla is consisted of 12 medicinal plants which has been recognised as traditional herbal medicines for arthrosis. PMG Pharm is ready to expand its business by licensing out Layla.

Focus Area : DMARD, DMOAD, NSAID

Company Profile

PMG PHARM Co., LtdRepresentativeHeadquarter Address


Young Chin Chun

21 Sinangbukro 4-gil, Sangnok-gu, Ansan-si, Gyeonggi-do, Korea

Dec. 2001

DMARDS, DMOADS, NSAIDS

101

82-31-439-5470

82-31-439-5471

www.pmgpharm.co.kr


Ji-Won Kim

82-31-439-5470

[email protected]

157


1. Layla Tab (12 herbal extracts 405.4mg) Osteoarthritis

2. Rheumakin Tab 10, 20mg (leflunomide)

Rheumatoid arthritis

3. Duroc Tab 100, 200, 400mg (Hydroxychloroquine sulfate)


4. Admin Forte Tab (cholecalciferol, VitD 1000IU)

VitD deficiency

5. SynflexSafe Tab (Naproxen /Esomeprazole 500/20mg)

NSAID

6. Indometa Cap 25mg (Indomethacin) NSAID

7. Morix Cap 7.5, 15mg (meloxicam) NSAID

8. PMG Loxiprofen 60mg (loxoprofen) NSAID

9. Cenatone Tab 500mg (nabumetone) NSAID

10. Droban Tab 150mg (Ibandronate) anti-osteoporosis

11. Risena Tab 35mg (Risedronate Na) anti-osteoporosis

Main Products


Layla Tab(12 herbal extracts 405.4mg) Osteoarthritis 2012.03.13/Korea



PMG1001 Blood circulation Development of bioassay

PMG1003 Benign prostatic hyperplasia Screening active ingredients

PMG1203 DepressionPartial purification & identification of active ingredients

PMG1301 DMARD In-vitro test

PMG1401 Anti-osteoporosis Screening active ingredients

R&D Pipeline



Fiscal Year 2008 2009 2010

Sales 25,192 32,744 41,414

R&D Expenditure 950 1,229 1,589

Capital 500 500 500

Financial Figures

Richwood Pharmaceutical Co., Ltd. a reliable CMO company with global standards in pharmaceutical manufacturing, has competitive advantages such as holding specialized formulation technologies using a 3-layer tablet machine and a GPCG series, a strategic partnership with CRO, and development pipelines of herbal medicine.

Company Profile

Richwood Trading Co., Ltd.RepresentativeHeadquarter Address


JeongSuk Lee

16F, Danam B/D, 10, Sowol-ro, Jung-gu, Seoul, Korea

Mar. 1974

Finished drug, Herbal medicine

146

82-2-778-2351

82-2-756-5402

www.richwood.net

159

Main Products


1. Acetracet Tab. (acetaminophen, tramadol HCl)

Pain relief

2. Ebaco SR Cap. (pseudoephedrine, ebastin)

Allergic rhinitis

3. Gli-M Tab. 2/500mg (glimepiride, metformin)

Type II diabetes

4. Limaprost 0.17mg (limaprost)Buerger's disease, acquired spinal

canal stenosis

5. Cetirizine Tab. (cetirizine) Allergic rhinitis

6. Livaduet Tab. (atrovastatine,amlodipine besylate)

Hypertension

R&D Pipeline


Oxycodone hydrochloride Opioid analgesic Clinical trial



Fiscal Year 2012 2013 2014

Sales 76,650 80,391 91,518

R&D Expenditure 1,360 1,787 1,978

Capital 10,000 10,000 10,526

Financial Figures

SamChunDang(SCD) Pharm. Co., Ltd. is one of the leading pharmaceutical company specializing in all kinds of ophthalmic products including multi-dose and mono-dose certified by MHRA, UK (EU GMP certificate) in 2015. SCD is a well known company as a manufacturer and distributor of quality pharmaceuticals in Korea as well as global markets. With our prior experience to work with more than 25 overseas countries for more than 20 years, we are now supplying our eye drops to most of Asian countries, Central America, Latin America and Middle East Countries with high quality and reasonable price on a long term basis.

Focus Area : Ophthalmic product

Company Profile

Sam Chun Dang Pharm. Co., Ltd.RepresentativeHeadquarter AddressFoundation DateResearch FocusTotal StaffRepresentative PhoneRepresentative Fax Web

Jeon Kyo, Park

351 Hyoryeong-ro, Seocho-gu, Seoul, Korea

Dec. 29. 1943

Ophthalmic Product

335

82-2-2046-1100

82-2-2046-1102

www.scd.co.kr


Brian Kim

82-2-2046-1255

[email protected]

161


1. Hameron Eye Drops (Sodium Hyaluronate 0.1%)

Artificial TearsVietnam, Jordan, Philippines, etc.

Modo-dose & Multi-dose

2. Tobaren Eye Drops (Tobramycin 0.3%, Dexamethasone 0.1%)

AntibacterialVietnam, Hong Kong,

Myanmar, etc.

3. Moxista Eye Drops (Moxifloxacin 0.5%)

Antibacterial Vietnam, etc.

4. Tolon Eye Drops (Fluorometholone 0.1%)

Anti-Inflammatory

China, Costa Rica, etc.

5. Tetzoline Eye Drops (Tetrahydrozoline HCl 0.05%)

Artificial Tears (Redness relief )

USA

Main Products


Tranilast 0.5% Eye DropsAllergic

conjunctivitisFormulation development

Loteprednol Etabonate 0.5% Eye Drops Anti-Inflammatory Test method development

Fluorometholone 0.1%, Tetrahydrozoline HCl 0.025% Eye Drops

Anti-InflammatoryManufacturing process

development

Diquafosol Sodium 3% Eye Drops Artificial Tears Formulation development

R&D Pipeline



Fiscal Year 2012 2013 2014

Sales 56,572 54,637 59,894

R&D Expenditure 3,849 3,821 4,100(E)

Capital 144,788 147,045 145,864

Financial Figures

SAMA is Korea’s number one pediatrics company, and also one of the top leaders in the respiratory and ENT segments. Founded in 1945, we have our own GMP-certified manufacturing plant, R&D center, and over 140 sales reps within our own nation-wide sales and marketing network. We are also expending into new therapeutic fields via R&D and licensing deals. In addition, SAMA is one of the first companies in Korea to start an international licensing business.

SAMA’s credibility as a trust-worthy business entity and partner is unparalleled both internationally and domestically due to our solid financial status and transparent management. Given this reputation, SAMA has been able to maintain decades-long partnerships with major companies in Japan such as Astellas, Dainippon-Sumitomo, and Kowa, as well as some European companies. We are trying to expand into other fields such as Gastrointestinal(GI) and cardiovascular(CV) drugs.

Focus Area : Pediatrics, Respiratory, ENT, Dermatology, GI, and CV

Company Profile

SamA Pharm. Co., Ltd.RepresentativeHeadquarter Address


Jun Hur

49 Dongwha gongdan-ro, Munmak-eup, Wonju-si, Gangwon-do, Korea

Oct. 4. 1945

Pediatrics, Respiratory, ENT, Dermatology, GI and CV

320

82-2-2056-7200

82-2-2056-7210

www.samapharm.co.kr


Soojin Lee

82-2-2056-7283

[email protected]

163


Remarks

1. SETOPHEN (Acetaminophen / tablets ER tablets & Dry syrup & suspension)

NSAIDs (Fever, Pains, Headache, Menstrual pain etc.)

2. CODENAL (Dihydrocodeine, etc ./ tablets & syrup)

Cough, Phlegm Hong Kong

3. ATOCK (Formoterol fumarate/tablets & dry syrup)

Acute & chronic bronchitis, Bronchial asthma

4. LIDOMEX (Prednisolone valeroacetate / topical lotion & cream)

Eczema, Dermatitis,Prurigo, Psoriasis, etc.

5. CITUS (Pranlukast/ dispersible tablets & dry syrup)

Bronchial asthma, Perennial allergic rhinitis

6. TANTUM (Benzydamine HC l/ gargle solution & nebulizer)

Gingivitis glossitis,Pharyngitis, Laryngitis, Tonsillitis etc.

7. HEBRON (Ivy leaves extract/tablets & syrup)

Chronic inflammatory bronchial disease, acute inflammation of respiratory tract

8. BEPORIN (Bepotastatine salicylate/tablets)

Anti-histamines

9. COBIAN-S(Chlorpheniramine maleate, Phenylephrine HCl/ tablets & syrup)

Improvement of all symptoms due to common cold or allergic rhinitis cough

10. NOMA (Multivitamins, Minerals /gummies & chewable tablets)

Growth promotion, nutritional deficiency, supply for vitamins & minerals

Main Products


TD13 TDIQ Erectile dysfunction NDA filing (MFDS)

SA09012 SA09012 Bronchial Asthma, Allergic rhinitis Phase 2 clinical trudy

PR13 PRIT Bronchial Asthma, Allergic rhinitis Discovery

PR13 PRIC Bronchial Asthma, Allergic rhinitis Discovery

R&D Pipeline



Fiscal Year 2012 2013 2014

Sales 35,000 37,000 40,000


Capital 702 702 702

Financial Figures

Since established in 1973, Samik has been focusing all our efforts to improve the Quality of Life with natural scientific value through the production and quality development of a number of OTC and ETC. Also we have exported medicines to several countries in asia, and expanded the market territory constantly.

Focus Area : Drug for circulatory system disease

Company Profile

Samik Pharm. Co., Ltd.RepresentativeHeadquarter Address


Lee Choong Whan

4F, Dongbo B/D, 413, Jong-ro, Jongno-gu, Seoul, Korea

1973

Circulatory system diseases

137

82-2-928-0661~4

82-2-924-3749

www.samik.co.kr


Yu Li Kim

82-2-928-0661(Etx.555)

[email protected]

165


1. CEZAR TAB. (Losartan potassium 50mg/100mg)

Antihypotensive

2. CEZAR PLUS TAB. (Losartan potassium 50mg, Hydrochlorothiazide 12.5mg)

Antihypotensive

3. TAMITRA TAB. (Acetaminophen 325mg, Tramadol hydrochloride 37.5mg)

NSAID’s

4. SERODIN SYR. (Loratadine 5mg) Antihistamine

5. HEPA-WORLD (Caraus marianus extract 100mg, Thiamin Hydrochlorid 4mg, Riboflavin 4mg, Pyridoxin Hydrochlorid 4mg, Nicotinamide 12mg, Calcium Pantothenate 8mg, Cyanocobalamin 0.1% 1.2mg)

Hepatic disorder Vietnam

6. T-MODUVAX CAP. (Thymomodulin 80mg)Immune

enhancementVietnam

7. PHARTINO TAB. (Bromelain 40mg, Crystallized trypsin 1mg)

Anti-inflammation Vietnam

8. SONA-TIUM TAB. (Alendronate 70mg) Osteoporosis Vietnam

Main Products


SIP-1101 Erectile dysfunction BE Test

SIP-1102 Allergic rhinitis Clinical Test

SIP-1103Liver function improvement

Clinical Test

R&D Pipeline


Company overview

· 1947 - The establishment of Samil Pharm. Co., Ltd.

· 1969 - Technical alliance with Boots Co. of the UK for Brufen

· 1985 - Korea stock exchange IPO (000520)

· 1985 - Completion of KGMP (Korean Good Manufacturing Practice) in Ansan

· 1987 - Establishment of Central R&D Center / Set up ophthalmic business division

· 2003 - Newly established Thea business division

· 2008 - Joint Venture contract with Allergan Inc, of USA

· 2011 - Joint Venture contract with Mon-samil LLC of Mongolia

· 2014 - $9 Million export contract with Iran

Export country

Hong Kong, Japan, Myanmar, Mongolia, Philippines, USA, Vietnam, Yemen

Subsidiary company

Samil H&T Co., Ltd., Samil Medical Co., Ltd. (detistry, medical device)

Focus Area : Ophthalmology, Gastro-intestinal, Respiratory, Circulatory, Cardiovascular, Dermatology

Company Profile

Samil Pharm. Co., Ltd.RepresentativeHeadquarter Address



Kang Huh

155, Hyoryeong-ro, Seocho-gu, Seoul, Korea

Oct. 7. 1947

Ophthalmology, Gastro-intestinal, Respiratory, Circulatory, Cardiovascular, Dermatology

396

82-2-520-0300

82-2-588-5924

www.samil-pharm.com


Shin-ku Kang

82-2-520-0324

[email protected]

167


1. Ofloxacin 3mg/mL Ophthalmic Soln. & Oint.

Susceptible strains of the microorganisms

Asia, Mid-East under registration (Asia, Mid-East, Europe)

2. Tobramycin 3mg/mL / Ophthalmic Solution & Ointment


Asia, Mid-Eastunder registration (Asia, Mid-East)

3. Polymyxin B sulfate 6,000IU, Neomycin sulfate 3mg (potency), Dexamethasone 1mg Ophthalmic Suspension & Ointment

conjunctivitis, blepharitis, and keratitis

Asia, Mid-Eastunder registration (Asia)

4. Levofloxacin 5mg/mL Ophthalmic Solution


Asiaunder registration (Asia, Mid-East)

5. Sodium Hyaluronate 1mg/mL Ophthalmic Solution

Sjogren's syndrome, Stevens-Johnson Syndrome, dry eye syndrome, drug-induced, injury, contact lenses


6. Diclofenac sodium 1mg/mL Ophthalmic Solution

a nonsteroidal anti-inflammatory product

Asia, Mid-Eastunder registration (Mid-East)

7. Povidone 20mg/mL Ophthalmic Solution

a lubricant alleviating dry eyes

Asiaunder registration (Mid-East)

8. Acyclovir 30mg/g Ophthalmic Ointment

keratitis caused by herpes simplex virus


9. Fluorometholone 1mg/mL Ophthalmic suspension

corticosteroid-responsive inflammation of outer and anterior segments of the globe


10. Losartan Potassium, HCTZ 50mg, 50/12.5mg, 100/12.5mg Tablets

hypertension Asia

Main Products

Compound Name Patent No. Title Date of patent

Trimebutine 1020100002507Stable pharmaceutical composition comprising Trimebutine and prokinetic agent

12 JAN. 2010

Limaprost alfadex 1020100068304Pharmaceutical composition in tablet form for oral administration comprising Limaprost

15 JUL. 2010

Sulglycotide 1020110013635

Multi layer pharmaceutical tablet with improved stability comprising Sulglycotide and H2 antagonists and preparation method thereof

16 FEB. 2011

Telmisartan 1020120079809Pharmaceutical composition comprising Telmisartan with improved stability and preparation method thereof

23 JUL. 2012

Telmisartan & Hydrochlorothiazide

1020120114062Pharmaceutical composition comprising Telmisartan and HCTZ

15 OCT. 2012

R&D Pipeline



Fiscal Year 2012 2013 2014

Sales 185,702 192,007 201,305

R&D Expenditure 11,030 12,397 13,855

Capital 13,900 13,900 13,900

Financial Figures

All human beings have the right to enjoy a healthy and happy life.

However, the complicated social structure of modern society and the development of material civilization cause the advent of new diseases.

In order to protect human health from these diseases and fundamentally get rid of diseases, Samjin pharm Co., Ltd secures excellent personnel and latest equipment and continues to challenge the development of excellent pharmaceutical drug by utilizing advanced pharmaceutical information and technology.

Samjin pharm Co., Ltd always strives for a better future on the basis of dignity of human life and company philosophy.

The company pioneering a healthy life of people and challenging the prosperous future with mind of creation.

Focus Area : Cardiovascular system drugs, Analgesics & Antipyretics, etc.

Company Profile

Samjin Pharm. Co., Ltd.RepresentativeHeadquarter Address


Sung-Woo Lee

121 Wawoosan-Ro (Seogyo-dong), Mapo-Gu, Seoul, Korea

Apr. 18. 1968

AIDS, Dry eye, etc.

626

82-2-3140-0700

82-2-5312-2001

www.samjinpharm.co.kr


Seo-Yeon Yang

82-2-3140-0708

[email protected]

169


1. PLATLESS TAB.Antithrombotics, Antiplatelet Agents

Philippines, Cambodia, Singapore

2. NEUSTATIN-A TAB. Antilipidemic Agents

3. NEURACETAM TAB. Nootropics & Neurotonics

4. NEUTOIN TAB. Nootropics & Neurotonics

5. TIROXIN CAP. Cephalosporins.

6. BAMEDN TAB. Antiulcerants Cambodia

7. SYNERJET TAB. Analgesics & Antipyretics Philippine

8. MAROBIVEN-A. Inj. Antiinflammatory Enzymes

9. GEWORIN TAB. Analgesics & AntipyreticsVietnam, Cambodia

Mongolia, PhilippinesOTC

10. TRESTAN CAP. Appetite Stimulants OTC

Main Products


SJ-3366 AIDS Phase1/Preclinical

SA001 Dry eye Preclinical

SA002 Obesity Preclinical

SA003 Arthritis Preclinical

SJ001M Tissue Protection Preclinical

SJ3548 Diabetes Biological Test

SJ2395 Alzheimer’s Disease Biological Test

R&D Pipeline



Fiscal Year 2012 2013 2014

Sales 44,130 50,672 57,186

R&D Expenditure 7,494 7,819 7,748

Capital 101,288 207,129 210,810

Financial Figures

Samyang Biopharmaceuticals Corporation (SYB), with its central research center has been engaged in development and marketing of novel drug delivery systems and medical devices. SYB has been focusing its efforts on healthcare as its core strategic business of the 21st century.

After the recent merger with its sister company, Samyang Genexbio Corporation, SYB is now a fully integrated company with R&D, GMP facility for APIs as well as finished dosage forms (injections & patches), and Medical devices. SYB has been expanding its relationship with excellent partners in many markets, and is looking to find more potential companies that would create a good synergy.

Focus Area : Oncology, GMP Manufacturing(APIs, Injections, Patches), DDS Technology

Company Profile

Samyang Biopharm. Corp.RepresentativeHeadquarter Address



Taeung Eom

31, Jong-ro 33-gil, Jongno-gu, Seoul, Korea

Nov. 1. 2011

Novel drug delivery systems and medical devices

200

82-2-740-7163

82-2-740-7269

www.samyangbiopharm.com


Jae-Wook Joo

82-2-740-7163

[email protected]

171


1. GenexolⓇ Inj. (Paclitaxel) Anti-CancerEurope, Asia, Midddle-East

2. Genexol-PMⓇ Inj. (Paclitaxel) Anti-Cancer Asia, Africa

3. NanoxelⓇ-M Inj. (Docetaxel) Anti-Cancer

4. PemedⓇ Inj. (Pemetrexed) Anti-Cancer

5. ZolenicⓇ Inj. (Zoledronic Acid) Bone metastasis

6. RheumastopⓇ Transdermal patch (Diclofenac Diethylamine)


Middle-East,Asia

7. Tulobuterol Transdermal Patch Asthma acute bronchitis

8. FentadermⓇ Transdermal Patch (Fentanyl)

Severe Pain

9. Rivastigmine Transdermal Patch Anti-Alzheimer

Main Products


Polymeric Micelle InjectionGenexol-PMⓇ Marketed

NanoxelⓇ-M Marketed

Polymeric Nano-Particle InjectionDocetaxel-PNP Clinical (Phase I)

Voriconazole-PNP Clinical (Phase I)

Polymeric Micro-Particle Injection hGH-PMP SR Non-clinical

TDS(Transdermal Drug Delivery

System)Transdermal Capsaicin Clinical (Phase II)

R&D Pipeline



Fiscal Year 2012 2013 2014

Sales 46,377 42,043 43,816

R&D Expenditure 5,505 4,734 4,175

Capital 25,384 32,252 31,100

Financial Figures

Seoul Pharma Co., Ltd. founded in 1976, has engaged in the pharmaceutical manufacturing and distribution business, and in 1997, established the R&D Center and has researched and developed new drug delivery technology since then. The sales revenue was 40 Million USD in 2014.

Being focused its R&D on the innovative and creative DDS technology such as special formulations, the company has developed a new platform technology (named as SmartFilmⓇ Technology) to produce Orally Disintegrating Film (ODF) products and planned to penetrate the global market through SmartFilmⓇ Technology with a new cGMP/EU-GMP factory that was built in Osong city. ODF means a pharmaceutical formulation which makes drug with a shape like thin square film, so drug can be dissolved within 3 minutes, ideally 10 seconds, with maximal expansion of its surface area in tongue.

Focus Area : ED, CNS

Company Profile

Seoul Pharma Co., Ltd.RepresentativeHeadquarter AddressFoundation DateResearch FocusTotal StaffRepresentative PhoneRepresentative Fax Web

Younha Lee

21, Banpo-daero, Seocho-gu, Seoul, Korea

Aug. 1976

NME, IMD, ODF

226

82-2-3470-2300

82-2-3470-2395

www.seoulpharma.com


Dong-churl Seo

82-2-3470-2386

[email protected]

173


1. Auclatin tab./Dry syrup (amoxicillin + K clavulanate)

antibiotics

2. Diflu cap. (fluconazole) antifungal Tanzania

3. Sebron cap./syrup (acetylcysteine)

mycolytics

4. Levobacter tab. (levofloxacin) antibiotics Mongolia

5. Duvelac cap. (bacillus licheniformis)

probiotics

6. Ossobone tab. (ossopan substance)

Ca supplement

7. Lead-Me cap. (green tea ex.) anti-obesity

8. Aliver susp. (l-leucine, l-isoleucine, l-valine)

hypoalbuminemia

9. Vultis ODF (Sildenafil citrate) erectile dysfunctionLaunched as

Viagra L in Korea

10. Vulteum ODF (Tadalafil) erectile dysfunction

Main Products


SPC-702 COPD Preclinical

SPX-601 Arthritis Phase IIa clinical

Artpezil ODF (Donepezil HCl) SPO-1112 Dementia Registered

Aripiprazole ODF SPO-1113 Schizophrenia Registered

SPO-1107 Anti-emetic Formulation Research

SPO-1411 Dementia Formulation Research

SPO-1307 Hepatitis Formulation Research

SPO-1109 NSAID Formulation Research

SPO-1405 Obesity Formulation Research

R&D Pipeline



Fiscal Year 2012 2013 2014

Sales 212,010 206,471 209,584

R&D Expenditure 7,925 8,797 9,395

Capital 185,644 185,886 185,485

Financial Figures

Under the management philosophy of ‘for the health of the people’, Shin Poong Pharm.Co.,Ltd specializes in manufacturing remedy drugs with sincere efforts put into producing every single tablet of life-saving drugs ranging from ingredients to finished products based on our state-of-the-art manufacturing facilities and quality assurance system. We are committed to realizing the spirit of Shin Poong 3V (Vision, Venture and Victory) with top-notch competitiveness based on in-house ingredient synthesizing technologies obtained through rigorous R&D efforts and to further developing the company into the one that receives confidence from our customers and that contributes to promoting the wellbeing of human beings. In 2011, Shin Poong developed PYRAMAX¢ç in cooperation with Medicines for Malaria Venture and approved by Korean FDA. PYRAMAX® is the first artemisinin-based combination therapy to receive an Article 58 positive Scientific opinion from EMA for the treatment of both strains of malaria: P.falciparum and P.vivax, in adults and children over 20kg and was listed on WHO prequalified medicines in May, 2012.

Focus Area : Prescription drugs in the Surgery market

Company Profile

Shin Poong Pharm. Co., Ltd.RepresentativeHeadquarter AddressFoundation DateResearch Focus


Jei Man Ryu

161, Yeoksam-ro, Gangnam-gu, Seoul, Korea

Jun. 9. 1962

New Drugs, Incrementally Modified Drugs, Generics

841

82-2-2189-3400

82-2-557-4372

www.shinpoong.co.kr


Paul Choen

82-2-2189-3471

[email protected]

175


1. Pyramax (Artesunate, Pyronaridine / Inj) Anti-malaria NME

2. Loxfen CR (Loxoprofen / Tab) Analgesic IMD

3. Hyal Forte (Sodium Hyaluronate / Inj) Arthritis Generic

4. Clamoxin (Amoxicillin Sodium / Tab) Anti-biotics Generic

5. Medicurtain (Sodium Hyaluronate, HES / Inj)

Adhesion Barrier Medical device

Main Products


SP-8203 SP4C001 Stroke Phase I

SP-35454 SP-35454 Osteoporosis IND approval

SP-2236 SP-2236 Heart failure Candidates

SP5M001 SP5M001 Osteoarthritis IND applications

Free Wink SP5V003 Anti-wrinkle Non-clinical

Pyramax granule SP1P001 Anti-malaria NDA applications

CR tablet SP3R001 Anti-histamine Phase I

R&D Pipeline


Pyramax Tab Anti-malaria2011.8 / Korea

2012.2 / EU




Fiscal Year 2012 2013 2014

Sales 9,376 8,704 8,631

R&D Expenditure

Capital

Financial Figures

In the year 1959, few years after Korean war, SINSIN Pharmaceutical Company was established during the reconstruction of post-war period for the purpose of improving the national health. Amidst the devastating conditions of the 1950’s SINSIN committed to the development of top professional staff, research and development of new products and to the improvement of the Korean pharmaceutical market. SINSIN’s efforts were successful in replacing the expensive Japanese Plaster and through superior quality management became the #1 Plaster company in Korea. SINSIN began to export it’s products in 1971 and at present time it ships to over 30 different countries worldwide with trememdous success. SINSIN has been given various awards including the Outstanding Company Award and the Presidential award. These awards have motivated SINSIN to work harder to promote national health, which is both our responsibility to society and our original goal as a leading pharmaceutical company. From environmental concerns to national health SINSIN Pharmaceutical will continue to diligently work for the improvement of life.Thank you for all of your support.

Focus Area : Pain reliving patches, Liniment, Aerosol, Wound care product.

Company Profile

Sinsin Pharm. Co., Ltd.RepresentativeHeadquarter Address


Hanki Kim

Korea Bio Park C-4F, 700, Daewangpangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, Korea

1955

Pain reliving and wound care etc.

240

82-31-776-1111

82-31-776-1117

www.sinsin.com


Woongjin Han

82-31-776-1141

[email protected]

177


1. SINSINPAS-RX Active ingredient : Out of 1 sheet (10x14cm, 2,301.24mg) L-menthol 90.9mg, dl-camphor 34.1mg, Mentha oil 45.46mg, Methyl salicylate 90.90mg, Vanillyl Nonylamide 0.114mg

IndicationMuscular pain, Joint pain, Shoulder pain, backache, Bruise, Sprain

U.S.A, Asian countries Pain Relief Patch

2. SINSIN PAS Pain relief Patch Active ingredient : Out of 1 sheet (6.2x 4.1cm, 453.29mg) Methyl salicylate 29.98mg, Thymol 0.77mg, L-menthol 36.32mg, DL-camphor 15.63mg, Borneol 1.20mg

IndicationMuscular pain, Joint pain, Shoulder pain, backache, Bruise, Sprain

U.S.A, EU, Asian countries.

Pain Relief Patch

3. SINSIN CAPSICUM PATCH Active ingredient : Out of 1 sheet (13x18cm, 2,400mg) Capsicum extract 0.025%

IndicationMuscular pain, Joint pain, Shoulder pain,Neuralgia, Rheumatism, backache

U.S.A, Middle East, Asian countries.

Pain Relief Patch

4. ICE COLD PAIN RELIEF PATCH Active ingredients (out of 8x12cm, 5.2g) • L-Menthol 5%

Indication• Muscular pain• Joint pain• Shoulder pain • backache• Bruise • Sprain

Exporting countryOver 15 countries including :• U.S.A (CVS, Wal green)• Poland• U.K (Boots )• Asia• RussiaICE COLD PAIN RELIEF PATCHPAIN RELIEF HYDRO GEL PATCHCode :SSP 3405

Pain Relief Patch

5. KETOCLIN PLASTER Active ingredients (out of 10×7cm, 0.7g ) • Ketoprofen 30mg

Indication• Arthritis Deformans • Peri-arthritis of shoulder• Tendinitis• Peri-tendinitis• Myalgia

Exporting countryOver 10 countries including :• HK• Vietnam• Macao• Iran• Guatemala

Pain Relief Patch,Transdermal Drug Delivery System (TDDS).

Main Products



Fiscal Year 2012 2013 2014

Sales 258,952 303,383 350,270

R&D Expenditure 24,500 30,621 34,910

Capital

Financial Figures

SK Chemicals is a member company of SK Group, the third largest company group in Korea.

Since founded in 1969, SK Chemicals has focused on the development of drug products targeting the diseases with unmet treatment needs in order to fulfill its vision; “Healthcare and Earthcare”.

The R&D area of SK Chemicals covers a broad range of product lines, including new chemical entities, new herbal extract drugs, reformulated generics, vaccines and blood products. Owing to its continuous efforts on R&D, SK Chemicals was able to develop three new chemical entities (NCEs), novel drug delivery system (DDS) flat foam technologies, recombinant DNA technology and in-house premium vaccines.

On the basis of this strong R&D capability together with its outstanding marketing operations, SK Chemicals was selected as a member of the Korea Innovative Pharmaceutical Company.

Company Profile

SK Chemicals Life ScienceRepresentativeHeadquarter Address


In-Serk Lee

310, Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, Korea

Jul. 1. 1969.

NCE, Herbal, Biologics

1593

82-2-2008-2008

82-2-2008-2959

www.skchemicals.com

179

Main Products


1. OMED Tab. (Omeprazole) Gastric Ulcer EU

2. SID710 Patch (Rivastigmine) Alzheimer's Disease EU

3. SK Albumin Inj. 20% (Human Albumin) Albumin DeficiencyEgypt, India, China, Hong Kong, Mongolia Dominican Republic

4. LIV-Gamma Inj. (Human IgG) IgG Deficiency Thailand, Peru, India, Egypt

5. Trast Patch (Piroxicam) Arthritis Saudi Arabia, China, Philippines

6. Ginexin Tab. (Ginko biloba) Blood Circulation Enhancer Saudi Arabia

7. Joins Tab. Arthritis Australia

8. SID530 Inj. (Docetaxel) Anti-cancer EU

9. SID820 Cap. (Esomeprazole) Gastric Ulcer EU

10. MvixS ODF (Mirodenafil) Erectile Dysfunction N/A



SUNPLA (Heptaplatin) Anti-cancer 1999

JOINS (Herbal Extracts) Arthritis 2002

Mvix (Mirodenafil) Erectile Dysfunction 2007

R&D Pipeline


NCE 401 Fibrosis Pre-clinical

NCE 403 Endometriosis Pre-clinical

HMP 301 Asthma Phase III

HMP 302 Alzheimer's Disease Phase III

HMP 304 Irritable Bowel Disease Phase II

NBP 606Prevention of infection caused by

Pneumococcal bacteriaPhase I

NBP 607 Prevention of infection caused by Influenza virus Phase I



Fiscal Year 2008 2009 2010

Sales 101,606 107,816 124,860


Capital 5,902 6,084 6,084

Financial Figures

Since Establishment in 1973, Suheung Capsule Co., Ltd have sought to produce only the highest quality capsules and thus grown to be one of the world’s leading manufacturers

and exporters of empty hard gelatin, fish and HPMC capsules.

Company Profile

Suheung Capsule. Co., Ltd.RepresentativeHeadquarter Address


Joo Hwan, YANG

Jung-An B/D 6F, 40, Janghan-ro, Dongdaemun-gu, Seoul, Korea

1973

500

82-2-2210-8193

82-2-2217-2356

www.suheung.com

181

Main Products


1. Empty hard gelatin capsules more than 40

2. Empty hard fish capsules more than 40

3. Empty hard HPMC capsules more than 40



Fiscal Year 2012 2013 2014

Sales 95,043,027 94,325,508 90,905,789

R&D Expenditure 4,836,463 6,355,765 7,686,165

Capital 92,603,127 101,850,598 91,917,685

Financial Figures

Taejoon Pharm., founded in 1978, is a global pharmaceutical company accomplished in exporting aseptic eye drops to Europe for the first time in Korea. In addition, we are the first specialized company to have technologies to make all three fields of contrast media products: X-ray, MRI, and CT. Taejoon Pharm’s Yongin plant, which was built in October, 2005, became Korea’s first EU-GMP certified plant to produce qualified pharmaceutical products that export to Europe.

Taejoon is implementing a marketing strategy, targeting countries of the world and continuously reinforcing pioneering movement by actively participating in internationally renowned academies and exhibitions. As a result, we were able to create a strong sales network among more than 50 countries, including 30 European countries. On this basis, we plan to strengthen the sales network with the goal of simultaneous release into the world in the event of global product launch. We expect to increase the company’s brand value by establishing the sales network through localized sales marketing in particular countries, such as the U.S., China, Russia, and Europe.

Focus Area : Ophthalmology, Gastrointestinal agents, Contrast media, etc.

Company Profile

Taejoon Pharm. Co., Ltd.RepresentativeHeadquarter Address



Tae Young Lee

8 Daesagwan-ro 31-gil, Yongsan-gu, Seoul, Korea

1978

Ophthalmology, Gastrointestinal agents, Contrast media, etc

385

82-2-799-0072

82-2-798-6665

www.taejoon.co.kr


Andy Lee

82-2-799-0072

[email protected]

183


Remarks

Ophthalmic solution

1. Cyporin N ophthalmic solution (Cyclosporine)

The increase of tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca

2. MC Free ophthalmic solution (Sodium carboxymethylcellulose)

Dry eyes for the temporary relief of burning, irritation and discomfort EU, USA

3. Hyaluni ophthalmic solution (Hyaluronic acid)

Bond and repair corneal epithelial cells, helps cure corneal injuries and retain and stabilize tears, dysfunction tear syndrome

4. Taejoon Ultra ophthalmic solution(Polyethylene Glycol)

Temporary relief of irritation and burning due to dryness of the eye USA

5. Xalost Plus ophthalmic solution (Latanoprost + Timolol maleate)

Reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension

EU, Russia, China

6. Xalost ophthalmic solution (Lataonoprost)

Reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension

EU, Russia, China

7. Alpaday ophthalmic solution (Olopatadine HCl)

Relief of allergic conjunctivitis

8. Fluvin ophthalmic solution (Fluorometholone)

Inflammatory diseases of the anterior/external segment of the eye (blepharitis, conjunctivitis, keratitis, etc)

Gastrointestinal agents

9. Coolprep (PEG 3350) Preparation for colonoscopy

10. Lamina G (Sodium Alginate)Hemostasis and remission of subjective symptom in gastric & duodenal ulcer, erosive gastritis

11. Gasocol Susp. (Simethicone) For elimination of gastric bubble for gastroendoscopy

12. Colyte (PEG 3350) Preparation for colonoscopy

13. Colyte F (PEG 3350) Preparation for colonoscopy

Contrast Media14. MRbester injection (Gadopentetate dimeglumine)

Contrast medium for cranial and spinal MRI/ whole body MRI Asia

15. Iobrix injection (Iohexol)Myelography, angiography, urography, contrast enhancement of computerized tomography

Asia

16. Radisense injection (Iopamidol)

Angiography throughout the cardiovascular system, including cerebral and peripheral arteriography, coronary arteriography and ventriculography, pediatric angiocardiography, selective visceral arteriography and aortography, peripheral venography (phlebography), and adult and pediatric intravenous excretory urography and intravenous adult and pediatric contrast enhancement of computed tomographic (CECT) head and body imaging

Asia

17. Iversense injection (Ioversol)For cerebral angiography and peripheral arteriography, contrast enhanced computed tomographic imaging of the head and body, venography, and intravenous excretory urography

18. Visisense injection (Iodixadol)

1. Intra-arterial intra-arterial digital subtraction angiography angiocardiography (left ventriculography and selective coronary arteriography), peripheral arteriography, visceral arteriography, and cerebralarteriography

2. Intravenous CECT imaging of the head and body, excretoryurography, and peripheral venography.

19. Solotop-HD (Barium sulfate)

Contrast enhanced x-rays or computed tomographic imaging (CAT scan, CT scan; a type of body scan that uses a computer to put together x-ray images to create cross-sectional or three dimensional pictures of the inside of the body) of the esophagus (tube that connects the mouth and stomach), stomach, and intestine

Asia

Main Products


Age-related Macular Degeneration (New Biological Entity)

AMD Phase 2/3

Antibiotic product (New Chemical Entity)

Bacterial conjunctivitis Pre-clinical

Dry eye product(New Chemical Entity)

Dry eye Pre-clinical

Combination or Improved drugs Ophthalmic/GI indications Phase 3 ~ Pre-clinical

R&D Pipeline



Fiscal Year 2012 2013 2014

Sales 38,000 43,000 50,000


Capital 16,000 17,000 20,000

Financial Figures

“Supply best quality pharmaceutical products to customer.” Since established in 1957, Tai Guk Pharm. Co., Ltd. has been manufacturing pharmaceutical products. We have focused on development of OTC products such a hydroquinone cream and professional and leading manufacturer of ointments(ointment, cream, gel) in Korea. We have largest plant in Korea for ointments at Buyeo and pushing to FDA approved Buyeo plant. We can also undertake contact manufacturing Tablet, Capsule, Internal & External liquid, and specially Ointments. We are export to USA and many other countries.

Focus Area : Ointment & Cream

Company Profile

Taiguk Pharm. Co., Ltd.RepresentativeHeadquarter Address


Chang Koo Lee

123, Jeyakgongdan 3-gil, Hyangnam-eup, Hwaseong-si, Gyeonggi-do, Korea

1957

284

82-2-3474-7761

82-2-2051-2597

www.taiguk.co.kr


You Mi Kim

82-2-3474-7761

[email protected]

185


1. Highrosone Cream (Hydrocortisone / Cream) Dermatitis Cambodia

2. Paracool Cream (Methyl Salicylate, l-Menthol, dl-Camphor / Cream)

Pain Relief Vietnam

3. Pramyxin Ointment (Bacitracin Zinc, Neomycin sulfate , Polymyxin B Sulfate, Pramoxine HCl / Ointment)

Antibiotics Hongkong

4. Partygel Suspension (Almagate / Gel) Hyperacid Vietnam

5. Miobi soft cap. (Vitamin A and other ingredients / Capsule)

Multi Vitamin Ecuador

Main Products



Fiscal Year 2012 2013 2014

Sales 65,757 56,398 52,244

R&D Expenditure 5,710 3,914 2,815

Capital 13,627 13,887 13,887

Financial Figures

THERAGEN ETEX CO., LTD. is a leading pharmaceutical company to develop innovative and personalized new drugs having a world class analysis technology of individual genome.

Excellent System : We have manufactured outstanding pharmaceuticals by controlling all lines at GMPs factory from manufacturing to quality controls in compliance with WHO/ICH Guideline.

Best Bio center : Our laboratory having the best analysis technology and excellent analysts of the genome in Korea. The first and the best results of studies to be recognized in the world - Whole genome mapping of woman, tigers and whales(the first in the world) - Commercialized personal genome analysis service(the first in Asia)

Innovative New drug : THERAGEN ETEX CO., LTD. has built databases and infrastructures to develop personalized pharmaceuticals by analysing individual’s disease genes as the only pharmaceutical manufacturing facilities and genome analysis service in Korea.

Focus Area : E.N.T & Cardiovascular

Company Profile

Theragen Etex Co., Ltd.RepresentativeHeadquarter Address


Kyu won Ji

5F, 32, Nonhyeon-ro 30-gil, Gangnam-gu, Seoul, Korea

Oct. 1. 1990

First Generic & Slow release type drug

216

82-2-3463-7111

82-2-3463-8111

www.thera-gen.com


Sun-Hee, Kim

82-2-3463-7111

[email protected]

187


1. ETEXCITICOLINE Tab. (Cilticoline 500mg)Memory disorderIschemic stroke

Vietnam

2. CELEMIN Cap. 200mg (Celecoxib 200mg) NSAID Vietnam

3. NEXON Tab. 20mg/40mg (Esomeprazole 20mg/40mg)

Gastritis Vietnam

4. RABEZOLE 10mg/20mg (Rabeprazole 10mg/20mg)

Gastritis Vietnam

5. EXPERA Tab. 5/80 (Amlodipine 5mg + Valsartan 80mg)

Hypertension Philippines

6. ATOSEN Tab. (Atorvastatin 10mg) Hyperlipidemia Vietnam

7. ETEX ROSUVASTATIN Ca Tab. (Rosuvastatin Ca 5mg/10mg/20mg)

Hyperlipidemia Philippines

8. ZAKUTEX Dry syrup 156.25mg/5mL (Amoxicillin hydrate 21.6248g + Diluted potassium calvulanate 10.8124g)

Chronic branchitis Myanmar

9. ZAKUTEX Neo Dry syrup (Amoxicillin hydrate 54.5454g + Diluted potassium calvulanate 7.8g)

Acute otitis media for children

Vietnam

10. CLAROCIN Tab. (Clarithromycin 250mg) Antibiotics Vietnam

11. UMCKAMAX Syrup (Pelargonium sidoides 11%EtoH ext.17.16mg)

BronchitisLaryngopharyngitis

Vietnam

12. CRANTOL Syrup (Ambroxol HCl 150mg + Clenbuterol HCl 0.1g)

Cough Nigeria

13. CITLEN Solution (Citrulline maleate 1g) Fatigue recovery Vietnam

14. ETEX CYCLOSERINE Cap. (Cycloserine 250mg)

Tuberculosis Vietnam

15. ZENTOX Tab. (Albendazole 400mg) AnthelminthicUzbekistanAzerbaijanKyrgyzstan

16. OEANZIL Vaginal Soft Cap. (Neomycin 35,000IU, Nystatin 10,000IU, Polymyxin B sulfate 35,000IU)

Vaginal infectionMyanmarCambodia

17. SIMTUM-TWO Tab. (Acetaminophen 325mg, Phenylphrine HCl 5mg, Dextromethorphan hydrobromide 10mg, Chlorpheniramine maleate 2mg)

Cold Hongkong

Main Products



Fiscal Year 2012 2013 2014

Sales 42,294 40,467 48,715


Capital 2,100 2,100 2,100

Financial Figures

Union Korea Pharma is pharma manufacturing company, certificated GMP compliance of tablet, capsule, injection(ample, vial) and cephalosporin powder from MFDS Korea.

We have exported to Vietnam, Cambodia, Philippines, Hongkong, Mongo, Peru, Chile, Bolivia, Yemen, Azerbaijan etc, and we had received Presidental Award by small and medium enterprise export support center in 2009.

Focus Area : Antibiotics(Cepha inj.), Cardiovascular, Degenerative Disease, Contrast media, Ophthalmology

Company Profile

Union Korea Pharm. Co., Ltd.RepresentativeHeadquarter Address


Sung Jun Kim

6F, ABN Tower B/D, 331, Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, Korea

Nov. 1956

Infectious disease

220

82-2-489-3611

82-2-487-3611

www.ukp.co.kr


Jeongsu Ock

82-2-489-3611(Ext.311)

[email protected]

189


1. Unitiaxone Inj. (Ceftriaxone Sodium 1g)

Respiratory system infection, infection related otolaryngology renal and urinary tract infection, septicemia meningitis, prophylactic of pre/post operation infection, osteoarthritis, skin and soft tissue infection, cholecystitis, G.I. tract infection.

Vietnam, Philippines,

Yemen

2. Uni-Infusion Inj. (L-Ornithine-L-Aspartate 500mg)

Hepatic dysfunction - Acute and chronic hepatitis, alcoholic liver disease; post hepatitis convalescence, cirrhosis, along with hepatotoxic drugs.

Vietnam, Mongol

3. Union Cefuroxime Sodium Inj. (Cefuroxime Sodium 750mg)

Acute or chronic bronchitis, bronchiectasis, bacterial pneumonia, pneumonial abscess, post-operational chest infection, sinusitis, tonsilitis, pharyngitis, nephropyelitis, cystitis, cellulitis, eryspelas

Vietnam, Philippines

4. Climycin Inj. (Clindamycin phosphate 600mg)

Infections caused by susceptible anaerobic bacteria

Vietnam, Philippines

5. Unifenac Inj. (Diclofenac Sodium 75mg)

Fever and pain due to cold, headache, neurodynia, muscle ache, menstrual cramps, rheumatoid arthritis, arthralgia, toothache

Vietnam

Main Products


Combined antibiotics with beta-lactamase

bacterial infections (upper respiratory tract infections).

Phase III trial

R&D Pipeline



Fiscal Year 2008 2009 2010

Sales 92,915 99,387 105,687

R&D Expenditure 4,534 4,385 5,995

Capital 97,843 108,436 124,881

Financial Figures

We are pursuing a healthy society through supplying good medicines to medical profession. Having established in 1978 as a specialized manufacturer of psychotherapeutics, we have been devoting ourselves to become a leading specialty company in Korea by satisfying the needs in the following areas where we have special competencies :

- CNS disorders & Neurodegenerative diseases

- Age related disorders

- New areas of unmet medical needs

Company Profile

Whan In Pharm. Co., Ltd.RepresentativeHeadquarter Address



WonBum Lee

117, Saemal-ro, Songpa-gu, Seoul, Korea

Jun. 5. 1978

CNS disorders & Neurodegenerative diseases, Age-related disorders and new areas of unmet medical needs

407

82-2-405-3000

82-2-405-3182

www.whanin.com

191

Main Products


1. RIPERIDONE (Risperidone) Antipsychotics

2. QUETAPINE (Quetiapine) Antipsychotics

3. ALPRAM (Alprazolam) Tranquilizer

4. URANTAC (Ranitidine) Pepticulcer

5. ZOLPILAM (Zolpidem) Anxiolytics & Hypnotics

6. WI ACAMPROSATE (Acamprosate) Alcohol dependence

7. WI GRANDAXIN (Tofisopam) Anxiolytics

8. METADATE CD (Methylpenidate) ADHD

9. NUREPTOL (Gabapentin) Anticonvulsants

10. WI DONEPEZIL (Donepezil) Antidementia



NEPONID (Nemonapride) Antipsychotics Jan. 1994

R&D Pipeline


WIN-34B Osteoarthritis under PhaseⅡ

WIP-901C Osteoarthritis Pre-clinical

WIN-901X Asthma Pre-clinical

WIN-902A Anti-obesity Pre-clinical

WIN-1001X Anti-parkinsonism Pre-clinical



Fiscal Year 2008 2009 2010

Sales 2,790,000,000 3,125,000,000 3,567,000,000

R&D Expenditure 4,500 3,600 3,200

Capital 3,000,000,000 3,000,000,000 3,000,000,000

Financial Figures

Founded by Wonkwang University on the basis of Bohwadang, a pharmacy established in 1934 under the slogan ”Save all living things from distress and sickness” Wonpharm Co., Ltd. manufactures over 180 medicines, lncluing Gyeongokgo under strict quality control, and over 20 health foods, incluing Wonkwang Bohwaokgo and Hyosam Forte, at its KGMP-certified factory equipped with clean facilities.

Wonpharm CO., Ltd., which has been designated as cooperative business for research in pharrmaceutical resources as well as the practice factory for Pharmacy College, Wonkwang University, devotes itself to technical development for a society free from disease.

it has aiso established a solid educational industrial research system with medical College, Oriental Medical Center of Wonkwang University.

Company Profile

Won Kwang Pharm. Co., LtdRepresentativeHeadquarter Address


Yong Jeong Park

165, Seogam-ro 11-gil, Chunpo-myeon, Iksan-si, Jeollabuk-do, Korea

May. 1934

Save all livings from distress and sickness

40

82-80-359-3333

82-63-833-4114

www.wonpharm.co.kr

193

Main Products

BoHwa KyungOkKo is composed of Korean Ginseng Hoelen, Rehmannia juice, and sweet honey based on the prescription of the korean traditional medical book known as Dong Eui Bo Kam (UNESCO recognizes as a world legacy of the record). This product is well recognized as a restorative enforcing the vitality of whole organs, and also as elimination fatigues, exhaustion followed by weariness. Because of the special properties that had no any interferences against any foods, this product has been used by the ancient royal family and the nobles. Especially this product improves the growth of children and the

recovery from weariness due to illness of stress.


1. Bohwa Kyungokgo

2. Bohwa Sohap won

3. Woohwang chungsimwon Suspension liquid



Fiscal Year 2012 2013 2014

Sales 74,169 75,372 85,651

R&D Expenditure 3,535 2,640 3,418

Capital 3,000 3,000 3,000

Financial Figures

Yooyoung has established a foothold for growth through consistent increasing sales, and we are growing as a leading pharmaceutical company in Korea by fulfilling our medium and long term mission.

Focus Area : Arthritis, Anti-Thrombosis, Mixed-Dylipidemia, etc.

Company Profile

Yoo Young Pharm. Co., Ltd.Woo-Pyoung Yoo

Yooyoung B/D, 93, Hyoryeong-ro, Seocho-gu, Seoul, Korea

Dec. 23. 1981

New Drug & IMD

320

82-2-6207-6114

82-2-6202-7067

www.yypharm.co.kr




Mr. Choi

82-2-6202-7116

[email protected]

195


1. Atri InjectionArthritis, Scapular periarthritis

Poland, Syria, UAE, Russia, Vietnam, Japan

CTD Dossier Available

2. Atri Plus InjectionArthritis, Scapular periarthritis

Poland, UAE, Russia, Malaysia


3. Cnoxane InjectionLMWH : Anti-Coagulant

Russia, Syria, Philippines, Vietnam


4. Asasulfan Tablet Ulcerative colitis Japan

Main Products


Stem cell Neuronata-R ALS On Market

IMD/DDS Artis-FR Gastric ulcer Registration

Monoclonal Antibody YYB101 Anti-cancer Phase 1

IMD/DDS YY1201 OA Phase 1

IMD/New combination YYC301Neuropathic

PainPreclinical

IMD/Release control YYD601 GERD Preclinical

IMD/New HA filter YYD701 Dermal Filler Preclinical

Fusion Protein YYB102 Anti-cancer Discovery

R&D Pipeline



Fiscal Year 2008 2009 2010

Sales 595,720 630,347 649,324

R&D Expenditure 34,317 35,495 41,208

Capital 862,941 967,425 1,072,464

Financial Figures

Founded in 1926 with the mission of supporting South Korea by enhancing the quality of life for all people, Yuhan has been providing high quality medicines for the last 85 years as one of the leading pharmaceutical companies in South Korea.

Since its foundation, Yuhan has set the foremost priority to provide the best medicines by building its R&D. In 2005, Yuhan moved its central research to Giheung, Gyeonggi-do, and opened the largest R&D center in the South Korean pharmaceutical industry. With state-of-the-art facilities, Yuhan is committed to deliver advanced and innovative medicines to enhance quality of life.

Yuhan is focusing its R&D capabilities on developing new chemical entities, herbal medicines, market-oriented IMDs(Incrementally modified drugs), and APIs/intermediates for overseas markets.

Company Profile

Yuhan Corp.RepresentativeHeadquarter AddressFoundation DateResearch Focus


Yoon Searb Kim

74, Noryangjin-ro,Dongjak-gu, Seoul, Korea

Dec. 1926

Gastrointestinal disease, Cardiovascular disease, Metabolic disease

1,480

82-2-828-0429

82-2-828-0080

www.yuhan.co.kr

197

Main Products


1. Piperacillin Monohydrate Antibiotic USA, Europe

2. CMO-HIV New Drug (API 1) HIV USA, Europe



5. Ribavirin HCV USA, Europe

6. Cilostazol Anti-platelet USA

7. CMO-HCV New Drug (API4) HCV USA

8. PEG-Thiol Coagulant USA

9. PEG-NHS Coagulant USA

10. Levofloxacin Antibiotic Canada, Japan



Revanex (Revaprazan) Duodenal Ulcer, Gastiric Ulcer, Gastritis Sep. 2005

R&D Pipeline


IMD1 Anti-platelet Phase I

IMD2 Cardiovascular Disease Phase I

IMD3 Pain Phase I

IMD4 NERD Phase II

YHD1044 Premature Ejaculation Phase II

YH14617 Diabetes Phase II

YH14642 Periodontal Disease Phase II

YHD1023 Erectile Dysfunction Phase II

YHD001 Asthma/Bronchitis Phase II

YH4808 GERD Phase II

YH14618 Degenerative Disc Phase I/II

YH14619 Osteo Arthritis Phase I

YH14810 Cancer (Immune modulator) Phase I

YHB1411-2 Rheumatoid Arthritis Phase I

YH**** Diabetes Phase I

YH**** Irritable Bowel Syndrome Phase I



Fiscal Year 2008 2009 2010

Sales 45,014 47,900 52,027

R&D Expenditure 1,023 1,421 487

Capital 64,591 70,458 70,642

Financial Figures

Yuyu Pharma Inc, established in 1941, is a company that sales, markets and manufactures pharmaceutical products in Korea and has developed its business through not only in-house developed new drugs but also various partnerships with global companies such as Sanofi-Aventis, Pfizer, GSK and Novartis by incensing in their original products for the Korean market.

Yuyu Pharma has focused on how to serve the aging population, as people are living longer and searching for ways to live a healthier life. This has led us to be a specialist in the fields of neurology, osteoporosis, cardiovascular and nephrology. Yuyu’s treatment in these areas has proven to be fruitful and we will continue to focus on these therapeutic categories. In order to expand the business, we are also expanding our presence in the field of gastrointestinal diseases and antibiotics.

Also, Yuyu has completed new state-of-art factory in 2006. The factory designed in accordance with cGMP and EU GMP. Tablets, capsules and cream are manufactured with advanced equipment under cGMP compliance.

We would like to have an opportunity for the business relationship with your company who is dealing with imported finished pharmaceutical products.

Company Profile

Yuyu Pharma, Inc.RepresentativeHeadquarter AddressFoundation DateResearch FocusTotal StaffRepresentative PhoneRepresentative Fax Web

Seungpil Yu

Yuyu B/D, 197, Dongho-ro, Jung-gu, Seoul, Korea

1941

New Drug, Botanical Drug

257

82-2-2253-6600

82-2-2253-6200

www.yuyu.co.kr

199

Main Products


1. Maxmarvil tablet (Alendronate, Calcitriol) Osteoporosis Thailand

2. Yuclid tablet (Ticlopidine, Ginkgo biloba) Antithrombotics

3. Bonky soft capsule (Calcitriol) Osteoporosis Malaysia, Vietnam

4. Bonky Injection (Calcitriol) Hypocalcemia Malaysia, Pakistan

5. Yupan-C tablet Vitamin-C Philippines

6. Venoforte Injection (Aesculus hipp. ext.) post-operative swelling Syria

7. Venoforet gel (Heparine,Aescine,Glycol) Swelling Hongkong

8. Mycobutin tablet (Rifabutin) Antitubercular agent

9. Yucezone Injection (Cefezone) Antibiotic Vietnam

10. Yuroxim Injection (Cefuroxime) Antibiotic Vietnam

R&D Pipeline


Ginkgo Blood circulation Launched

Alendronate Osteopoeosis Launched

vitamin D3 Osteodystrophy Launched

Ticlopidine Ischemic stroke Launched

Ginseng, Ginkgo ADHD Phase Ⅲ


C&R ResearchRepresentativeHeadquarter Address


Moon Tae Yoon

Daechi MS B/D, 412, Yeoksam-ro, Gangnam-gu, Seoul, Korea

1997

Contract Research Organization

+220

82-2-6251-1500

82-2-6251-1504

www.cnrres.com

C&R Research Inc. (hereinafter “C&R”), the first CRO (Contract Research Organization) in South Korea was established in 1997 leading the development of Korean CRO industry with a market share of over 30% in the past five years (2011~2014).

From accumulated proven capability, C&R is the No. 1 CRO in the field of regulatory clinical trials encompassing clinical development phase I-III in South Korea with the most extensive experience and know-how. C&R has conducted more than 750 clinical trial projects in various global therapeutic areas with over 140 customers around the world successfully.

More than 50% of all clinical trials being performed is a global type and C&R is getting regular system audit and being confirmed of competency and qualification constantly from the global sponsor and has secured an excellent global clinical trial execution capabilities accordingly.

In 2008 C&R was awarded as “South Korea Clinical Research Organization of the year” from Frost & Sullivan which was awarded for the first time in CRO companies in Korea.

Also, C&R has been selected as MAIN-BIZ / INNO-BIZ certificated for business innovation and technology, and established C&R R&D Center (Research Laboratory) that provides data analysis and publishes trend analysis and forecast report about clinical trial in South Korea.

C&R is running a specialized Oncology & Biology team and Marketing & LPS (Late Phase Study) team. Oncology & Biology team have been dedicated to the oncology and biology clinical trials. It was selected as a CRO partner of National Onco Venture, a

government agency focusing on R&D for anticancer drugs, which is being currently operated. Marketing & LPS (Late Phase Study) team is specialized division for the enhancement of the Phase IV stage providing services of consulting, planning and clinical services targeting for Phase IV, Observational Study and Post Market Surveillance.

C&R Research China Inc. was established in Beijing in 2010 by focusing on the Chinese market providing drug registration, clinical trial services and China market entry strategy consulting services, and C&R is planning to set up additional subsidiaries in China in 2015.

In 2012, an Asia CRO alliance called, A-PACT (Alliance for Pac-Asia Clinical Trials) was established with the founding members including C&R Research, performing its role as a leading CRO community in Asia-Pacific region. Through strong network relationships with competitive global CROs and regional CROs over five, C&R can provide a multinational clinical trial service including Asia-Pacific regions.

Moreover, C&R has implemented a consistent internal training to strengthen the recruitment and staff competencies by operating training & Operations practice team and also have contributed to the development of clinical experts through C&R Academy.

C&R has the largest QA organization among Korea CRO which was established C&R QA separately from C&R Research in Aug 2014. It has been providing a variety of professional QA services with more than five auditors.

Company Profile


Bomi Jeon

82-70-4033-3010

[email protected]

201

Introduction of C&R Academy

Introduction

C&R Academy was founded in May 2010 aimed at being a clinical trial training center in Northeast Asia, offering a wide range of training programs related clinical trials.Now C&R Academy provides professional, comprehensive and practical “hand-on” clinical research training and continuous education programs to researchers (PI) and research nurses (CRC) as well as CRA, PM, CRM to improve the quality of clinical trials.Training programs of C&R Academy is consists of Fundamental Course, Basic Course, Monitoring Practice, Clinical Project Management, GCP Training, Oncology Clinical Trial, Early Phase Study, Introduction to Clinical Trial and so on. All training programs can expect the effect of intensive training workshop conducted in the form of a small two-way communication.In addition, since 2011, C&R Academy introduced LMS (Learning Management System) and have been strived to improve the validation and quality of educational services for all C&R Academy as ISO9001 certified company. C&R Academy will to be oriented to international standards of clinical training services continuously.

Training programs

Instructor-led Courses - Fundamental of Clinical Research & Practice - Basic Course of Clinical Research & Practice - Clinical Project Management - Monitoring Practice for Clinical Research - Introduction to Clinical Trial - Good Clinical Practice Training

- Oncology Clinical Trial - Early Phase StudyOnline Training Courses - Clinical Trial Guidance - Monitoring in Clinical Research, GCP Guidelines,

Overview of Drug DevelopmentIn-Company Training Courses

Contact information Help Desk: +82 70 4033 3017 e-mail: [email protected] Web: www.cnracademy.org

Introduction of C&R QA

Introduction

C&R QA Inc. (hereinafter C&R QA), founded in Aug 2014, is the first company specialized in quality assurance of clinical trials in South Korea. C&R QA is established for the purpose of enhancing the professionalism of the quality assurance work of clinical trials independently from C&R Research that had provided quality assurance services such as audits in a variety of therapeutic areas, education and preparation for government authority inspection. As the importance of quality assurance of clinical trials has been increasingly emphasized, C&R QA is aiming to provide quality assurance services of clinical trials to customers with credibility. All auditors of C&R QA have a membership of RQA (Research Quality Assurance) and Auditor certificates, especially lead auditors have a certificate of ‘Registered Quality Assurance Professional’ by SQA(Society of Quality Assurance). C&R QA will continue to devote itself to be the best partner for customers in the field of quality assurance of clinical trials by ensuring that the clinical trial is performed and the data are generated, documented (recorded), and reported in compliance with Good Clinical Practice (GCP) and the applicable regulatory requirement(s).

Services

- Risk-based Quality Management - Good Clinical Practice Audit - Good Laboratory Practice Audit - Good Pharmacovigillance Practice Audit

- Due Diligence Audit - Mock Inspection - Quality Assurance Consultation - Standard Operation Procedure Development - Training

Contact information Contact Person: Jiyeon Hwang TEL: +82 70 4033 3054 E-mail: [email protected] Web: www.cnrqa.com

Main Service

Regulatory Affairs Services IMPD prep. & Consulting, IRB submission, IND submission, NDA submission & approval

Medical Affairs Services Protocol development, CRF development, ICF development, CSR writing, Medical translation

Statistical Analysis Services Statistical programming/ analysis, Randomization, Sample size calculation

Clinical Operation Services Site feasibility & contract, Project management, Monitoring, Budget management, Inspection

Data Management Services DB design, Paper & EDC based data management (manual & programming), Clinical Coding , AE report to KIDS etc

Electronic Data Capture Services EDC system develop. & maintenance (Medidata RAVE, Oracle Inform GTM, etc, ...), IWRS

Medical Translation Services Medical document translation & verification

Quality Assurance Services External audit, GCP & GLP & GPP Audit, CQMS, Due diligence, Mock inspection, SOP development

C&R China Services Multinational Trial Consulting-Market Feasibility Assess in China, CRO service, Pharmaceutical Licensing

Asia Pacific Clinical Trial Services Multinational Trial Consulting-Market Feasibility Assess in China, CRO service, Pharmaceutical Licensing

Global Clinical Trial Services US FDA pre-IND consulting/IND Submission, US Phase I & II Trial


CrystalGenomics, Inc. is a commercial stage biopharmaceutical company that is dedicated to the discovery and development of novel pharmaceuticals with innovative platform technologies to address significant unmet medical needs in the therapeutic areas of infectious disease, oncology and inflammatory diseases. The Company is headquartered in Korea and has a US presence for multi-national clinical development in California, and is publicly traded on the KOSDAQ exchange.

CrystalGenomics’ first product, Acelex® (polmacoxib), has recently been approved by the Korean MFDS and is expected to be launched within the first half of 2015. Acelex is a next generation NSAID for the relief of signs and symptoms of osteoarthritis.

CrystalGenomics has two therapeutic programs in the clinic. The first program is CG400549, a first-in-class antibiotic candidate for MRSA where its phase 2a skin infection study in the US had been completed with an excellent positive outcome of 100% clinical cure rate. The second program is CG200745, a molecular targeted anti-cancer therapeutic for various types of liquid and solid tumors of which is ready for a phase 1b/2 MDS (Myelodysplastic Syndromes) study in Korea.

The business model of CrystalGenomics is to independently conduct discovery through clinical proof-of-concept phase and then out-license the ex-Korea rights to either multi-national or local pharmaceutical companies for specific regions for further development and commercialization outside of Korea, while independently conducting development and commercialization for the Korean market. By leveraging its capabilities and the know-how in novel drug R&D, CrystalGenomics will continue to strive in making significant contributions in the improvement of human health.

Focus Area : Infectious disease, oncology and inflammatory diseases

Company Profile

CrystalgenomicsRepresentativeHeadquarter Address



Joong Myung Cho

5F, Korea Bio Park A, 700 Daewangpangyoro, Bundanggu, Seongnamsi, Gyeonggido, Korea

Jul. 7. 2000

Discovery and development of novel therapeutics in unmet medical need areas

80

82-31-628-2700

82-31-628-2701

www.cgxinc.com


Steven Kim

82-31-628-2720

[email protected]

203


Fiscal Year 2012 2013 2014

Sales 3,719 4,796 4,536

R&D Expenditure 7,029 6,646 6,558

Capital 22,514 36,931 55,729

Financial Figures



Acelex® (polmacoxib)Indicated for the relief of signs and symptoms of osteoarthritis

February 5, 2015 / Korea

R&D Pipeline


HDAC Inhibitor CG200745Various solid and liquid tumors including MDS, AML, pancreatic and liver cancer

Phase 1b/2 ready

FabI Inhibitor CG400549

MRSA (Methicillin Resistant Staphylococcus aureus) and other serious infections associated with Staph aureus

Phase 2a completed

BTK/FLT3 Inhibitor CG026806 AML Preclinical


Acelex® (polmacoxib)

Indicated for the relief of signs and symptoms of osteoarthritis

Currently none

Currently in discussions with multiple potential partner companies from the Emerging markets including China, Russia, Turkey and South America

Main Products


GL PharmTech (GLPT ) has focused on developing improved vers ions of the cur rent ly mar keted pharmaceutical products with reduced side effects, greater therapeutic efficacy and better patient compliance using our proprietary drug formulation and delivery technologies since 2002.

We have provided more than 50 pharmaceutical companies in Korea with value-added drug formulations and delivery technologies for generic and improved version of marketed drug.

We are now transitioning from a being a technology transfer-based operat ion to being a specialty pharmaceutical company capable of developing and delivering new product lines by ourselves from 2010. We are doing this based on intensive investment in various clinical studies of products currently in our pipelines and using our already-established drug delivery platform technologies.

*Technology - GLARS(Geometrically Long Absorption Regulated System)

Conventional sustained release drug delivery systems such as ALZA’s OROS (Osmotic Release Oral System) and Skyepharma’s Geomatrix, have enjoyed great success in the field of a drug dosage form reformulation. Although these systems extend the drug release up to 24 or 48 hours, the simple extension of drug release time would be meaningless because a practical absorption site of overall drugs is generally limited to a small intestine consider the total transit time along the small intestine with absorption will be only 4 to 6 hrs. This means that

relatively large amounts of the incorporated drug would pass out without a sufficient practical absorption. To overcome the shortcomings of the currently existing sustained release drug delivery technologies we have recently developed a novel drug delivery system to enable a drug to be dissolved irrespective of the surrounding environment and further absorbed up to colon. We coined this “Geometrically Long Absorption Regulated System (GLARS)”. Basically, this system is a triple-layered tablet, comprised of upper and lower layers that swell and draw a sufficient amount of water, plus a highly water-soluble middle layer that rapidly draw water into the tablet core simultaneously.

As the middle layer induces a rapid water draw into the tablet core, the penetrated water also diffuses to the upper and lower layers, which makes the tablet to rapidly swell and controls drug release. At virtually the same time, the swollen upper and lower layers form to surround a lateral side of the middle layer, which can, in turn, further control drug release. This relatively rigid swollen matrix structure makes drug release not affected by surrounding mechanical flux, which can provide relatively consistent in vivo drug release irrespective of degree of gastrointestinal motility. The water drawn into the tablet (about 3 to 5 times the weight of the tablet itself ) functions as an additional media which enables additional and later drug release out of the dosage form. This serves to overcome the shortage of surrounding media that has been reported to be one of the key reasons for mal-absorption of a drug in colon.

Focus Area : IMD(Incrementally Modified Drugs)

Company Profile

GL Pharm TechRepresentativeHeadquarter Address


Hunsik, Wang

#714 Jungang Induspia V, 137, Sagimakgol-ro, Jungwon-gu, Seongnam-si, Gyeonggi-do, Korea

Aug. 2002

IMD(Incrementally Modified Drugs)

27

82-31-739-5220~3

82-31-739-5224

www.glpt.co.kr


Jun Sang Park

82-31-739-5220(Ext. 324)

[email protected]

205

Main Products


1. G-soren Tab. (Artemisiae Argyi Folium Isopropanol ext.(20→1))

Gastritis

2. GL2803(Glimepiride plus Metformin XL) Diabetes

3. GL1203(Tamsulosin)BPH (Benign Prostatic Hyperplasia)

4. GL1204(Felodipine ER) Hypertension

5. GL1314(Ramipril) Hypertension

6. GL1317(Pantoprazole) Gastric ulcer

7. GL1319(Nifedipine SR) Hypertension

8. GL1320(Doxazosin XL) BPH

9. GL1405(Paroxetine CR) Depression

10. GL1502(Limaprost) Buerger's disease

11. GL1505(Tolterodine LA) BPH

12. GL1507(Rabeprazole) Gastric ulcer

13. GL1606(Tramadol plus acetaminophen) Pain

14. GL1608(Atorvastatin) Hyperlipidemia

15. GL1712(Tacrolimus) Immunosuppressant

R&D Pipeline


Tamsulosin plus Finasteride FDC GL2701 BPH Phase III

Tamsulosin new QD GL2702 BPH Phase III

Oxycodone XL GL2907 Pain Phase I

Pregabalin QD GLA5PR Pain Phase I

Paroxetine CR GLE3PA Vasomotor Symptoms Phase III

Ropinirole XL GL1901 Parkinson's disease BE test


Fiscal Year 2012 2013 2014

Sales 4,021 3,765 7,301

R&D Expenditure 1,007 1,088 1,158

Capital 1,162 1,162 1,162

Financial Figures

No Company Phone Fax Address Homepage

1 Aestura Corporation 100 Cheonggyecheon-ro, Jung-gu, Seoul www.aestura.com/

2 Ahn-Gook Pharm. Co., Ltd. 82-2-3289-4200 82-2-847-8867 993-75 Daelim-dong, Yeongdeungpo-gu, Seoul www.ahn-gook.com

3 Aju Pharm Co., Ltd. 82-2-2630-0700 82-2-2636-7519 413-13 Shindolim-dong, Guro-gu, Seoul www.asiapharm.co.kr

4 Alcon Korea Ltd. 82-2-2007-5000 82-2-2007-5001 Glasstower, Teheran-ro 534, Gangnam-gu, Seoul 135-708 www.alcon.com

5 Alpha Pharm. Co., Ltd. 82-54-552-5381 82-2-54-552-5385 662 Jinjeong-ri, Sanyang-myeon, Mungyeong-si, Gyeongsangbuk-do www.alphapharm.co.kr

6 Arlico.co.Ltd. 82-2-520-6943 82-2-3474-3281 Alico Building, 70-5 Yangjae-dong, Seocho-gu, Seoul www.arlico.co.kr

7 ASTELLAS Pharm Korea, Inc 82-2-3448-0504 82-2-3448-0510 GumHa B/D 6F 41-2 Chungdam-dong, Gangnam-gu, Seoul www.astellas.com/kr

8 B. Braun Korea. Co., Ltd 82-2-3459-7800 82-2-3453-3060 Posco center 13F, 892 Daechi-dong, Gangnam-gu, Seoul www.bbraun.co.kr

9 Baxter Inc. 82-2-6262-7100 82-2-6272-7101 KNTO B/D 5F,10 Da-dong, Jung-gu, Seoul www.baxter.co.kr

10 Bc world pharm. Co.,Ltd. 82-2-2182-0403 82-2-574-5064 Kyung B/D .Gaepo-dong 1184-8 , Gangnam-gu, Seoul www.bcwp.co.kr

11 Binex Co., Ltd. 82-6710-7235 82-2-6710-7299 Ilshin B/D, Dohwa-dong 541, Mapo-gu, Seoul www.bi-nex.com

12 Bolak. Co., Ltd. 82-31-352-6455 82-31-352-4341 307-1 Songsan-ri, Yanggam-myeion, Hwaseong-si, Gyeonggi-do www.bolak.co.kr

13 Boryung Pharm. Co., Ltd. 82-2-708-8000 82-2-708-8439 Boryung B/D, 66-21 Wonnam-dong, Jongno-gu, Seoul www.boryung.co.kr

14 BTO Pharm. Co., Ltd. 82-2-501-4720 82-2-543-8401 3F Daebo Building, 102-6 Munjeong-dong, Songpa-gu, Seoul www.btopharm.com

15 Bukwang Pharm. Co., Ltd. 82-2-828-8114 82-2-828-8029 398-1 Daebang-dong, Dongjak-gu, Seoul www.bukwang.co.kr

16 Celltrion Pharm. Inc 82-32-850-5000 82-32-850-4309 13-6, Songdo-dong, Yeonsu-gu, Incheon www.celltrionph.com

17 Chemtros Co., Ltd 82-31-491-0653 82-31-491-0881 7 Neungan-ro, Danwon-gu, Ansan-si, Gyeonggi-do www.chemtros.com

18 Cho-a Pharm. Co., Ltd. 82-2-2166-4000 82-2-2166-4111 Ace Techno Town 1F, 55-7 Moonrae-dong 3 ga,Youngduengpo-gu, Seoul www.choa.co.kr

19 Chodang Pharm. Co., Ltd. 82-2-869-0181 82-2-869-1192 44 Guro 5-dong, Guro-gu, Seoul www.chodang.com

20 Chong Kun Dang Pharm. Corp. 82-2-2194-0300 82-2-2194-0369 Chong Kun Dang B/D 368, Chungjeongno 3-ga,

Seodaemun-gu, Seoul www.ckdpharm.com

21 Chunhedang Pharm. Co., Ltd. 82-31-675-5561 82-31-676-6320 246-47 Dodang-dong, Wonmi-gu, Pucheon-si, Gyeonggi-Do

22 CJ Healthcare CJ Cheiljedang Center, 330, Dongho-ro, Jung-gu, Seoul 100-400, Korea www.cjp.co.kr/

23 CMG Pharmaceutical CO.,Ltd. 82-2-3453-8816 82-2-3453-8819 7F MJL Building, 204-5 Nonhyun-dong, Gangnam-

gu, Seoul www.cmgpharma.co.kr

24 Cmic CMO Korea Co.,Ltd. 82-32-678-5771 82-32-675-3385 157-3 Dodang-dong, Wonmi-gu, Pucheon-si, Gyeonggi-Do www.cmic-cmo.co.kr

25 Crown Pharm. Co., Ltd. 82-31-443-3922 82-31-443-3921 218-7 Anyang7-dong Manan-gu, Anyang si, Gyeonggi-Do www.crownpharm.co.kr

26 CTCBIO, Inc 82-2-70-4033-0200 82-2-449-6966 CTC Building, 13 Jungdaero 40 gil, Songpa-gu, Seoul www.ctcbio.com

27 C-Tri 82-31-557-0001 82-31-557-6622 778-1 Ilpae-dong, Namyangju-si, Gyeonggi-do www.c-tri.co.kr

28 Dae Lim Pharm Co., Ltd. 82-2-232-1819 82-2-232-7018 164-98, Annyung-dong, Hwaseog-si, Gyeonggi-Do

29 Dae Woo Pharm. Ind. Co., Ltd. 82-51-204-3831 82-51-202-3397 153 Dadaero, Saha-gu, Busan www.daewoopharm.com

30 Daebong LS 82-32-712-8800 82-32-817-8808 122B-9L, 692-8, Gojan-dong, Namdong-gu, Incheon www.daebongls.co.kr

31 Daehwa Pharm. Co., Ltd. 82-33-342-5140 82-33-342-0576 308 Masan-ri, Heongseong-gun, Gangwon-do www.dhpharm.co.kr

32 Daewon Pharm. Co., Ltd. 82-2-2204-7000 82-2-498-9108 229-3 Yongdap-dong, Seongdong-gu, Seoul www.daewonpharm.com

33 Daewoong Pharm. Co., Ltd. 82-2-550-8800 82-2-550-3530 163-3 Samsung-dong, Gangnam-gu, Seoul www.daewoong.co.kr

34 Dai Han Pharm. Co., Ltd. 82-2-2678-8445 82-2-2671-9636 8-3 Yangpyeong-dong 4-ga, Yeongdeungpo-gu, Seoul www.daihan.com

Regular Members(2015. 4)



35 Daiichi Sankyo Korea Co.,Ltd. 82-2-3453-3300 82-2-3452-9756 Posco West 3F, Daechi4-dong, Kangnam-gu, Seoul www.daiichisankyo.co.kr

36 Dalim Biotech Co., Ltd. 82-31-535-6091 82-31-535-6093 907-5 Sangsan-ri, Hyangnam-eup, Hwaseong-si, Geonggi-do www.dalimmedical.co.kr

37 DHP Korea Co., Ltd. 82-43-239-3303 82-43-239-3308 491 Mansu-ri, Gangwoe-myeon, Cheonggwon-gun, Chungcheongbuk-do www.dhpkorea.co.kr

38 Dong In Dang Pharm. Co., Ltd. 82-31-319-1990 82-31-319-1995 Shiwah Complex 1 Ra No.603,1248-8 Jungwang-

dong, Siheung-si, Gyeonggi-do www.dongin-dang.co.kr

39 Dong Koo Pharm. Co., Ltd. 82-2-2688-5421 82-2-2681-1880 195-2 Gocheok 2-dong, Guro-gu, Seoul www.dongkoo.co.kr

40 Dong Kook Pharm. Co., Ltd. 82-2-2191-9900 82-2-566-8542 997-8 Daechi 3-dong, Gangnam-gu, Seoul www.dkpharm.co.kr

41 Dong Kwang Pharm. Co., Ltd. 82-2-776-7641 82-2-777-4874 Yeongak tower 12F, 25-5 Chungmuro 1-ga, Jung-gu,

Seoul www.dkpco.co.kr

42 Dong Wha Pharm. Ind. Co., Ltd. 82-2-2021-9300 82-2-778-2336 5 Sunwha-dong, Jung-gu, Seoul www.dong-wha.co.kr

43 Dong-A Pharmaceutical 64 Cheonhodaero, Dongdaemun-gu, Seoul en.dapharm.com

44 Dong-A ST 64 Cheonhodaero, Dongdaemun-gu, Seoul en.donga-st.com/

45 Dongsung Pharm. Co., Ltd. 82-2-6911-3600 82-50-5191-69081 703-14 Banghak-dong, Dobong-gu, Seoul www.dongsung-pharm.co.kr

46 Dongwoo Syntech Co., Ltd. 82-43-882-7280 82-43-882-7283 152-1, Bondae-Ri, Geumwang-Eup, Eumsung-

Gun, Choongcheongbook-Do www.dongwookr.com

47 Dream Pharma Corp. 82-2-729-4115 82-2-729-4127 Hanwha B/D 13F, 1 Jangkyo-dong, Jung-gu, Seoul www.dreampharma.co.kr

48 Eisai Korea Inc. 82-2-3451-5500 82-2-3451-5599 Revessant B/D 10F, 147-17Samseong-dong, Gangnam-gu, Seoul www.eisaikorea.com

49 Elyson Pharmaceutical Co. Ltd. 82-2-6342-7001 82-2-6342-7003 2F Kyungpung Building, 788-26 Yeoksam-dong,

Gangnam-gu, Seoul www.elyson.co.kr

50 Estech Pharma Co., Ltd. 82-2-3471-2078 82-2-3471-2079 Daekwan B/D 5F, 15-1 Yangjae-dong, Seocho-gu, Seoul www.estechpharma.com

51 Ferring Pharm. Korea Co.,Ltd. 82-2-534-2761 82-2-534-2956 Songwon B/D 7F, 59-5 Banpo-dong, Seocho-gu,

Seoul www.ferring.co.kr

52 Fresenius Kabi Korea Ltd. 82-2-3484-0900 82-2-3484-0957 SaemaeulUndong B/D 3F, 1008-4 Daechi-dong, Gangnam-gu, Seoul www.fresenius-kabi.com

53 Fresenius medical care korea co.,Ltd 82-2-2112-8800 82-2-2112-8804 Landmarktower 7F, 837-36 yeoksam-dong,

Gangnam-gu, Seoul www.fmc-korea.co.kr

54 Galderma Korea Ltd. 82-2-6717-2000 82-2-6717-2001 Bando B/D 7F, 48-1 Banpo-dong, Seocho-gu, Seoul www.galdermakorea.com

55 GlaxoSmithKline Korea 82-2-709-4116 82-2-796-4710 Kukjecenter B/D 9F, 191 Hangangno 2-ga, Yongsan-gu, Seoul www.gsk-korea.co.kr

56 Green Pharm. Co., Ltd. 82-2-842-1301 82-2-842-1302 2F, 4159 Shingil 6-dong, Yeoungdeungpo-gu, Seoul

57 Greencross Corporation 82-31-260-9300 82-31-260-9413 303 Bojeong-dogn, Giheung-gu, Yongin-si, Gyeonggi-do www.greencross.com

58 Guerbet Korea. Ltd. 82-2-3453-1212 82-2-3453-2634 IS B/D 6F, 719-35 Yeoksam-dong, Gangnam-gu, Seoul www.guerbet.co.kr

59 Guju Pharm. Co., Ltd. 82-2-2672-1122 82-2-2679-7569 94-119 Yeoungdeungpo-dong 2-ga, Yeongdeungpo-gu, Seoul www.gujup.co.kr

60 Hamsoa Pharm. Co., Ltd. 82-2-2176-2180 82-2-3443-0825 8F Joil Building 62 Nonhyeon-dong, Gangnam-gu, Seoul www.hamsoapharm.com

61 Han Kook Korus Pharm. Co., Ltd. 82-33-264-5771 82-33-264-5774 1181 Geodu-ri, Dongnae-myeon, Chuncheon-si,

Gangwon-do www.koruspharm.co.kr

62 Hana Pharm. Co., Ltd. 82-2-577-7667 82-2-577-6003 Rocket B/D 6~7F, 747-29 Yeogsam-dong, Gangnam-gu, Seoul www.hanaph.co.kr

63 Hanall Bio Pharm. Co., Ltd. 82-2-2204-1928 82-2-2414-7474 Jamsil I-Space 6F, 11-10 Shinchon-dong, Songpa-gu, Seoul www.hanall.co.kr

64 Handok Pharm. Co., Ltd. 82-2-527-0114 82-2-527-5001 132 Teheran-ro, Gangnam-gu, Seoul www.handok.co.kr

65 Hankooksinyak Pharm. Co., Ltd. 82-41-740-8900 82-41-740-8849 805-15 Jungsan-ri, Yangchon-myeon, Nonsan-si,

Chungcheongnam-do www.hsp.co.kr

66 Hanlim Pharm. Co., Ltd. 82-2-3489-6000 82-2-3489-6101 1656-10 Seocho-dong, Seocho-gu, Seoul www.hanlim.com

67 Hanmi Pharm. Co., Ltd. 82-2-410-9114 82-2-410-9259 Hanmi Tower, 45 Bangi-dong, Songpa-gu, Seoul www.hanmi.co.kr

207


68 Hanpoong Pharm. Co., Ltd. 82-2-586-5211 82-2-583-8584 981-52 Banbae-dong, Seocho-gu, Seoul www.hanpoong.co.kr

69 Hansol Pharm. Co., Ltd. 82-43-881-6333 82-43-881-6332Chungpyeong-gil 2-11 (Docheong-lee 33-32), Geumwang-eup, Eumsung-gun, Choongcheongbook-Do

www.hansolpharm.com

70 Hanwha Pharma. Co., Ltd. 82-2-959-3161 82-2-959-3621 261 Seokkwan 2-dong, Seongbuk-gu, Seoul www.hwpharm.com

71 Hanzung Pharm. Co., Ltd. 82-42-936-5858 82-42-936-2525 165-7, Sangseo-dong, Daedeok-gu, Daejeon www.hzpharm.co.kr

72 Hawon Pharm. Co. 82-2-554-2012 82-2-554-4557 788-1 Yeogsam-dong, Gangnam-gu, Seoul www.hawonpharm.co.kr

73 Hospira, Inc 82-2-3497-1870 82-2-2009-4801 8F IKP Building, 300-6 Yeomgok-dong, Seocho-gu, Seoul www.hospira.co.kr

74 Humedix. Co., Ltd. 82-70-7492-5600 82-31-420-5650 Room 502 Anyang-megavalley, 268 Hagui-ro, Dongan-gu, Anyang-si, Gyeonggi-do humedix.com

75 Huniz. Co., Ltd. 82-51-831-1030 82-51-831-1040 1529-4, Songjeong-dong, Gangseo-gu, Busan www.huniz.kr

76 Huons Co., Ltd 82-31-854-4700 82-31-6455-0740 C-901 PangyoInoBelly, 621 Sampyeong-dong, Bundang-gu, Seongnam-si, Gyeonggi-do www.huons.com

77 Hutecs Korea Co., Ltd 82-31-377-7900 82-31-377-7911 555-2 Yeongchun-ri, Dongtan-myeon, Hwaseong-si, Gyeonggi-do www.hutecs.co.kr

78 Hyundai Pharm. Ind. Co., Ltd. 82-2-2600-3813 82-2-2693-7628 Hyungai pharm B/D, 204-4 Nonhyeon-dong,

Gangnam-gu, Seoul www.hyundaipharm.co.kr

79 Icure Pharm. Inc. 82-31-776-3776 82-31-776-3770 Room 1305 Technopark Techcentre, 190-1 Sangdaewon-dong, Jungwon-gu, Seongnam-si www.icure.co.kr

80 Ik-Su Pharm. Co., Ltd. 82-2-416-1112 82-2-416-1118 Iksoo B/D, Amsa-dong 488-20, Kangdong-gu, Seoul www.iksu.co.kr

81 Il Dong Pharm. Co., Ltd. 82-2-526-3114 82-2-526-3030 60 Yangjae-dong, Seocho-gu, Seoul www.ildong.com

82 Ilsung Pharm Co., Ltd. 82-2-3271-8800 82-2-2701-6335 44-7 Wonhyoro1-ga, Yongsan-gu, Seoul www.ilsung-ph.co.kr

83 Ilwha Co., Ltd. 82-31-550-0100 82-31-550-0105 437 Sutaek1-dong, Guri-si, Gyeonggi-Do www.ilhwa.co.kr

84 Il-Yang Pharm. Co., Ltd. 82-2-570-3700 82-2-570-3708 544-5, Dogok-dong, Gangnam-gu, Seoul www.ilyang.co.kr

85 Ipsen Group 82-2-512-6693 82-2-512-6692 13F Sesin Building, 129-11 Cheongdam-dong, Gangnam-gu, Seoul www.ipsen.com

86 Isu Abxis Co., Ltd. 82-2-2227-8888 82-2-2227-8887 Yeonse medical school 6F, Sinchon-dong 134, Seodaemoon-gu, Seoul www.abxis.com

87 Janssen Korea Ltd. 82-2- 2094-4500 82-2- 538-5632 25F LG Yongsan Tower B/D, 191 Hangang-ro 2ga , Yongsan-gu, Seoul www.janssenkorea.com

88 Je Il Pharm. Co., Ltd. 82-53-583-6226 82-53-583-5775 Daechun-dong 739, Dalseo-gu, Daegu city www.jeilphar.co.kr

89 Jeil Pharm. Co., Ltd. 82-2-549-7451 82-2-549-4045 343, Sapyeong-daero, Seocho-gu, Seoul www.jeilpharm.co.kr

90 Jin Yang Pharm. Co., Ltd. 82-2-3470-0300 82-2-3470-0390 1532-9 Seocho-dong, Seocho-gu, Seoul www.jinyangpharm.com

91 JRP Co., Ltd. 82-31-353-6551 82-31-354-1539 900-2, Sangsin-ri, Hyangnam-myeon, Hwaseong-si, Gyeonggi-do www.ejrp.co.kr

92 JW Pharmaceutical 82-2-840-6777 82-2-841-1213 698 Shindaebang-dong, Dongjak-gu, Seoul www.jw-pharma.co.kr

93 JW Shinyak 82-2-2109-3300 82-2-2109-3388 3F 13cha Daeryung Techno Tower, Gasan-dong, Geumcheon-gu, Seoul www.jw-shinyak.co.kr

94 KMS Pharm Co., Ltd. 82-31-215-5456 82-31-215-5925 492-12, Maetan 3-dong, Yeongtong-gu, Suwon-si, Gyeonggi-do www.kmspharm.com

95 Kolmar Korea 82-41-862-1057 82-41-862-7637 170-7 Seojeong-ri, Jeonui-myeon, Yeongi-gun, Chungcheongnam-do www.kolmar.co.kr

96 Kolmar pharma 82-43-640-0088 82-43-640-0007 93 Biovalley 2-ro, Jecheon-si, Chungcheongbuk-do www.kolmar.co.kr

97 Kolon Pharma 82-2-2120-8300 82-2-2120-8301 6F Annex to Kolon Tower, 1-22 Byeoryang-dong, Gwacheon-si, Gyeonggi-do www.kolonpharm.co.kr

98 Korea Atomic Energy Research Institute 82-42-868-4641 82-42-868-2106 Advanced Reactor Development Institute, Daedeok-

daero 989-11, Yuseong-gu, Daejeon www.kaeri.re.kr

99 Korea Global Pharm. Co., Ltd. 82-41-951-4300 82-41-951-4344 417-4, Seokchon-ri, Jongcheon-myeon, Seocheon-

gun, Chungcheongnam-do www.globalpharm.co.kr

100 Korea INS Pharm. Inc. 82-61-371-3000 82-61-371-3015 1065 Daepo-ri ,Dong-myeon ,Hwasun-gun, Jeollanam-do www.inspharm.co.kr



101 Korea Jinseng Corp. 82-2-2189-6500 82-2-2189-6559 Cosmo tower, Daechi-dong 1002, Kangnam-gu, Seoul www.kgc.or.kr

102 Korea Kowa Company Ltd. 82-2-6930-4800 82-2-6930-4808 7F Gookmin-1 B/D, 302 Yeongdong-daero,

Gangnam-gu, Seoul www.kowakorea.com

103 Korea mcnulty. Co., Ltd. 82-31-378-1460 82-31-378-1468 713-2, Jung-ri, Dongtan-myeon, Hwaseong-si, Gyeonggi-do www.koreamcnulty.co.kr

104 Korea Otsuka Pharm. Co., Ltd. 82-2-3287-9000 82-2-3287-9019 770-9 Yeoksam-dong, Gangnam-gu, Seoul www.otsuka.co.kr

105 Korea Pharma Co., Ltd. 82-2-558-1277 82-2-558-1677 Baeklim B/D 8F, 823-33 Yeogsam-dong, Gangnam-gu, Seoul www.koreapharma.co.kr

106 Korea Prime Pharm. Co., Ltd. 82-62-233-1110 82-62-233-3298 Daein Building, 158-3 Daein-dong, Dong-gu,

Gwangu www.koreaprime.co.kr

107 Korea United Pharm. Inc. 82-2-512-9981 82-2-548-4599 154-8 Nonhyun-dong, Gangnam-gu, Seoul www.kup.co.kr

108 Korea Vaccine Co., Ltd. 82-2-443-1961 82-2-443-4484 Doowon B/D, 87-3 Garak-dong, Songpa-gu, Seoul www.koreavaccine.com

109 Korean Drug Co., Ltd. 82-2-529-6100 82-2-529-6114 423-2 Dogok-dong, Gangnam-gu, Seoul www.nicepharma.com

110 Kuhnil Pharm. Co., Ltd. 82-2-714-0091 82-2-719-0493 Osong B/D 27-11Jeong-dong, Jung-gu, Seoul www.kuhnil.com

111 Kukbo Science Co., Ltd. 82-43-264-7765~8 82-43-267-7769 49 Sandan-ro, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do www.kukboscience.co.kr

112 Kukje Pharm. Ind. Co., Ltd. 82-31-781-9081 82-31-781-6040 513-2 Yatap-dong, Bundang-gu, Seongnam-si,

Gyeonggi-do www.kukjepharm.co.kr

113 Kunwha Pharm. Co., Ltd. 82-2-2047-7700 82-2-443-0589 1002 Yangjae-daero, Songpa-gu, Seoul www.kunwha.com

114 Kwang Dong Pharm. Co., Ltd. 82-2-6006-7777 82-2-6006-7024 1577-4 Seocho-dong, Seocho-gu, Seoul www.ekdp.com

115 Kyongbo Pharm. Co., Ltd. 82-41-545-0456 82-41-546-8427 345-6 Silok-dong, Asan-si, Chuncheongnam-do www.kbpharma.co.kr

116 Kyowa Hakko Kirin Korea Co. Ltd. 82-2-3471-4921 82-2-3471-4322 5F Poonglim Building, 823 Yeoksam-dong,

Gangnam-gu, Seoulwww.kyowa-kirin-korea.com

117 Kyung Dong Pharm. Co., Ltd. 82-2-576-6121 82-2-577-5195 1659-5 Inheon-dong, Gwanak-gu, Seoul www.kdpharma.co.kr

118 Kyung Nam Pharm. Co., Ltd. 82-2- 3490-5105 82-2- 3490-5129 889-13 Daechi-dong ,Gangnam-gu, Seoul www.kyungnampharm.

co.kr

119 Laboratorios Cinfa Ltd. 82-2-3488-6400 82-2-3488-6401 7F Medica Building, 1489-2, Seocho-dong, Seocho-gu, Seoul www.cinfakorea.com

120 LG Life Sciences, Ltd. 82-2-3773-1114 82-2-6924-3051 LG Gwangwamoon Building, 92 Sinmun-ro 2ga, jongno-gu, Seoul www.lgls.co.kr

121 Medicakorea Co., Ltd. 82-70-4018-8000 82-2585-9689 3, 8F Medica Building, 1489-2 Seocho 3 dong, Seocho-gu, Seoul www.medicakorea.com

122 MG Co., Ltd. 82-2-2057-1002 82-2-2057-1003 Yangjae B/D, Yangjae-dong 261, Seocho-gu, Seoul www.medi-green.co.kr

123 Mirae Pharma. Korea 82-2-583-9077 82-2-583-7421 174 Saimdang-ro, Seocho-gu, Seoul www.miraepharmkorea.co.kr

124 Mitsubishi Tanabe Pharma Korea Co., Ltd 82-2-579-0121 82-2-579-0125 R902 9F Yookyung Building, 239-1 Nonhyeon-dong,

Gangnam-gu, Seoulwww.mt-pharma-korea.com

125 Mother's Pharmaceutical co., Ltd 82-2-2026-8890 82-2-2026-8094 1-702 Gasandigital 2-ro, Geumcheon-gu, Seoul www.motherspharm.com

126 Mundipharma Korea 82-2-568-5689 82-2-568-5634 541 Namdaemoon-ro 5, Jung-gu, Seoul www.mundipharma.co.kr

127 Myung In Pharm. Co., Ltd. 82-2-587-9060 82-2-585-0352 Myungin B/D, 1539-9 Seocho-dong, Seocho-gu, Seoul www.myunginph.co.kr

128 Myung Moon Pharm. Co., Ltd. 82-2-6711-2000 82-2-572-5137 Myungmoon B/D, 946-18 Dogok-dong, Gangnam-

gu, Seoul www.mmpharm.co.kr

129 Nelson Korea Pharm Co.,Ltd. 82-2-588-0941 82-2-588-0170 Nelson B/D 3F, Seocho-dong 1462-17, Seocho-gu,

Seoul www.nelsonkorea.co.kr

130 Nensys Co., Ltd. 82-31-232-5285 82-31-234-4410 836 Seryu3-dong, Gwonsun-gu, Suwon-si, Gyeonggi-Do www.nensys.co.kr

131 Newgenpharm Inc. 82-2-580-5900 82-2-580-5999 BK Tower 11F, 942-2 Daechi 2, Gangnam-gu, Seoul www.newgenpharm.com

132 Novo Nordisk Pharma Korea Ltd. 82-2-2188-8947 82-2-2188-8980 16F Korea AD Culture Center, Sincheon-dong

,Songpa-gu, Seoul www.novonordisk.co.kr

133 Ono Pharma Korea Co., LTD. 82-2-928-8423 82-2-925-2151 13F, The-K twin towers B, 50 Jong-ro 1-gil, Jongno-

gu, Seoul www.ono.co.jp/eng/

209


134 Pharmaking Co., Ltd. 82-43-882-3501 82-43-882-3502 363 Ogung-ri, Gamgok-myeon, Eumseong-gun, Chungcheongbuk-do www.pharmaking.co.kr

135 Pharmbio Korea Co., Ltd 82-2-587-2551 82-2-587-2552 7F Samhomulsan Building A, 275-1 Yangjae-dong, Seocho-gu, Seoul www.pharmbio.co.kr

136 Pharvis Bio Tech Korea Corp. 82-2-579-6262 82-2-579-0880 517-9 Doggok-dong, Gangnam-gu, Seoul www.pharvis.co.kr

137 PMG PHARM Co., Ltd 82-31-439-5470 82-31-405-5471 726-4 Bugok-dong, Sanrok-gu, Ansan-si, Gyeonggi-do

138 Reyon Pharm. Co., Ltd. 82-2-793-5557 82-2-798-7538 38-6 Dongbinggo-dong, Yongsan-gu, Seoul www.reyonpharm.co.kr

139 Richwood Trading Co., Ltd. 82-2-757-3071 82-2-3789-6993 Danam B/D 22F, 120 Namdaemoonno 5-ga, Jung-gu,

Seoul www.richwood.net

140 RP corp., Inc 82-2-568-0051 82-2-554-0871 163-3 Samsung-dong, Gangnam-gu, Seoul www.rpskorea.com

141 Sae Han Pharm. Co., Ltd. 82-2-533-7417 82-2-553-7416 Samoh B/D 4F, Yeoksam1-dong 751-10, Kangnam-gu, Seoul www.shpharm.co.kr

142 Sam Chun Dang Pharm. Co., Ltd. 82-2-2046-1100 82-2-2046-1101 Seocho-dong 1606-1, Seocho-gu, Seoul www.scd.co.kr

143 SamA Pharm. Co., Ltd. 82-2-2056-7200 82-2-2056-7300 Sama B/D, 80-18 Cheongdam-dong, Gangnam-gu, Seoul www.samapharm.co.kr

144 Samik Pharm. Co., Ltd. 82-2-928-0661 82-2-924-3749 Dongbo B/D 4F, 1253 Sungin-dong, Jongno-gu, Seoul www.samik.co.kr

145 Samil Pharm. Co., Ltd. 82-2-520-0300 82-2-588-5924 990-1 Bangbae1-dong, Seocho-gu, Seoul www.samil-pharm.com

146 Samjin Pharm. Co., Ltd. 82-2-3140-0605 82-2-338-8032 338-8 Seokyo-dong, Mapo-gu, Seoul www.samjinpharm.co.kr

147 Samnam Pharm. Co., Ltd. 82-41-754-3771 82-41-752-0086 99-1 Sang-ri, Geumsan-eup, Geumsan-gun, Chuncheongnam-do www.samnam51.com

148 Samsung Pharm. Ind. Co., Ltd. 82-2-3408-4500 82-2-3408-4702 614-4 Junggok-dong, Gwangjin-gu, Seoul www.sspharm.co.kr

149 Samyang Biopharm. Corp. 82-2-740-7116 82-2-743-6626 263 Yeonji-dong, Jongno-gu, Seoul www.samyangbiopharm.

co.kr

150 Samyang Chemical Co., Ltd. 82-2-3488-5592 82-2-521-3100 1500-10 Seocho 3-dong, Seocho-gu, Seoul www.samyangchem.com

151 SANDOZ Korea Co., Ltd 82-2-768-9300 82-2-753-1287 Yonsei severance B/D 18F, 84-11 Namdaemonn-ro 5ga, Junggu, Seoul www.sandoz.com

152 Santen Pharm. Korea Co., Ltd. 82-2-754-1434 82-2-754-2929 1678-4 Seocho-dong, Seocho-gu, Seoul

153 SBP 82-41-857-3686 82-41-857-7854 533-2 Bongkok-ri, Banpo-myun, Gongju-si, Chungchungnam-do www.sbp.com

154 Schnell BioPharmaceuticals., Inc 82-2-561-4011 82-2-561-4012 L2 Hanrasigmavalley 442-2 Sangdaewon-dong,

Jungwon-gu, Seongnam-si, Gyeonggi-do www.schnell.kr

155 Seoul Pharma co. Ltd. 82-31-497-1931 82-31-431-0715 Kyungje-ro 59, Siheung-si, Gyeonggi-do www.seoulpharma.com

156 Sewon Cellontech Co.,Ltd 82-2-2167-9000 82-2-2167-9157 11F GooodmorningShinhan Tower, Yeouidae-ro 70, Yeongdeungpo-gu, Seoul www.sewoncellontech.com

157 Shin Poong Pharm. Co., Ltd. 82-2-2189-3426 82-2-2189-3439 748-31 Yeoksam-dong, Gangnam-gu, Seoul www.shinpoong.co.kr

158 Sinil Pharm. Co., Ltd. 82-2-2211-6700 82-2-2212-6539 Sinil B/D, 315-18 Jangan 2-dong ,Dongdaemun-gu, Seoul www.sinilpharm.com

159 Sinsin Pharm. Co., Ltd. 82-31-491-6151 82-31-491-6153 776-6 Wonsi-dong, Danwon-gu, Gyeonggi-do www.sinsin.com

160 SK Chemicals Life Science 82-2-2008-2008 82-2-2008-2009 686 Sampyung-dong, Bundang-gu, Seongnam-si, Gyeonggi-do www.skchemicals.com

161 SS Pharm Co.,Ltd 82-31-491-6311 82-31-491-4797 533-2 Bongkok-ri, Banpo-myun, Gongju-si, Chungchungnam-do www.susungpharm.co.kr

162 Suheung Capsule. Co., Ltd. 82-2-2210-8116 82-2-2217-2357 435-5 Jangan 3-dong, Dongdaemun-gu, Seoul www.suheung.co.kr

163 Sung Kwang Pharm. Co., Ltd. 82-41-566-8283 82-41-566-8322 555-42 Baekseok-dong, Seobuk-gu, Cheonan-si,

Chungcheongnam-do www.skpharm.net

164 Sungwon Adcock Pharm. Co., Ltd. 82-2-3665-2872 82-2-3665-2874 Room 302 Gayang-technotown, 1487 Gayang

3-dong, Gangseo-gu, Seoul www.swpharm.com

165 Taejoon Pharm. Co., Ltd. 82-2-798-6601 82-2-795-8873 657-87 Hannam-dong, Yongsan-gu, Seoul www.taejoon.co.kr



166 Taiguk Pharm. Co., Ltd. 82-80-3474-7761 82-2-3472-5501 Seowoo B/D 6F, Yeoksam-dong 837-12, Kangnam-gu, Seoul www.taiguk.co.kr

167 Takeda Pharmaceuticals Korea Co., Ltd. 82-2-3484-0800 82-2-3484-0808 12F KT&G Cosmodaechi Tower, 945-10 Daechi-dong,

Gangnam-gu, Seoul www.takeda-asia.com

168 Teva-Handok. Co., Ltd. 82-2-521-5501 82-2-527-5510 132 Teheran-ro, Gangnam-gu, Seoul

169 Theragen Etex Pharm. Inc. 82-2- 3463-7111 82-2- 3463-8111 Kyunghee B/D 5F, 517-5 Dogok-dong, Gangnam-gu,

Seoul www.etexpharm.com

170 UK Chemipharm Co., Ltd. 82-31-310-1983 82-31-310-1985 R38 6F Asandigital Park, 1123 Shingil-dong, Danwon-gu, Ansan-si, Kyunggi-do www.ukchemipharm.com

171 Unimed Pharm. Inc. 82-2-2240-5100 82-2-2240-5115 Unimed B/D, 250-8 Jamsilbon-dong, Songpa-gu, Seoul www.unimed.co.kr

172 Union Korea Pharm. Co., Ltd. 82-2-489-3611 82-2-487-3611 Wonwae B/D 5F, 389-1 Poongnap 2-dong, Songpa-

gu, Seoul www.ukp.co.kr

173 Whan In Pharm. Co., Ltd. 82-2-405-3000 82-2-404-2518 84-1 Munjeong-dong, Songpa-gu, Seoul www.whanin.com

174 White Global Pharmaceutical Corp. 82-2-541-4884 82-2-541-8448 621, Yeongdong-daero, Gangnam-gu, Seoul www.whpharma.com

175 Won Kwang Pharm. Co., Ltd 82-63-832-3114 82-63-833-4114 827 Shindong-ri, Chunpo-myeon, Iksan-si,

Jeonrabuk-do www.wonpharm.co.kr

176 YD Diagnostics Co., Ltd. 82-31-329-2000 82-31-329-2002 Seo-ri 173, Idong-myun, Cheoin-gu, Yongin-si, Kyunggi-do www.yd-diagnostics.com

177 Yoo Young Pharm. Co., Ltd. 82-2-6207-6114 82-2-6207-6135 915-9 Bandbae 1-dong, Seocho-gu, Seoul www.yypharm.co.kr

178 Young Poong Pharm. Co., Ltd. 82-2-823-3251 82-2-821-2913 402-1 Daebang-dong, Dongjak-gu, Seoul www.yppharm.co.kr

179 Yuhan Corp. 82-2-828-0181 82-2-828-0300 49-6 Daebang-dong, Dongjak-gu, Seoul www.yuhan.co.kr

180 Yuhan Medica Corp. 82-43-215-9435 82-43-215-1738 807-1 Yangcheong-ri, Ochang-eup, Cheongwon-gun, Chungcheongbuk-do www.yuhanmedica.co.kr

181 Yuhan-clorox Co., Ltd. 82-2-702-6561 82-2-702-6606 Sungwoo B/D 6F, 51-1 Dohwa-dong, Mapo-gu, Seoul www.yuhanclorox.co.kr

182 Yuil Pharm Tech. Co., Ltd. 82-43-537-2161 82-43-537-2163 365-1 Shinwon-ri, Iwol-myeon, Jincheon-gun, Chungcheongbuk-do

183 Yungjin Pharm. Co., Ltd. 82-2-2041-8200 82-2-2041-8219 451-20 Chonho 3-dong, Gangdong-gu, Seoul www.yungjin.co.kr

184 Yuyu Pharma, Inc. 82-2-2253-6600 82-2-2253-6200 Yu Yu B/D, 358-9 Shindang-dong, Jung-gu, Seoul www.yuyu.co.kr

211


1 Abnoba Korea Co.,Ltd 82-2-6340-5114 82-2-6340-5588 Room1704 Ace High-end Tower2, 222-14 Guro3-dong, Guro-gu, Seoul www.krabnoba.com

2 Bioland 82-41-564-8615 82-564-8619 394 Songjeong-ri, Byungcheon-myeon, Dongnam-gu, Cheonan-si, Chungcheongnam-do www.biolandkorea.com

3 BioLeaders 82-42-934-7671 82-42-934-7670 13 Techno8-ro, Yuseong-gu, Daejeon, Korea www.bioleaders.co.kr

4 C&R Research 82-2-6251-1500 82-2-6251-1504 3F Leeyangwon Building, 63-7 Kyungwoon-dong, Jongno-gu, Seoul www.cnrres.co.kr

5 Crystalgenomics 82-31-628-2700 82-31-628-2701 5F, Tower A, Korea Bio Park 700, Daewangpangyo-ro, Bundang-gu, Seongnam-si, Cyeonggi-do www.crystalgenomics.com

6Daegu-Gyeongbuk Medical Innovation Foundation

82-53-790-5113 82-53-790-5119 2387 dalgubeol-daero, Suseong-gu, Daegu www.medivalley.re.kr

7 DreamCIS Inc. 82-2010-4500 82-2-720-5385 R1010 Jeokseon-Hyundai Building, 80 Jeokseon-dong, Jongno-gu, Seoul www.dreamcis.com

8 Genexine Co.,Ltd. 82-31-628-3200 82-31-628-3229 B-4F Korea Bio Park, 694-1, Sampyeong-dong, Bundang-gu, Seongnam-si, Gyeonggi-do www.genexine.com

9 Glpharmtech.corp. 82-31-739-5220~3 82-31-739-5224 R714 Chungang Induspia 5th, Sangdaewon-dong, Jungwon-gu, Seongnam-si, Gyeonggi-do

10 Korea Institute of Toxicology 82-42-610-8250 82-42-610-8085 141 Gajeong-ro, Yuseong-gu, Daejeon 305-343 www.kitox.re.kr

11 KT&G Life Sciences Corp. 82-31-303-8831 82-31-303-5831B-1004~6 Digital Empire BLDG, 16, Deogyeong-daero 1556beon-gil, Yeongtong-gu, Suwon-si, Gyeonggi-do

www.ktngls.com

12 Medihelpline 82-2-2026-0707 82-2-2026-0708 R1207 Woorim Lions Building B, 371-28 Gasan-dong, Geumcheon-gu, Seoul www.medihelpline.co.kr

13 Modern Cell & Tissue Technology 82-2-3446-8884 82-2-3445-1380 R519 Seoul Technopark, 172 Gongneung 2-dong,

Nowon-gu, Seoul www.mctt.co.k

14 PHARMICELL Co.,Ltd 82-2-3496-0114 82-2- 3496-0159 12F Chungho Building, 120 Dosandae-ro, Gangnam-gu, Seoul www.pharmicell.com

15 Samsung Bioepis Co., Ltd 82-32-455-3114 82-32-455-6119 107, Cheomdan-daero, Yeonsu-gu, Incheon www.samsungbioepis.com

16 YD Global Life Science Company 82-2-576-9331 82-2-576-9334 R212 Dongseoul Onette, 339-1 Gil-dong, Gangdong-

gu, Seoul www.bioyd.co.kr

Associated Members(2015. 4)


MEMO

213

MEMO


MEMO

215

MEMO


2016 directory of korean pharmaceutical industry 제약협회 영문디렉토리_내지... ·...

Documents